: The AMEDEO Literature Guide

Home The Word Brain

My Amedeo

FAQ

Privacy

About

2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.

Dermatology

Free Subscription

Articles published in Br J Dermatol
Retrieve available abstracts of 1123 articles:
HTML format

Single Articles

April 2024

PHILLIPS C, Russell E, McNiven A, McPherson T, et al
A Qualitative Study of the Psychological Morbidity in Paediatric Survivors of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis.
Br J Dermatol. 2024 Apr 12:ljae154. doi: 10.1093.
PubMed

BLANCHARD M, Morren MA, Busschots AM, Hauben E, et al
Paediatric onset lymphomatoid papulosis: results of a multicentre retrospective cohort study, on behalf of the EORTC Cutaneous Lymphoma Tumours Group (CLTG).
Br J Dermatol. 2024 Apr 10:ljae150. doi: 10.1093.
PubMed Abstract available

SIMPSON EL, Eckert L, Gadkari A, Brown TM, et al
Evaluating the clinical utility of the Atopic Dermatitis Control Tool: measurement properties and agreement between patients' responses and clinicians' impressions of atopic dermatitis control.
Br J Dermatol. 2024 Apr 9:ljae056. doi: 10.1093.
PubMed

JONES OT, Matin RN, Walter FM
Using artificial intelligence-based technologies to support the diagnosis and early detection of melanoma in primary care.
Br J Dermatol. 2024 Apr 9:ljae094. doi: 10.1093.
PubMed

CAO Q, Li M
GLMN variants cause skin hyperpigmentation: a promising potential therapeutic target.
Br J Dermatol. 2024 Apr 8:ljae149. doi: 10.1093.
PubMed

ROCCUZZO G, Calvao J, Dobos G, Morsia E, et al
Cutaneous T-cell lymphoma care across Europe: insights from the Horizon Project.
Br J Dermatol. 2024 Apr 5:ljae145. doi: 10.1093.
PubMed

March 2024

KIM SR, Choi YG, Jo SJ
Effect of smoking cessation on psoriasis vulgaris, palmoplantar pustulosis, and generalized pustular psoriasis.
Br J Dermatol. 2024 Mar 27:ljae130. doi: 10.1093.
PubMed Abstract available

SANDER N, Stolzl D, Fonfara M, Hartmann J, et al
Blockade of IL-13 signaling improves skin barrier function and biology in patients with moderate to severe atopic dermatitis.
Br J Dermatol. 2024 Mar 26:ljae138. doi: 10.1093.
PubMed Abstract available

BENTZ P, Weisshaar E
Biomarkers as key concepts in managing atopic dermatitis and psoriasis: Unlocking new ways of care for patient suffering from chronic hand dermatoses.
Br J Dermatol. 2024 Mar 26:ljae127. doi: 10.1093.
PubMed

JOHNSON C, Liao W
Food for thought: A comment on 'Breast-feeding decreases the risk of developing psoriasis through early adulthood'.
Br J Dermatol. 2024 Mar 26:ljae135. doi: 10.1093.
PubMed

SOROKIN AV, Gelfand JM
New Prospective Cohort Study and Mendelian Randomization Analysis Reveals a Link Between Psoriasis and Cardiovascular Risk Trough Elevated Plasma Triglycerides.
Br J Dermatol. 2024 Mar 22:ljae129. doi: 10.1093.
PubMed

TALTY R, Richmond R, Micevic G
Melanoma TIL therapy commences era of cell-based immunotherapies.
Br J Dermatol. 2024 Mar 22:ljae126. doi: 10.1093.
PubMed

Correction to: Circulating biomarkers are associated with disease severity of chronic hand eczema and atopic dermatitis.
Br J Dermatol. 2024 Mar 22:ljae112. doi: 10.1093.
PubMed

STRANDMOE AL, Bremer J, Diercks GFH, Gostynski A, et al
Beyond The Skin: B Cells in Pemphigus Vulgaris, Tolerance and Treatment.
Br J Dermatol. 2024 Mar 20:ljae107. doi: 10.1093.
PubMed Abstract available

JIANG X, Yang C, Wang Z, Liang L, et al
Loss-of-function variants in GLMN are associated with generalized skin hyperpigmentation with or without glomuvenous malformation.
Br J Dermatol. 2024 Mar 15:ljae108. doi: 10.1093.
PubMed Abstract available

AMBRA1 and loricrin as a test to identify low-risk early-stage melanoma.
Br J Dermatol. 2024;190:e46.
PubMed

Blood monitoring during psoriasis treatment with biologics.
Br J Dermatol. 2024;190:e47.
PubMed

Safety of bimekizumab over 3 years in patients with psoriasis.
Br J Dermatol. 2024;190:e38.
PubMed

International trends in the incidence of cutaneous squamous cell carcinoma and melanoma.
Br J Dermatol. 2024;190:e40.
PubMed

Skin barrier dysfunction drives skin inflammation via formylpeptide receptor 1.
Br J Dermatol. 2024;190:e45.
PubMed

2024 British Skin Foundation Small Grants are NOW AVAILABLE.
Br J Dermatol. 2024;190:603.
PubMed

Comparison of topical permethrin 5% and benzyl benzoate 25% for treating scabies.
Br J Dermatol. 2024;190:e39.
PubMed

Global consensus process to establish a core dataset for hidradenitis suppurativa registries.
Br J Dermatol. 2024;190:e42.
PubMed

The relationship between paediatric eczema and cognition.
Br J Dermatol. 2024;190:e41.
PubMed

A guide to using the core outcome set for eczema.
Br J Dermatol. 2024;190:e44.
PubMed

GARMAN KA, Thoreson N, Strong J, Hallaert P, et al
Mycophenolate mofetil inhibits Merkel cell carcinoma growth.
Br J Dermatol. 2024;190:593-595.
PubMed Abstract available

CORNMAN HL, Whang KA, Ma E, Aggarwal P, et al
Severity, impact on quality of life and mental health burden of pruritus in prurigo nodularis: a cross-sectional study of a diverse patient cohort.
Br J Dermatol. 2024;190:571-572.
PubMed

CLAIRE FULLER L, Sunderkotter C
Scabies therapy update: Should 25% benzyl benzoate emulsion be reconsidered as a first-line agent in classical scabies?
Br J Dermatol. 2024;190:459-460.
PubMed

NIELSEN W, Drucker AM
The need and benefit of the Harmonising Outcome Measures for Eczema user's guide.
Br J Dermatol. 2024;190:462-463.
PubMed

XIE W, Kong X, Zheng H, Mei H, et al
Rapid emergence of recalcitrant dermatophytosis caused by a cluster of multidrug-resistant Trichophyton indotineae in China.
Br J Dermatol. 2024;190:585-587.
PubMed

NANDA A, Chang YH, Cheng HC, Lai IT, et al
Autosomal recessive plantar keratoderma with ragged periungual hyperkeratosis caused by a homozygous missense variant in KRT16.
Br J Dermatol. 2024;190:588-590.
PubMed

COWPER R
For itch and insanity.
Br J Dermatol. 2024;190:568.
PubMed

BARLOW R, Ahmed A, Fellows J, Goulding J, et al
Assessing and managing the mental health of people with vitiligo: a UK-wide consultation exercise.
Br J Dermatol. 2024;190:574-576.
PubMed

MEYERSBURG D, Hoellwerth M, Brandlmaier M, Handisurya A, et al
Comparison of topical permethrin 5% vs. benzyl benzoate 25% treatment in scabies: a double-blinded randomized controlled trial.
Br J Dermatol. 2024;190:486-491.
PubMed Abstract available

MOSCARELLA E, Di Brizzi EV, Alpi P, Arcelli A, et al
Indications for adjuvant radiotherapy in high-risk cutaneous squamous cell carcinoma with clear margins: a Delphi consensus.
Br J Dermatol. 2024;190:578-579.
PubMed

DONHAUSER T, Gabes M, Ozkan E, Masur C, et al
What do Hyperhidrosis Quality of Life Index (HidroQoL(c)) scores mean? Transferring science into practice by establishing a score banding system.
Br J Dermatol. 2024;190:519-526.
PubMed Abstract available

WAINMAN HE, Chandran NS, Frew JW, Garg A, et al
Global consensus process to establish a core dataset for hidradenitis suppurativa registries.
Br J Dermatol. 2024;190:510-518.
PubMed Abstract available

GEORGE CD, Lee T, Hollestein LM, Asgari MM, et al
Global epidemiology of actinic keratosis in the general population: a systematic review and meta-analysis.
Br J Dermatol. 2024;190:465-476.
PubMed Abstract available

NALDI L, Cassalia F
Actinic keratosis epidemiology: the good, the bad and the ugly.
Br J Dermatol. 2024;190:457-458.
PubMed

OYESIKU L, Dlova N, Ahmed S, Owen DR, et al
Inclusive and equitable language for skin colour in the British Journal of Dermatology: acknowledging our past and laying the foundations to move forward.
Br J Dermatol. 2024 Mar 13:ljae064. doi: 10.1093.
PubMed

AALA WJF, Hou PC, Hong YK, Lin YC, et al
Dominant dystrophic epidermolysis bullosa is associated with glycolytically active GATA3+ Th2 cells which may contribute to pruritus in lesional skin.
Br J Dermatol. 2024 Mar 13:ljae110. doi: 10.1093.
PubMed Abstract available

Correction to: Malignancy risk in patients with atopic dermatitis: a population-based cohort study.
Br J Dermatol. 2024 Mar 12:ljae093. doi: 10.1093.
PubMed

CANTISANI C, Taliano A, Longo C, Bortone G, et al
Dynamic Optical Coherence Tomography and Reflectance Confocal Microscopy of Basal Cell Carcinoma of the Nipple-Areola Complex.
Br J Dermatol. 2024 Mar 12:ljae104. doi: 10.1093.
PubMed

ARMATO U, Dal Pra I
Discovering skin-rejuvenating matrikines - a basic and applied Dermatology new frontier.
Br J Dermatol. 2024 Mar 12:ljae100. doi: 10.1093.
PubMed

CHEN GF, Xu S, White MA, Cohen JM, et al
Association between atopic dermatitis and eating disorders: a cross-sectional study in the All of Us Research Program.
Br J Dermatol. 2024 Mar 11:ljae103. doi: 10.1093.
PubMed

RA AG, Littlewood Z, Barton A, Keevil B, et al
The use of serum methotrexate level as an assessment of biochemical drug adherence in psoriasis.
Br J Dermatol. 2024 Mar 8:ljae096. doi: 10.1093.
PubMed

REHBINDER EM, Warnberg Gerdin S, Hoyer A, Bradley M, et al
Frequent oil-baths and skin barrier during infancy in the PreventADALL study.
Br J Dermatol. 2024 Mar 6:ljae091. doi: 10.1093.
PubMed Abstract available

EL HACHEM M, De Marco R, Soria de Francisco JM, Audouze A, et al
Ichthyosis: multinational European study on patient characteristics and body sites involved with impact on quality of life.
Br J Dermatol. 2024 Mar 1:ljae082. doi: 10.1093.
PubMed

February 2024

RIBERO S, Quaglino P, Roccuzzo G
Unveiling cutaneous adverse events and prognosis in immunotherapy for melanoma and squamous cell carcinoma.
Br J Dermatol. 2024 Feb 29:ljae092. doi: 10.1093.
PubMed

RAMESSUR R, Dand N, Langan SM, Saklatvala J, et al
Defining disease severity in atopic dermatitis and psoriasis for the application to biomarker research- an inter-disciplinary perspective.
Br J Dermatol. 2024 Feb 29:ljae080. doi: 10.1093.
PubMed Abstract available

GREVE AM, Wulff AB, Bojesen SE, Nordestgaard BG, et al
Elevated plasma triglycerides increase risk of psoriasis: A cohort and Mendelian randomization study.
Br J Dermatol. 2024 Feb 27:ljae089. doi: 10.1093.
PubMed Abstract available

STAMMLER R, Ta VA, Cohen E, Ram-Wolff C, et al
Failure of second challenge with Mogamulizumab in CCR4-positive cutaneous T-cell lymphoma.
Br J Dermatol. 2024 Feb 23:ljae085. doi: 10.1093.
PubMed

HUGHES O, Thompson AR
Dealing with Flares in Skin Conditions: How Can We Meet Patient Need?
Br J Dermatol. 2024 Feb 23:ljae084. doi: 10.1093.
PubMed

Correction to: How to recognize and manage skin toxicities associated with immune checkpoint inhibitors: a practical approach.
Br J Dermatol. 2024 Feb 21:ljae060. doi: 10.1093.
PubMed

JARIWALA N, Ozols M, Eckersley A, Mambwe B, et al
Prediction, screening and characterization of novel bioactive tetra-peptide matrikines for skin rejuvenation.
Br J Dermatol. 2024 Feb 20:ljae061. doi: 10.1093.
PubMed Abstract available

GLEESON D, Naveed M, Moorhead L, McAteer H, et al
Acceptability of 'as needed' biologic therapy in psoriasis: insights from a multi-stakeholder mixed methods study.
Br J Dermatol. 2024 Feb 17:ljae068. doi: 10.1093.
PubMed Abstract available

BABAKINEJAD P, Lapsley R, Forster L, McPherson S, et al
Cumulative methotrexate dose is not associated with liver fibrosis in patients with a history of moderate to severe psoriasis.
Br J Dermatol. 2024 Feb 17:ljae069. doi: 10.1093.
PubMed Abstract available

Alopecia areata and comorbidities associated with it in Germany.
Br J Dermatol. 2024;190:e32.
PubMed

Macrophages dampen skin inflammation after stem cell transplantation.
Br J Dermatol. 2024;190:e35.
PubMed

Safety of combination therapy for psoriasis: findings from the BIOBADADERM registry.
Br J Dermatol. 2024;190:e30.
PubMed

Comorbidities in people with psoriasis.
Br J Dermatol. 2024;190:e31.
PubMed

A clinical trial investigating if antibacterial therapeutic clothing could improve atopic dermatitis.
Br J Dermatol. 2024;190:e29.
PubMed

A review of the role of the NLRP1 inflammasome in skin conditions.
Br J Dermatol. 2024;190:e27.
PubMed

Greater understanding about the role of a long non-coding RNA in the development of cutaneous squamous cell carcinoma.
Br J Dermatol. 2024;190:e36.
PubMed

Results from the Treatment of Hidradenitis Suppurativa Evaluation Study (THESEUS).
Br J Dermatol. 2024;190:e33.
PubMed

Outcomes that need to be assessed in pyoderma gangrenosum clinical trials.
Br J Dermatol. 2024;190:e34.
PubMed

ALABAS OA, Yiu ZZN
A sprinkle of methotrexate to go with biologics: a safe recipe?
Br J Dermatol. 2024;190:302-303.
PubMed

LIU Y, Mo R, Chen Z, Yang Y, et al
Novel variants in ABCA12 cause erythrokeratodermia variabilis.
Br J Dermatol. 2024;190:454.
PubMed

HOPKINS ZH, Chada LMP, Duffin KC
Defining what matters through core outcomes set development: uniting stakeholder perspectives, empowering patient voices.
Br J Dermatol. 2024;190:301-302.
PubMed

BREHON A, Bensefa-Colas L, D'Andrea C, Jeziorski E, et al
Guidelines for cold urticaria management established by the Centre of Evidence of Dermatology and the Urticaria Group of the French Society of Dermatology.
Br J Dermatol. 2024;190:445-447.
PubMed

JACOBSON ME, Rick JW, Gerbens LAA, Baghoomian W, et al
A core domain set for pyoderma gangrenosum trial outcomes: an international eDelphi and consensus study from the UPGRADE initiative.
Br J Dermatol. 2024;190:392-401.
PubMed Abstract available

KINOSHITA-ISE M
Updated epidemiology of alopecia areata in Germany: the data tell a lot but hide a lot.
Br J Dermatol. 2024;190:297-298.
PubMed

JUNG JM, Cho HS, Kim GH, Won CH, et al
Psoriasiform mycosis fungoides: a clinical and prognostic retrospective cohort study.
Br J Dermatol. 2024;190:432-434.
PubMed

AUGUSTIN M, Ben-Anaya N, Muller K, Hagenstrom K, et al
Epidemiology of alopecia areata and population-wide comorbidities in Germany: analysis of longitudinal claims data.
Br J Dermatol. 2024;190:374-381.
PubMed Abstract available

INGRAM JR, Bates J, Cannings-John R, Collier F, et al
Treatment of Hidradenitis Suppurativa Evaluation Study (THESEUS): a prospective cohort study.
Br J Dermatol. 2024;190:382-391.
PubMed Abstract available

GARG A, Mastacouris N, Ingram JR, Strunk A, et al
Addressing high placebo response rates in randomized clinical trials for hidradenitis suppurativa.
Br J Dermatol. 2024;190:427-429.
PubMed

VYAS J, Johns JR, Ali FM, Singh RK, et al
A systematic review of 454 randomized controlled trials using the Dermatology Life Quality Index: experience in 69 diseases and 43 countries.
Br J Dermatol. 2024;190:315-339.
PubMed Abstract available

CAI L, Jiang C, Zhang G, Fang H, et al
A multicenter, randomized, double-blinded, placebo-controlled, phase ? study evaluating the efficacy and safety of Xeligekimab (GR1501) in patients with moderate-to-severe plaque psoriasis.
Br J Dermatol. 2024 Feb 15:ljae062. doi: 10.1093.
PubMed Abstract available

WAN G, Khattab S, Leung BW, Zhang S, et al
Cancer Type and Histology Influence Cutaneous Immunotherapy Toxicities: A Multi-Institutional Cohort Study.
Br J Dermatol. 2024 Feb 15:ljae053. doi: 10.1093.
PubMed Abstract available

ZHANG J, Schuttelaar MLA
How can we better address patients' needs in topical psoriasis treatment?
Br J Dermatol. 2024 Feb 5:ljae046. doi: 10.1093.
PubMed

KOBYLETZKI LBV, Svensson A
Long term outcome measures of atopic dermatitis gain importance: a validation study filling a research gap.
Br J Dermatol. 2024 Feb 5:ljae049. doi: 10.1093.
PubMed

EGELER MD, Ryll B
Survival is not enough: understanding the mental burden of cutaneous melanoma.
Br J Dermatol. 2024 Feb 3:ljae050. doi: 10.1093.
PubMed

DAS D, Thimjo J, Lebena A, Guo A, et al
Breast-feeding decreases the risk of developing psoriasis through early adulthood.
Br J Dermatol. 2024 Feb 2:ljae043. doi: 10.1093.
PubMed Abstract available

WEISS M, Ferre VM, Deschamps L, Evrard D, et al
Detection of alpha-papillomaviruses in extragenital cutaneous squamous cell carcinomas.
Br J Dermatol. 2024 Feb 2:ljae047. doi: 10.1093.
PubMed

January 2024

MUKHTAR AB, Morgan HJ, Gibbs A, Davies GE, et al
Targeting CD20-expressing malignant melanoma cells augments BRAF inhibitor killing.
Br J Dermatol. 2024 Jan 30:ljad502. doi: 10.1093.
PubMed Abstract available

DAINTY KN, Thibau IJC, Amog K, Drucker AM, et al
Towards a patient-centered definition for atopic dermatitis flare: A qualitative study among adults with atopic dermatitis.
Br J Dermatol. 2024 Jan 30:ljae037. doi: 10.1093.
PubMed Abstract available

TRUM NA, Chen L, Zain J, Rosen ST, et al
Significant survival disparity in Black patients with cutaneous lymphoma: a retrospective cohort study.
Br J Dermatol. 2024 Jan 29:ljae039. doi: 10.1093.
PubMed

BERGAMASCHI D
Improving cancer stem cells killing in malignant melanoma.
Br J Dermatol. 2024 Jan 29:ljae035. doi: 10.1093.
PubMed

GROLLEAU C, Walter-Petrich A, Dupin N, Chanal J, et al
Effectiveness and safety of major systemic treatments in classic and endemic Kaposi sarcoma: a multicenter retrospective study of 110 patients.
Br J Dermatol. 2024 Jan 25:ljae032. doi: 10.1093.
PubMed

Hidradenitis suppurativa: a review with new insights into disease mechanisms and potential future treatments.
Br J Dermatol. 2024;190:e14.
PubMed

Comparing systemic treatments for eczema.
Br J Dermatol. 2024;190:e16.
PubMed

Risk factors for developing a new primary melanoma in people with a melanoma.
Br J Dermatol. 2024;190:e15.
PubMed

Targeting Skp2 in blood vessels may be a promising approach to treat psoriasis.
Br J Dermatol. 2024;190:e22.
PubMed

A study using machine learning to help identify subgroups of adults with atopic dermatitis.
Br J Dermatol. 2024;190:e19.
PubMed

Omalizumab used to treat bullous pemphigoid resistant to other treatments.
Br J Dermatol. 2024;190:e23.
PubMed

Genes associated with nodular melanoma.
Br J Dermatol. 2024;190:e18.
PubMed

A decreasing trend of atopic dermatitis among children in Sweden.
Br J Dermatol. 2024;190:e17.
PubMed

Outcomes that need to be assessed in clinical trials for cutaneous neurofibromas in people with neurofibromatosis type 1.
Br J Dermatol. 2024;190:e20.
PubMed

ROMO CG, Sarin KY, Blakeley JO
Toward risk stratification and personalized therapy for neurofibromas in neurofibromatosis type 1.
Br J Dermatol. 2024;190:145-146.
PubMed

KHAN SS, Fuller LC
Is there a growing global threat of scabies treatment failure? An opportunity to discuss health inequity within UK dermatology.
Br J Dermatol. 2024;190:139-140.
PubMed

FAIRLEY JA, Messingham KAN
Omalizumab therapy of bullous pemphigoid.
Br J Dermatol. 2024;190:142-143.
PubMed

KIM EJ, Reusch DB, Anthony H, Schmidt B, et al
Disseminated juvenile xanthogranulomas with underlying neurotrophic tyrosine receptor kinase fusion and response to larotrectinib.
Br J Dermatol. 2024;190:283-284.
PubMed

SOEGIHARTO R, Westmeijer M, Boekema-Bakker N, Groenewegen IAM, et al
Prevalence of chronic urticaria and healthcare usage of patients with the condition in primary care: a population-based study in the Netherlands.
Br J Dermatol. 2024;190:287-289.
PubMed

CEDERLOF M, Jebril W, Larsson H, Curman P, et al
Individuals with Darier disease have an increased risk of suicide and self-injurious behaviours.
Br J Dermatol. 2024;190:284-285.
PubMed

NIELSEN VW, Ring HC, Holgersen N, Thomsen SF, et al
Elderly male patients with hidradenitis suppurativa have more severe disease independent of disease duration.
Br J Dermatol. 2024;190:292-293.
PubMed

WU W, Chen J, Zhu L, Sha Y, et al
Janus kinase inhibitor for anti-transcription intermediary factor 1-gamma positive cancer-associated dermatomyositis.
Br J Dermatol. 2024;190:285-287.
PubMed

KIRTSCHIG G, Singh S
Interventions for bullous pemphigoid: summary of a Cochrane Review.
Br J Dermatol. 2024;190:277-279.
PubMed

FONJUNGO FE, Barnes LA, Cai ZR, Naik HB, et al
Longitudinal remote monitoring of hidradenitis suppurativa: a pilot study.
Br J Dermatol. 2024;190:274-276.
PubMed Abstract available

KORTE EWH, Spuls PI, van den Akker PC, Kiritsi D, et al
Harmonization of outcomes in epidermolysis bullosa: report of the Core Outcome Sets for Epidermolysis Bullosa (COSEB) kick-off meeting.
Br J Dermatol. 2024;190:268-270.
PubMed

CHEBANI R, Lombart F, Chaby G, Dadban A, et al
Omalizumab in the treatment of bullous pemphigoid resistant to first-line therapy: a French national multicentre retrospective study of 100 patients.
Br J Dermatol. 2024;190:258-265.
PubMed Abstract available

KRUEGER JG, Frew J, Jemec GBE, Kimball AB, et al
Hidradenitis suppurativa: new insights into disease mechanisms and an evolving treatment landscape.
Br J Dermatol. 2024;190:149-162.
PubMed Abstract available

MBUAGBAW L, Sadeghirad B, Morgan RL, Mertz D, et al
Failure of scabies treatment: a systematic review and meta-analysis.
Br J Dermatol. 2024;190:163-173.
PubMed Abstract available

PAPACHRISTOU P, Soderholm M, Pallon J, Taloyan M, et al
Evaluation of an artificial intelligence-based decision support for detection of cutaneous melanoma in primary care - a prospective, real-life, clinical trial.
Br J Dermatol. 2024 Jan 17:ljae021. doi: 10.1093.
PubMed Abstract available

LEBWOHL M, Warren RB, Sofen H, Imafuku S, et al
Deucravacitinib in plaque psoriasis: 2-year safety and efficacy results from the phase 3 poetyk trials.
Br J Dermatol. 2024 Jan 16:ljae014. doi: 10.1093.
PubMed Abstract available

PENA-MARTIN J, Garcia-Ortega MB, Palacios-Ferrer JL, Diaz C, et al
Identification of novel biomarkers for early diagnosis of malignant melanoma by untargeted LC-HRMS-based metabolomics: a pilot study.
Br J Dermatol. 2024 Jan 12:ljae013. doi: 10.1093.
PubMed Abstract available

BLOME C, Hulswitt L, Meineke A, Augustin M, et al
Goals and benefits in topical treatment for psoriasis: Development and pilot validation of a patient-reported outcomes tool (PBI-TOP).
Br J Dermatol. 2024 Jan 12:ljad484. doi: 10.1093.
PubMed Abstract available

COCCIMIGLIO M, Chiodo F, van Kooyk Y
The sialic acid-Siglec immune checkpoint: an opportunity to enhance immune responses and therapy effectiveness in melanoma.
Br J Dermatol. 2024 Jan 10:ljad517. doi: 10.1093.
PubMed Abstract available

KUNGWENGWE G, Gowthorpe C, Ali SR, Warren H, et al
Prevalence & Odds of Anxiety & Depression in Cutaneous Malignant Melanoma: A Proportional Meta-analysis & Regression.
Br J Dermatol. 2024 Jan 10:ljae011. doi: 10.1093.
PubMed Abstract available

FUNCH AB, Glindvad Ahlstrom M, Johansen JD, Geisler C, et al
Neutrophil Infiltration in Allergic Contact Dermatitis to Nickel.
Br J Dermatol. 2024 Jan 4:ljad499. doi: 10.1093.
PubMed

LI Q, Tsoi LC
Biologic survival: a novel approach for drug efficacy estimation in psoriasis.
Br J Dermatol. 2024 Jan 4:ljae007. doi: 10.1093.
PubMed

YOO LJH, Stefanovic N, Watchorn RE
Atopic Dermatitis and Autism: Tactile Hypersensitivity Impeding on Topical Therapy Use.
Br J Dermatol. 2024 Jan 4:ljae005. doi: 10.1093.
PubMed

SMITH KA, Hiyoshi A, Vingeliene S, von Kobyletzki L, et al
Atopic dermatitis and cognitive function: a sibling comparison study among males in Sweden.
Br J Dermatol. 2024 Jan 3:ljae004. doi: 10.1093.
PubMed

December 2023

GURI-LAMCE I, AlRokh Y, Kim Y, Maeshima R, et al
Topical gene editing therapeutics using lipid nanoparticles: "gene creams" for genetic skin diseases?
Br J Dermatol. 2023 Dec 27:ljad528. doi: 10.1093.
PubMed Abstract available

JOHNSON C, Smith P, Haran K, Kranyak A, et al
Comment on 'Dupilumab significantly improves sleep in adults with atopic dermatitis: results from the 12-week placebo-controlled period of the 24-week phase IV randomized double-blinded placebo-controlled DUPISTAD study'.
Br J Dermatol. 2023 Dec 27:ljad529. doi: 10.1093.
PubMed

JEREMIAN R, Malinowski A, Lytvyn Y, Georgakopoulos JR, et al
Skin photoaging following sun exposure is associated with decreased epigenetic and biological age and correlates with basal cell carcinoma phenotype.
Br J Dermatol. 2023 Dec 22:ljad527. doi: 10.1093.
PubMed

Nemolizumab reduces itch and improves other signs of atopic dermatitis in children aged 6-12 years.
Br J Dermatol. 2023;190:e2.
PubMed

A pharmacogenetic study of psoriasis supports the association between a gene (KLK7) and treatment response.
Br J Dermatol. 2023;190:e8.
PubMed

Greater understanding about differences in the long-term course of eczema and their risk factors in children.
Br J Dermatol. 2023;190:e5.
PubMed

A new method to measure facial depigmentation in vitiligo.
Br J Dermatol. 2023;190:e7.
PubMed

A study about how many people around the world have atopic dermatitis.
Br J Dermatol. 2023;190:e6.
PubMed

A study looking at a possible new drug, HB0017, for the treatment of psoriasis.
Br J Dermatol. 2023;190:e3.
PubMed

Hidradenitis suppurativa in older adults.
Br J Dermatol. 2023;190:e11.
PubMed

Genetics and melanoma screening.
Br J Dermatol. 2023;190:e4.
PubMed

A short RNA molecule and tumour aggressiveness in people with epidermolysis bullosa.
Br J Dermatol. 2023;190:e9.
PubMed

The role of enhancers in eczema and psoriasis.
Br J Dermatol. 2023;190:e1.
PubMed

O'SHAUGHNESSY RFL
Why are squamous cancers so aggressive in recessive dystrophic epidermolysis bullosa? Can we find new therapeutic approaches?
Br J Dermatol. 2023;190:7-8.
PubMed

MARQUEZ DG, Sadeghi NB, Westerkam LL, Blum FR, et al
A survey-based study on experiences with and perspectives toward medical providers among patients with hidradenitis suppurativa.
Br J Dermatol. 2023;190:127-129.
PubMed

ELEFTHERIADOU V, Seneschal J
Assessment of treatment response on facial vitiligo, a step forward. But what about the neck?
Br J Dermatol. 2023;190:5-6.
PubMed

SENENT-VALERO M, Matijasevich A, Jara-Rico N, Sivera F, et al
Drug survival of metformin in patients with hidradenitis suppurativa.
Br J Dermatol. 2023;190:125-127.
PubMed

TAN E, Kennedy H, Rademaker M
When science and evidence is not enough: challenging the recommendations from the Commission on Human Medicines Isotretinoin Expert Working Group.
Br J Dermatol. 2023;190:116-117.
PubMed

ILLMER J, Zauner R, Pinon Hofbauer J, Wimmer M, et al
MicroRNA-200b-mediated reversion of a spectrum of epithelial-to-mesenchymal transition states in recessive dystrophic epidermolysis bullosa squamous cell carcinomas.
Br J Dermatol. 2023;190:80-93.
PubMed Abstract available

BUONTEMPO MG, Sicco KL, Shapiro J
Comment on 'Treatment of moderate-to-severe alopecia areata with baricitinib in preadolescent children'.
Br J Dermatol. 2023;190:135.
PubMed

CHORAGUDI SC, Andrade LF, Yosipovitch G
Pruritus is associated with longer hospital stays and higher costs in psychiatric inpatients from the USA National Inpatient Sample (2012-2015): a cross-sectional study.
Br J Dermatol. 2023;190:119-120.
PubMed

ELEFTHERIADOU V, Hamzavi I, Bae JM, Ezzedine K, et al
Roadmap to VIRTUAL-GLOBAL: coordinating VItiligo RegisTries for adUlts And chiLdren internationally.
Br J Dermatol. 2023;190:114-116.
PubMed

VAN DER WEIJDEN DAY, Koerts NDK, van Munster BC, van der Zee HH, et al
Hidradenitis suppurativa tarda: defining an understudied elderly population.
Br J Dermatol. 2023;190:105-113.
PubMed Abstract available

MARIN DIT BERTOUD Q, Bertold C, Ezzedine K, Pandya AG, et al
Reliability and agreement testing of a new automated measurement method to determine facial vitiligo extent using standardized ultraviolet images and a dedicated algorithm.
Br J Dermatol. 2023;190:62-69.
PubMed Abstract available

NARAHARI SR, Aggithaya MG, Ryan TJ, Muralidharan K, et al
Self-care treatment for lymphoedema of lymphatic filariasis using integrative medicine.
Br J Dermatol. 2023;190:94-104.
PubMed Abstract available

ASFOUR L, Bokhari L, Bhoyrul B, Eisman S, et al
Comment on 'Treatment of moderate-to-severe alopecia areata with baricitinib in preadolescent children with baricitinib': authors' reply.
Br J Dermatol. 2023;190:136-137.
PubMed

TIERNEY E, Evans P, Broderick V, Wynn R, et al
Successful response to dupilumab in a refractory case of atopic dermatitis-like chronic cutaneous graft-versus-host disease.
Br J Dermatol. 2023 Dec 20:ljad526. doi: 10.1093.
PubMed

THOMAS KS, Howells L, Leshem YA, Simpson EL, et al
How to use the HOME Core Outcome Set for atopic dermatitis trials - a users' guide.
Br J Dermatol. 2023 Dec 20:ljad497. doi: 10.1093.
PubMed Abstract available

LEFRANCOIS P, Doueidari Z, Kleiner O, Manion R, et al
Top 10 research priorities for cutaneous squamous cell carcinoma: results of the Skin Investigation Network of Canada Priority Setting Initiative.
Br J Dermatol. 2023 Dec 19:ljad387. doi: 10.1093.
PubMed

ABDI P, Haq Z, Diaz MJ, Maibach HI, et al
Infectious disease among adults with allergic contact dermatitis: A propensity score-matched case-control study.
Br J Dermatol. 2023 Dec 19:ljad504. doi: 10.1093.
PubMed

NASLUND-KOCH C, Skov L
New insights in the complex relationship between psoriasis and vitamin D - and not to forget -obesity!
Br J Dermatol. 2023 Dec 19:ljad506. doi: 10.1093.
PubMed

EGGERMONT CJ, Eggermont AMM
Shifting landscape in skin cancer incidence: the rising tide of cutaneous squamous cell carcinoma and potential implications for prevention.
Br J Dermatol. 2023 Dec 14:ljad480. doi: 10.1093.
PubMed

CONTI A, Paolinelli M
A new approach in monitoring blood tests in anti-TNF-alpha therapies in psoriasis.
Br J Dermatol. 2023 Dec 13:ljad490. doi: 10.1093.
PubMed

ORTONNE N
How to score the impact of treatment on cutaneous neurofibromas in clinical trials?
Br J Dermatol. 2023 Dec 12:ljad492. doi: 10.1093.
PubMed

ISKANDAR IYK, Gawkrodger DJ, Gittins M, Byrne L, et al
Trends in occupational and work-related contact dermatitis attributed to nickel, chromium and cobalt in the UK: findings from The Health and Occupation Research network 1996-2019.
Br J Dermatol. 2023 Dec 7:ljad488. doi: 10.1093.
PubMed Abstract available

THORLACIUS L, Theut Riis P, Musaeus KD, Saunte DM, et al
Severity rating of specific skin lesions in hidradenitis suppurativa - the patient perspective.
Br J Dermatol. 2023 Dec 7:ljad491. doi: 10.1093.
PubMed

SOCKLER PG, Hooper SR, Abuabara K, Ma EZ, et al
Atopic dermatitis, cognitive function, and psychiatric comorbidities across early childhood and adolescence in a population-based UK birth cohort.
Br J Dermatol. 2023 Dec 7:ljad486. doi: 10.1093.
PubMed Abstract available

ALABAS OA, Mason KJ, Yiu ZZN, Warren RB, et al
The association of age at psoriasis onset and HLA-C*06:02 with biologic survival in patients with moderate-to-severe psoriasis: a cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR).
Br J Dermatol. 2023 Dec 5:ljad481. doi: 10.1093.
PubMed Abstract available

WEIDINGER S, Simpson EL, Silverberg JI, Barbarot S, et al
Burden of Atopic Dermatitis in Pediatric Patients: An International Cross-sectional Study.
Br J Dermatol. 2023 Dec 4:ljad449. doi: 10.1093.
PubMed Abstract available

BONE M, Inman GJ
Exon specific oncogenic function of the long non-coding RNA PVT1 in cutaneous squamous cell carcinoma, a promising potential therapeutic target.
Br J Dermatol. 2023 Dec 1:ljad476. doi: 10.1093.
PubMed

November 2023

MOHR C, Li Y, Navsaria LJ, Hinkston CL, et al
Melanoma risk in skin of color patients with a history of a keratinocyte carcinoma.
Br J Dermatol. 2023 Nov 30:ljad474. doi: 10.1093.
PubMed

YU J
Are perinatal antibiotics responsible for atopic dermatitis? The Debate Rages On.
Br J Dermatol. 2023 Nov 30:ljad477. doi: 10.1093.
PubMed

WANG Y, Arbiser JL
Skp2: A new therapeutic target of psoriasis.
Br J Dermatol. 2023 Nov 30:ljad479. doi: 10.1093.
PubMed

KIM M, Choi Y, Lee M, Kang J, et al
Maternal SARS-CoV-2 infection during pregnancy and subsequent risk of atopic dermatitis in offspring: a nationwide birth cohort study in South Korea.
Br J Dermatol. 2023 Nov 30:ljad478. doi: 10.1093.
PubMed

JENSSEN M, Furberg AS, Jorde R, Wilsgaard T, et al
The association between serum 25-hydroxyvitamin D levels and psoriasis in a large population-based cohort, a cross-sectional analysis of The Tromso Study 2015-16.
Br J Dermatol. 2023 Nov 28:ljad472. doi: 10.1093.
PubMed Abstract available

DOBEL T, Schakel K
Transcriptional landscape of macrophages in cutaneous graft-versus-host disease.
Br J Dermatol. 2023 Nov 28:ljad458. doi: 10.1093.
PubMed

GUENIN S, Andrews E, Lebwohl MG
Safety and Efficacy of Dual TYK2 Inhibitor and Monoclonal Antibody Therapy for Psoriasis and Psoriatic Arthritis.
Br J Dermatol. 2023 Nov 27:ljad473. doi: 10.1093.
PubMed

DAND N, Ramessur R
New analyses exploring multimorbidity in psoriasis.
Br J Dermatol. 2023 Nov 27:ljad475. doi: 10.1093.
PubMed

STROBL J, Gail LM, Krecu L, Madad S, et al
Diverse macrophage populations contribute to distinct manifestations of human cutaneous graft-versus-host disease.
Br J Dermatol. 2023 Nov 27:ljad402. doi: 10.1093.
PubMed Abstract available

EWEN T, Husain A, Stefanos N, Barrett P, et al
Validation of Epidermal AMBRA1 and Loricrin (AMBLor) as a prognostic biomarker for non-ulcerated AJCC stage I/II cutaneous melanoma.
Br J Dermatol. 2023 Nov 25:ljad459. doi: 10.1093.
PubMed Abstract available

SHOIMER I, Kleiner O, Manion R, Dutz J, et al
Top 10 research priorities for basal cell carcinoma: results of the Skin Investigation Network of Canada Priority Setting Initiative.
Br J Dermatol. 2023 Nov 21:ljad391. doi: 10.1093.
PubMed

SHAO S, Sun Z, Chu M, Chen J, et al
FPR1 contributes to epidermal barrier dysfunction-induced skin inflammation through NLRC4-dependent keratinocyte activation.
Br J Dermatol. 2023 Nov 18:ljad455. doi: 10.1093.
PubMed Abstract available

KAMMINGA NCW, Wakkee M, Swart I, Nijsten TEC, et al
Determining the core content of a digital survivorship care plan for melanoma survivors: A multi-stakeholder Delphi-consensus study.
Br J Dermatol. 2023 Nov 18:ljad450. doi: 10.1093.
PubMed

RAJ C, Singh S, Gupta A
Psychosocial Impact of Severe Autosomal Recessive Congenital Ichthyosis.
Br J Dermatol. 2023 Nov 17:ljad456. doi: 10.1093.
PubMed

CAZZANIGA S, Simon D
Decoding Atopic Dermatitis: Unveiling Phenotypes Through Data-Driven Methods.
Br J Dermatol. 2023 Nov 17:ljad453. doi: 10.1093.
PubMed

DESSINIOTI C, Stratigos AJ
Decoding the nodular melanoma subtype- what about genetics?
Br J Dermatol. 2023 Nov 17:ljad445. doi: 10.1093.
PubMed

Survival trends in people with melanoma in Sweden.
Br J Dermatol. 2023;189:e108.
PubMed

Improved sleep in adults with atopic dermatitis using the treatment dupilumab.
Br J Dermatol. 2023;189:e106.
PubMed

A clinical trial in children and young people with severe eczema comparing methotrexate with ciclosporin.
Br J Dermatol. 2023;189:e105.
PubMed

Short anagen hair syndrome is caused by mutations in the WNT10A gene and has a genetic overlap with male pattern hair loss.
Br J Dermatol. 2023;189:e112.
PubMed

A roadmap to help with the adoption of core outcome sets in eczema clinical trials.
Br J Dermatol. 2023;189:e109.
PubMed

There are early, gradual and late responders for scalp hair regrowth in patients with alopecia areata treated with baricitinib.
Br J Dermatol. 2023;189:e104.
PubMed

AHMED A, Eleftheriadou V
Global VALIANT study: 'lifting the lid' on disappointment and frustration with the lack of effective treatment for vitiligo.
Br J Dermatol. 2023;189:e99-e102.
PubMed

STERN RS
The limitations of persistence as a measure of efficacy of biologic therapies.
Br J Dermatol. 2023;189:e100-e101.
PubMed

CESARATO N, Schwieger-Briel A, Gossmann Y, Henne SK, et al
Short anagen hair syndrome: association with mono- and biallelic variants in WNT10A and a genetic overlap with male pattern hair loss.
Br J Dermatol. 2023;189:741-749.
PubMed Abstract available

REVANKAR RR, Blum F, Yeung H, Patel HA, et al
Factors influencing patient experience during incision and drainage procedures in hidradenitis suppurativa: an analysis of patient-reported outcomes.
Br J Dermatol. 2023;189:779-780.
PubMed

PETRASCA A, Hambly R, Kearney N, Smith CM, et al
Metformin has anti-inflammatory effects and induces immunometabolic reprogramming via multiple mechanisms in hidradenitis suppurativa.
Br J Dermatol. 2023;189:730-740.
PubMed Abstract available

KUMAR S, Hausen J, Sivalingam S, Humbatova A, et al
Altered Notch signalling in Dowling-Degos disease: a transcriptomic insight into disease pathogenesis.
Br J Dermatol. 2023;189:772-774.
PubMed

YOU Z, Ran Y
Symmetrical sporotrichosis on the face: pathogen spread from the nose along both sides of facial lymphatic vessels?
Br J Dermatol. 2023;189:784-785.
PubMed

SIA T, Webb T, Li S, Moskatel LS, et al
An exploratory comparative case series of calcitonin gene-related peptide monoclonal antibodies in patients with migraine with rosacea.
Br J Dermatol. 2023;189:776-778.
PubMed

LESHEM YA, Simpson EL, Apfelbacher C, Spuls PI, et al
The Harmonising Outcome Measures for Eczema (HOME) implementation roadmap.
Br J Dermatol. 2023;189:710-718.
PubMed Abstract available

CHERREZ-OJEDA I, Thomsen SF, Gimenez-Arnau A
Alexithymia prevalence in individuals with chronic urticaria and its association with illness severity and therapeutic profile.
Br J Dermatol. 2023;189:766-767.
PubMed

MAGHFOUR J, Dzuali F, Ezekwe N, Gordon J, et al
Evaluating the efficacy of continuous wave carbon dioxide laser therapy in conjunction with biologics for the management of hidradenitis suppurativa.
Br J Dermatol. 2023;189:764-783.
PubMed

Correction to: Efficacy and safety of ciclosporin versus methotrexate in the treatment of severe atopic dermatitis in children and young people (TREAT): a multicentre parallel group assessor-blinded clinical trial.
Br J Dermatol. 2023 Nov 16:ljad442. doi: 10.1093.
PubMed

The skin has memory: how it works and how to help it forget.
Br J Dermatol. 2023;189:e103.
PubMed

A study about the presence of Staphylococcus aureus growth at birth and at 2 months of age in children who developed atopic dermatitis in the first 2 years of life.
Br J Dermatol. 2023;189:e107.
PubMed

A non-invasive method using tape stripping for whole-genome skin profiling.
Br J Dermatol. 2023;189:e113.
PubMed

The antidiabetic medicine metformin has beneficial effects in hidradenitis suppurativa.
Br J Dermatol. 2023;189:e111.
PubMed

Interleukin-17A-expressing mast cells in hidradenitis suppurativa.
Br J Dermatol. 2023;189:e110.
PubMed

SACEDON R, de Arriba MC, Martinez-Santamaria L, Maseda R, et al
Gluten-sensitive enteropathy in recessive dystrophic epidermolysis bullosa.
Br J Dermatol. 2023;189:774-776.
PubMed

CHU CB, Yang CC, Hsueh YY, Chen PC, et al
Aberrant expression of interleukin-17A in mast cells contributes to the pathogenesis of hidradenitis suppurativa.
Br J Dermatol. 2023;189:719-729.
PubMed Abstract available

GIAMARELLOS-BOURBOULIS EJ
Interleukin-17A derived from mast cells: evidence for an autoinflammatory loop in hidradenitis suppurativa?
Br J Dermatol. 2023;189:651-652.
PubMed

ONOUFRIADIS A
WNT10A gene variants at the root of short anagen hair syndrome.
Br J Dermatol. 2023;189:653-654.
PubMed

KING B, Shapiro J, Ohyama M, Egeberg A, et al
When to expect scalp hair regrowth during treatment of severe alopecia areata with baricitinib: insights from trajectories analyses of patients enrolled in two phase III trials.
Br J Dermatol. 2023;189:666-673.
PubMed Abstract available

MASON KJ, Alabas OA, Dand N, Warren RB, et al
Characteristics of "Super-Responders" and "Super-Non-Responders" to First Biologic Monotherapy for Psoriasis: A Nested Case-control Study.
Br J Dermatol. 2023 Nov 11:ljad446. doi: 10.1093.
PubMed

WAN J
Changes in the epidemiology of atopic dermatitis: putting them into context.
Br J Dermatol. 2023 Nov 11:ljad443. doi: 10.1093.
PubMed

GORDON KB, Langley RG, Warren RB, Okubo Y, et al
Bimekizumab safety in patients with moderate to severe plaque psoriasis: Pooled data from up to three years of treatment in randomized phase 3 trials.
Br J Dermatol. 2023 Nov 10:ljad429. doi: 10.1093.
PubMed Abstract available

JUNG SY, Han K, Jung JH, Park H, et al
Cumulative exposure to metabolic syndrome affects the risk of psoriasis differently according to age group: a nationwide cohort study in S. Korea.
Br J Dermatol. 2023 Nov 9:ljad441. doi: 10.1093.
PubMed

SHIPMAN WD, Singh K, Cohen JM, Leventhal J, et al
Targeting interleukin (IL)-4/IL-13 in immune checkpoint inhibitor-induced bullous pemphigoid: a cautionary note on the beneficial effect of T helper 2 immunity in melanoma and immunotherapy: reply from the authors.
Br J Dermatol. 2023 Nov 8:ljad342. doi: 10.1093.
PubMed

SMIT AK, Cust AE
Unpacking factors contributing to melanoma overdiagnosis: does polygenic risk play a role?
Br J Dermatol. 2023 Nov 6:ljad431. doi: 10.1093.
PubMed

YOSIPOVITCH G, Lio PA, Rosmarin D, Serra-Baldrich E, et al
Lebrikizumab improved itch and reduced the extent of itch interference on sleep in patients with moderate-to-severe atopic dermatitis: two randomized, placebo-controlled, phase III trials.
Br J Dermatol. 2023 Nov 6:ljad435. doi: 10.1093.
PubMed

RAGAMIN A, Schappin R, de Graaf M, Tupker RA, et al
The effectiveness of antibacterial therapeutic clothing compared with non-antibacterial therapeutic clothing in patients with moderate-to-severe atopic dermatitis: A randomized controlled, observer-blind pragmatic trial (ABC trial).
Br J Dermatol. 2023 Nov 4:ljad437. doi: 10.1093.
PubMed Abstract available

JUMONVILLE G, Hong D, Khan A, DeWan A, et al
Digital biobanks are underutilized in dermatology and create opportunities to reduce the burden of skin disease.
Br J Dermatol. 2023 Nov 4:ljad439. doi: 10.1093.
PubMed

SHIMON SV, Desai K, Miteva M, Nadji M, et al
High Expression of Interleukin-17A in Cutaneous Sarcoidosis.
Br J Dermatol. 2023 Nov 4:ljad438. doi: 10.1093.
PubMed

DOOLAN BJ, McGrath JA, Mellerio JE
Beremagene geperpavec (B-VEC) gene therapy for the treatment of cutaneous wounds in patients with dystrophic epidermolysis bullosa: a critical appraisal.
Br J Dermatol. 2023 Nov 4:ljad433. doi: 10.1093.
PubMed

HAIDER S, Granell R, Curtin JA, Holloway JW, et al
Identification of eczema clusters and their association with filaggrin and atopic comorbidities: analysis of five birth cohorts.
Br J Dermatol. 2023 Nov 3:ljad326. doi: 10.1093.
PubMed Abstract available

MELNIK BC
Metformin attenuates mechanistic target of rapamycin complex 1/hypoxia-inducible factor-1alpha-driven glycolysis reducing keratinocyte and T helper 17 cell proliferation in hyperproliferative inflammatory skin diseases.
Br J Dermatol. 2023 Nov 2:ljad362. doi: 10.1093.
PubMed

LI C, Sun C, Mahapatra KD, Riihila P, et al
Long non-coding RNA PVT1 is overexpressed in cutaneous squamous cell carcinoma and exon 2 is critical for its oncogenicity.
Br J Dermatol. 2023 Nov 1:ljad419. doi: 10.1093.
PubMed Abstract available

October 2023

KAWSAR A, Hussain K, Fearfield L
How to recognize and manage skin toxicities associated with immune checkpoint inhibitors: a practical approach.
Br J Dermatol. 2023;189.
PubMed Abstract available

HUGHES O, Bewley A
Is it really ever 'just acne'? Considering the psychodermatology of acne.
Br J Dermatol. 2023;189.
PubMed Abstract available

AHMED A, Fearfield L, Griffiths TW
Resilience in skin disease.
Br J Dermatol. 2023;189.
PubMed

GRIFFITHS TW, Watson REB, Langton AK
Skin ageing and topical rejuvenation strategies.
Br J Dermatol. 2023;189.
PubMed Abstract available

CHIESA FUXENCH Z, Mitra N, Del Pozo D, Hoffstad O, et al
In utero or early in life exposure to antibiotics and the risk of childhood atopic dermatitis, a population-based cohort study.
Br J Dermatol. 2023 Oct 28:ljad428. doi: 10.1093.
PubMed Abstract available

OLSEN CM, Pandeya N, Ragaini BS, Neale RE, et al
International patterns and trends in the incidence of melanoma and cutaneous squamous cell carcinoma, 1989-2020.
Br J Dermatol. 2023 Oct 27:ljad425. doi: 10.1093.
PubMed Abstract available

CALABRESE L, Fiocco Z, Mellett M, Aoki R, et al
The Role of NLRP1 Inflammasome in Skin Cancer and Inflammatory Skin Diseases.
Br J Dermatol. 2023 Oct 27:ljad421. doi: 10.1093.
PubMed Abstract available

Multiple skin lesions, especially on the legs, predict a poorer prognosis in skin lymphoma with large tumour cells.
Br J Dermatol. 2023;189:e98.
PubMed

Lifetime burden of Stevens-Johnson syndrome/toxic epidermal necrolysis.
Br J Dermatol. 2023;189:e92.
PubMed

Safety and effectiveness of amlitelimab, a potential new treatment for atopic dermatitis: results of a clinical trial.
Br J Dermatol. 2023;189:e90.
PubMed

The effect of extracorporeal photopheresis on cytokines released by leukaemic cutaneous T-cell lymphoma.
Br J Dermatol. 2023;189:e97.
PubMed

Views on vitiligo disease course and treatment among people living with vitiligo and healthcare providers worldwide.
Br J Dermatol. 2023;189:e94.
PubMed

Understanding the biology of cutaneous squamous cell carcinoma.
Br J Dermatol. 2023;189:e96.
PubMed

Comparison of biologic treatments in psoriasis using treatment duration.
Br J Dermatol. 2023;189:e93.
PubMed

Greater understanding about interpreting the Recap of atopic eczema (RECAP) questionnaire.
Br J Dermatol. 2023;189:e95.
PubMed

Comparison of risankizumab with apremilast for the treatment of moderate psoriasis.
Br J Dermatol. 2023;189:e91.
PubMed

OFENLOCH RF
Filling the gap: investigating the interpretability of the Recap of atopic eczema questionnaire.
Br J Dermatol. 2023;189:506-507.
PubMed

SUH-YUN JOH C, Jeong S, Lee C, Lee HJ, et al
Spatial transcriptomic profiling reveals the pathophysiology of early-stage hidradenitis suppurativa.
Br J Dermatol. 2023;189:643-645.
PubMed

KUMAR N, Pourang A, Ezekwe N, Parks-Miller A, et al
A method for assessing rater reliability in applying the Vitiligo Area Scoring Index.
Br J Dermatol. 2023;189:645-647.
PubMed

CHENG Q, Yang F, Xue R, Wang H, et al
Postzygotic gain-of-function variants in FGFR2 in two patients with hair follicle naevus.
Br J Dermatol. 2023;189:641-643.
PubMed

SHIELDS A, Barbieri JS
Effectiveness of spironolactone for women with acne vulgaris (SAFA) trial: a critically appraised topic.
Br J Dermatol. 2023;189:509-510.
PubMed

HAMZAVI IH, Bibeau K, Grimes P, Harris JE, et al
Exploring the natural and treatment history of vitiligo: perceptions of patients and healthcare professionals from the global VALIANT study.
Br J Dermatol. 2023;189:569-577.
PubMed Abstract available

INGEN-HOUSZ-ORO S
Epidermal necrolysis: a chronic disease associated with loss-of-life expectancy and lifetime healthcare expenditure.
Br J Dermatol. 2023;189:505-506.
PubMed

LIU Y, Li Q, Chu C, Zhou Y, et al
Insights into Stevens-Johnson syndrome/toxic epidermal necrolysis lifetime burden: assessing life expectancy, healthcare costs and quality of life.
Br J Dermatol. 2023;189:648.
PubMed

ZHANG J, Ragamin A, Romeijn GLE, Loman L, et al
Validity, reliability, responsiveness and interpretability of the Recap of atopic eczema (RECAP) questionnaire.
Br J Dermatol. 2023;189:578-587.
PubMed Abstract available

CHEN GF, Shaw KS, Sanchez-Melendez S, Vleugels RA, et al
Increased risk of depression in patients with discoid lupus erythematosus: a nested, case-control study in the All of Us Research Program.
Br J Dermatol. 2023;189:628-629.
PubMed

WELFRINGER-MORIN A, Bataille P, Drummond D, Bellon N, et al
Comparison of idiopathic and drug-induced epidermal necrolysis in children.
Br J Dermatol. 2023;189:631-633.
PubMed

LI D, Technau-Hafsi K, Giehl K, Hoeger PH, et al
Targeted anti-interleukin-17 therapy for linear porokeratosis.
Br J Dermatol. 2023;189:630-631.
PubMed

SOW Y, Salame N, Siira MR, Flowers N, et al
Healthcare experiences among patients with hidradenitis suppurativa: a qualitative study.
Br J Dermatol. 2023;189:624-626.
PubMed Abstract available

FERTITTA L, Bergqvist C, Sarin K, Plotkin SR, et al
A core outcome domain set to assess cutaneous neurofibromas related to neurofibromatosis type 1 in clinical trials.
Br J Dermatol. 2023 Oct 25:ljad397. doi: 10.1093.
PubMed Abstract available

CHALITSIOS CV, Meena D, Manou M, Papagiannopoulos C, et al
Multiple long-term conditions in people with psoriasis: a latent class and bidirectional Mendelian randomisation analysis.
Br J Dermatol. 2023 Oct 24:ljad410. doi: 10.1093.
PubMed Abstract available

BERGERON A, Nessim C, Kleiner O, Manion R, et al
SkIN Canada Priority Setting Initiative ranks the Top Ten evidence uncertainties for Merkel cell carcinoma.
Br J Dermatol. 2023 Oct 21:ljad398. doi: 10.1093.
PubMed

VALLEEKANTHAN M, Cree H
Challenges in adult services for a young adult with a rare skin disease.
Br J Dermatol. 2023 Oct 21:ljad403. doi: 10.1093.
PubMed

NYMAND L, Nielsen ML, Vittrup I, Halling AS, et al
Atopic dermatitis phenotypes based on cluster analysis of the Danish Skin Cohort.
Br J Dermatol. 2023 Oct 18:ljad401. doi: 10.1093.
PubMed Abstract available

XIE X, Cui Q, Jiang T, Zhao Z, et al
A Critical Role of Endothelial Skp2/PTEN Axis in Angiogenesis and Psoriasis.
Br J Dermatol. 2023 Oct 18:ljad399. doi: 10.1093.
PubMed Abstract available

LLUCH-GALCERA JJ, Carrascosa JM, Gonzalez-Quesada A, Rivera-Diaz R, et al
Safety of biologic therapy in combination with methotrexate in moderate to severe psoriasis: a cohort study from the BIOBADADERM registry.
Br J Dermatol. 2023 Oct 17:ljad382. doi: 10.1093.
PubMed Abstract available

DRUCKER AM, Lam M, Elsawi R, Prieto-Merino D, et al
Comparing binary efficacy outcomes for systemic immunomodulatory treatments for atopic dermatitis in a living systematic review and network meta-analysis.
Br J Dermatol. 2023 Oct 13:ljad393. doi: 10.1093.
PubMed Abstract available

COLVIN A, Petukhova L
Who has skin in the game? Expanding patient opportunities for research engagement is a win-win for dermatology.
Br J Dermatol. 2023 Oct 13:ljad394. doi: 10.1093.
PubMed

BERGQVIST C
Is there room for another Anti-IL-17 in the Crowded Psoriasis Therapeutic Landscape?
Br J Dermatol. 2023 Oct 12:ljad383. doi: 10.1093.
PubMed

MURPHY MJ, Hwang E, Singh K, Lee T, et al
Machine learning analysis of pre-treatment skin biopsies predicts non-response to dupilumab in patients with eczematous dermatitis.
Br J Dermatol. 2023 Oct 11:ljad389. doi: 10.1093.
PubMed

HAUGAARD JH, Thein D, Egeberg A
Characteristics and Prognosis in First-Time Hospitalized Generalized Pustular Psoriasis Patients: Insights from National Databases.
Br J Dermatol. 2023 Oct 7:ljad384. doi: 10.1093.
PubMed

AUTIER P
Melanoma incidence and COVID-19 lockdowns in the Netherlands.
Br J Dermatol. 2023 Oct 4:ljad376. doi: 10.1093.
PubMed

September 2023

AF KLINTEBERG M, Winberg A, Andersson M, Ronmark E, et al
Decreasing prevalence of atopic dermatitis among Swedish schoolchildren. Three repeated population-based surveys.
Br J Dermatol. 2023 Sep 30:ljad370. doi: 10.1093.
PubMed Abstract available

REYNAUD B, Jacquemus J, Chabaud S, Ouldbey Y, et al
Benefit of skin surgical revision in high-risk basal cell carcinoma according to histopathological margins.
Br J Dermatol. 2023 Sep 28:ljad372. doi: 10.1093.
PubMed

STARK MS, Sturm RA, Pan Y, Smit DJ, et al
Assessing the genetic risk of nodular melanoma using a candidate gene approach.
Br J Dermatol. 2023 Sep 28:ljad365. doi: 10.1093.
PubMed Abstract available

SAKAI A, Shinkuma S, Miura N, Deguchi T, et al
Possible relation of cathepsin C activity and seasonal fluctuation of skin lesions in Papillon-Lefevre syndrome.
Br J Dermatol. 2023 Sep 27:ljad373. doi: 10.1093.
PubMed

Correction to: TMEM232 promotes the inflammatory response in atopic dermatitis via the nuclear factor-kappaB and signal transducer and activator of transcription 3 signalling pathways.
Br J Dermatol. 2023 Sep 23:ljad346. doi: 10.1093.
PubMed

Correction to: Efficacy and safety of topical brepocitinib cream for mild-to-moderate chronic plaque psoriasis: a phase IIb randomized double-blind vehicle-controlled parallel-group study.
Br J Dermatol. 2023 Sep 23:ljad340. doi: 10.1093.
PubMed

SMITH CH, Yiu ZZN, Bale T, Burden AD, et al
British Association of Dermatologists guidelines for biologic therapy for psoriasis 2023 - a pragmatic update.
Br J Dermatol. 2023 Sep 22:ljad347. doi: 10.1093.
PubMed

TOLAND AE
Expanding the feasibility of large genomics skin studies using epidermal DNA collected via tape-stripping.
Br J Dermatol. 2023 Sep 22:ljad360. doi: 10.1093.
PubMed

FLOHR C, Rosala-Hallas A, Jones AP, Beattie P, et al
Efficacy and safety of ciclosporin versus methotrexate in the treatment of severe atopic dermatitis in children and young people (TREAT): a multicentre, parallel group, assessor-blinded clinical trial.
Br J Dermatol. 2023 Sep 19:ljad281. doi: 10.1093.
PubMed Abstract available

The risk of deep-vein blood clots in people with atopic dermatitis (eczema).
Br J Dermatol. 2023;189:e75.
PubMed

A review of major adverse cardiovascular events in patients with atopic dermatitis treated with oral Janus kinase inhibitors.
Br J Dermatol. 2023;189:e69.
PubMed

Gaining a better understanding of the causes of hidradenitis suppurativa.
Br J Dermatol. 2023;189:e77.
PubMed

Clinical trial results for treatment of psoriasis with izokibep.
Br J Dermatol. 2023;189:e70.
PubMed

How common is generalized pustular psoriasis in Malaysia?
Br J Dermatol. 2023;189:e73.
PubMed

Once-daily roflumilast foam for treating scalp and body psoriasis.
Br J Dermatol. 2023;189:e71.
PubMed

Eleven recommendations to support mental health in children and young people with skin conditions.
Br J Dermatol. 2023;189:e78.
PubMed

HERBERT S, Haughton R, Liakos W, Wang J, et al
A qualitative exploration of patient experiences in pyoderma gangrenosum.
Br J Dermatol. 2023;189:496-498.
PubMed

SUHRKAMP I, Gerdes S
The interleukin-1 pathway as a treatment target in early-stage hidradenitis suppurativa?
Br J Dermatol. 2023;189:365-366.
PubMed

MARONESE CA, Ingram JR, Marzano AV
Has the time come to assess small-molecule/biologic drug combinations for the management of moderate-to-severe hidradenitis suppurativa?
Br J Dermatol. 2023;189:467-468.
PubMed

CHANDLER DJ, Yamamoto R, Hay RJ
Use of direct microscopy to diagnose superficial mycoses: a survey of UK dermatology practice.
Br J Dermatol. 2023;189:480-481.
PubMed

ORTNER VK, Zibert JR, Manole I, Mondragon AC, et al
Agreement and reliability of remote assessment of actinic keratosis: a proof-of-concept study using smartphone photographs.
Br J Dermatol. 2023;189:474-475.
PubMed

BRANS R
Promising results for treatment of severe chronic hand eczema with dupilumab.
Br J Dermatol. 2023;189:360-361.
PubMed

HARMAN KE, Barha J, Chalmers JR, Dart JKG, et al
The top 10 research priorities for the treatment of bullous pemphigoid, mucous membrane pemphigoid and pemphigus vulgaris in the UK: results of a James Lind Alliance Priority Setting Partnership.
Br J Dermatol. 2023;189:469-498.
PubMed

VOORBERG AN, Kamphuis E, Christoffers WA, Schuttelaar MLA, et al
Efficacy and safety of dupilumab in patients with severe chronic hand eczema with inadequate response or intolerance to alitretinoin: a randomized, double-blind, placebo-controlled phase IIb proof-of-concept study.
Br J Dermatol. 2023;189:400-409.
PubMed Abstract available

VAN DOORN R
Multiple Primary Melanoma: Risk Factors Reviewed.
Br J Dermatol. 2023 Sep 15:ljad343. doi: 10.1093.
PubMed

NAKAHARA T, Fujita H, Tajima Y, Arima K, et al
Evaluating the usefulness of the Atopic Dermatitis Control Tool for assessing disease control among individuals with atopic dermatitis in Japan.
Br J Dermatol. 2023 Sep 15:ljad344. doi: 10.1093.
PubMed

Patient assessment of psoriasis severity.
Br J Dermatol. 2023;189:e76.
PubMed

Features of very thin melanoma that predict lymph node involvement.
Br J Dermatol. 2023;189:e74.
PubMed

Correction to: Partner bereavement and risk of psoriasis and atopic eczema: cohort studies in the U.K. and Denmark, and to: Partner bereavement and risk of chronic urticaria, alopecia areata and vitiligo: cohort studies in the UK and Denmark.
Br J Dermatol. 2023 Sep 14:ljad338. doi: 10.1093.
PubMed

TIAN J, Zhang D, Yang Y, Huang Y, et al
The global epidemiology of atopic dermatitis: a comprehensive systematic analysis and modelling study.
Br J Dermatol. 2023 Sep 14:ljad339. doi: 10.1093.
PubMed Abstract available

GUERRERO-JUAREZ CF, Goyal PK, Amber KT
Targeting IL-4/IL-13 in immune checkpoint inhibitor induced bullous pemphigoid: a cautionary note on the beneficial effect of Th2 in melanoma and immunotherapy.
Br J Dermatol. 2023 Sep 13:ljad324. doi: 10.1093.
PubMed

GERDES S, Staubach P, Dirschka T, Wetzel D, et al
Izokibep for the treatment of moderate-to-severe plaque psoriasis: a phase II, randomized, placebo-controlled, double-blind, dose-finding multicentre study including long-term treatment.
Br J Dermatol. 2023 Sep 12:ljad186. doi: 10.1093.
PubMed Abstract available

PANDEYA N, Dusingize JC, Olsen CM, MacGregor S, et al
Does genetic risk modify the effect of skin screening on melanoma detection rates?
Br J Dermatol. 2023 Sep 8:ljad333. doi: 10.1093.
PubMed Abstract available

VEYSEY E
Risankizumab vs. apremilast in the era of skin clearance.
Br J Dermatol. 2023 Sep 6:ljad328. doi: 10.1093.
PubMed

ZHANG H, Patrick MT, Tejasvi T, Sarkar MK, et al
Retrospective pharmacogenetic study of psoriasis highlights the role of KLK7 in TNF signaling.
Br J Dermatol. 2023 Sep 6:ljad332. doi: 10.1093.
PubMed Abstract available

FUXENCH ZCC, Wan J, Wang S, Syed MN, et al
Atopic Dermatitis and risk for headache disorders and migraines: a population-based cohort study in children and adults from the United Kingdom.
Br J Dermatol. 2023 Sep 6:ljad325. doi: 10.1093.
PubMed

NGUYEN V, Gao C, Hochman ML, Kravitz J, et al
Endothelial cells differentiated from patient dermal fibroblast-derived induced pluripotent stem cells resemble vascular malformations of Port Wine Birthmark.
Br J Dermatol. 2023 Sep 6:ljad330. doi: 10.1093.
PubMed

JIANG C, Du Y, Liu X, Wang J, et al
Safety, tolerability, pharmacokinetics and efficacy of HB0017, a humanized monoclonal antibody targeting IL-17A, in healthy subjects and patients with moderate to severe plaque psoriasis (PsO).
Br J Dermatol. 2023 Sep 5:ljad315. doi: 10.1093.
PubMed Abstract available

RIDDLE AO, Jambusaria-Pahlajani A
Nicotinamide for Skin-Cancer Chemoprevention in Transplant Recipients: A Critically-appraised Research Paper.
Br J Dermatol. 2023 Sep 4:ljad318. doi: 10.1093.
PubMed

LLOYD-LAVERY A
Nemolizumab to target the itch-scratch cycle in paediatric atopic dermatitis.
Br J Dermatol. 2023 Sep 2:ljad319. doi: 10.1093.
PubMed

BANILA C, Green D, Katsanos D, Viana J, et al
A non-invasive method for whole genome skin methylome profiling.
Br J Dermatol. 2023 Sep 2:ljad316. doi: 10.1093.
PubMed Abstract available

SUI JY, Eichenfield DZ, Sun BK
The Role of Enhancers in Psoriasis and Atopic Dermatitis.
Br J Dermatol. 2023 Sep 2:ljad321. doi: 10.1093.
PubMed Abstract available

LEE EY, Drucker AM
A detailed evaluation of dupilumab's effect on sleep in adults with atopic dermatitis.
Br J Dermatol. 2023 Sep 2:ljad320. doi: 10.1093.
PubMed

WEINER D, Ly A, Talluru S, Munjal A, et al
Efficacy of single-agent chemotherapy with pegylated liposomal doxorubicin or gemcitabine in a diverse cohort of patients with recalcitrant cutaneous T-cell lymphoma.
Br J Dermatol. 2023 Sep 1:ljad311. doi: 10.1093.
PubMed

August 2023

HTET KZ, Griffiths CEM, Lwin SM
Essential Emergency Skincare: A Global Health Dermatology Innovation for Myanmar and Beyond.
Br J Dermatol. 2023 Aug 25:ljad302. doi: 10.1093.
PubMed

ELEFTHERIADOU V, Thompson AR
Skin is a window to one's inner world.
Br J Dermatol. 2023 Aug 25:ljad300. doi: 10.1093.
PubMed

Correction to: Validation of a microRNA liquid biopsy assay for diagnosis and risk stratification of invasive cutaneous melanoma.
Br J Dermatol. 2023 Aug 24:ljad288. doi: 10.1093.
PubMed

Validation of a blood test for melanoma.
Br J Dermatol. 2023;189:e65.
PubMed

The impact of a dose reduction of dupilumab when treating people with well-controlled atopic dermatitis.
Br J Dermatol. 2023;189:e68.
PubMed

Comparison of treatment for psoriasis with methotrexate and adalimumab.
Br J Dermatol. 2023;189:e64.
PubMed

CLAESON M
Real-world data show improved melanoma survival in Sweden.
Br J Dermatol. 2023 Aug 24:ljad309. doi: 10.1093.
PubMed

Greater understanding about the impact of house dust mites in vitiligo.
Br J Dermatol. 2023;189:e67.
PubMed

NG WHS, Smith SD
New considerations and implications with weekly patient-reported symptom monitoring and eczema severity.
Br J Dermatol. 2023;189:e58-e59.
PubMed

PICARDO M
Vitiligo and keratinocytes or keratinocytes and vitiligo?
Br J Dermatol. 2023;189:257.
PubMed

KEARNEY N, Kirby B
Moving toward structured, specialized hidradenitis suppurativa care to improve patient outcomes.
Br J Dermatol. 2023;189:e57-e58.
PubMed

ROESNER LM, Wittmann M
Hand eczema leaves systemic traces.
Br J Dermatol. 2023;189:e56-e59.
PubMed

MALOVITSKI K, Sarig O, Feller Y, Bergson S, et al
Defective cathepsin Z affects EGFR expression and causes autosomal dominant palmoplantar keratoderma.
Br J Dermatol. 2023;189:302-311.
PubMed Abstract available

WILLIAMS JC, Alhusayen R, Guilbault S, Ingram JR, et al
Patient-reported influences on COVID-19 vaccine acceptance and hesitancy in people with hidradenitis suppurativa.
Br J Dermatol. 2023;189:351-353.
PubMed Abstract available

LEIGHTON P, Howells L, Bates J, Gibbons A, et al
Research priorities in the management of hidradenitis suppurativa.
Br J Dermatol. 2023;189:343-345.
PubMed

BELLEFEUILLE G, Paiewonsky B, Khalid B, Freese RL, et al
Worst area local Hidradenitis suppurativa Activity and Severity Index-Revised (W-HASI-R): a study evaluating construct validity.
Br J Dermatol. 2023;189:338-354.
PubMed Abstract available

SHIPMAN WD, Singh K, Cohen JM, Leventhal J, et al
Immune checkpoint inhibitor-induced bullous pemphigoid is characterized by interleukin (IL)-4 and IL-13 expression and responds to dupilumab treatment.
Br J Dermatol. 2023;189:339-341.
PubMed

PHAM JP, Wark KJL, Woods J, Frew JW, et al
Resident cutaneous memory T-cells: A clinical review of their role in chronic inflammatory dermatoses and potential as therapeutic targets.
Br J Dermatol. 2023 Aug 21:ljad303. doi: 10.1093.
PubMed Abstract available

THOMAS SE, van den Reek JMPA, Seyger MMB, de Jong EMGJ, et al
How to define a 'super-responder' to biologics in psoriasis studies?
Br J Dermatol. 2023 Aug 18:ljad280. doi: 10.1093.
PubMed

SONG B, Wu C, Liu W, Wang Y, et al
Integrative serum proteomics analysis reveals distinct immune and cardiovascular profiles dysregulation in erythrodermic psoriasis.
Br J Dermatol. 2023 Aug 16:ljad283. doi: 10.1093.
PubMed

ARENTS BWM, van Zuuren EJ, Hughes O, Fedorowicz Z, et al
The future is now: the Global Atopic Dermatitis Atlas (GADA).
Br J Dermatol. 2023 Aug 11:ljad286. doi: 10.1093.
PubMed

SMITH J, Cust AE, Lo SN
Risk factors for subsequent primary melanoma for patients with previous melanoma: A systematic review and meta-analysis.
Br J Dermatol. 2023 Aug 10:ljad275. doi: 10.1093.
PubMed Abstract available

MEROLA JF, Chiou AS, During E, Costanzo A, et al
Dupilumab significantly improves sleep in adults with atopic dermatitis: results from the 12-week placebo-controlled period of the 24-week phase 4 randomized double-blinded placebo-controlled DUPISTAD study.
Br J Dermatol. 2023 Aug 10:ljad284. doi: 10.1093.
PubMed Abstract available

MIYAGAKI T, Inoue N, Kamijo H, Boki H, et al
Prognostic factors for primary cutaneous anaplastic large cell lymphoma: a multicenter retrospective study from Japan.
Br J Dermatol. 2023 Aug 4:ljad266. doi: 10.1093.
PubMed Abstract available

July 2023

IGARASHI A, Katsunuma T, Matsumura T, Komazaki H, et al
Efficacy and safety of nemolizumab in paediatric patients aged 6-12 years with atopic dermatitis with moderate-to-severe pruritus: Results from a phase III, randomised, double-blind, placebo-controlled, multicentre study.
Br J Dermatol. 2023 Jul 31:ljad268. doi: 10.1093.
PubMed Abstract available

PAN CX, Kim DY, Lau CB, Lau WC, et al
Comparative analysis of immune-related adverse events among patients with melanoma on immune checkpoint inhibitors: A retrospective cohort study.
Br J Dermatol. 2023 Jul 28:ljad271. doi: 10.1093.
PubMed

CHULAROJANAMONTRI L, Panjapakkul W, Chaiyabutr C, Pruksaeakanan C, et al
Blood-based Scoring Systems for Identifying Significant Liver Fibrosis in Psoriasis Patients.
Br J Dermatol. 2023 Jul 28:ljad269. doi: 10.1093.
PubMed

STEIN GOLD LF, Bagel J, Tyring SK, Hong HC, et al
Comparison of risankizumab and apremilast for the treatment of adult patients with moderate plaque psoriasis eligible for systemic therapy: results from a randomised, open-label, assessor-blinded phase IV (IMMpulse) study.
Br J Dermatol. 2023 Jul 25:ljad252. doi: 10.1093.
PubMed Abstract available

PILERI A, Pimpinelli N
The role of the immune system in cutaneous T-cell lymphoma, an area requiring more investigation.
Br J Dermatol. 2023 Jul 24:ljad255. doi: 10.1093.
PubMed

RINNOV MR, Gerner T, Halling AS, Liljendahl MS, et al
The association between S. aureus colonization on cheek skin at 2 months and subsequent atopic dermatitis in a prospective birth cohort.
Br J Dermatol. 2023 Jul 22:ljad249. doi: 10.1093.
PubMed Abstract available

MARCOMBES C, Penso L, Weill A, Dray-Spira R, et al
Persistence of second-line biologics in psoriasis after first-line biologic failure: a nationwide cohort study from the French health insurance database (SNDS).
Br J Dermatol. 2023 Jul 21:ljad248. doi: 10.1093.
PubMed Abstract available

MICEVIC G, Daniels A, Flavell RA
New insights into PD-1 blockade associated cutaneous immune-related adverse events.
Br J Dermatol. 2023 Jul 20:ljad236. doi: 10.1093.
PubMed

THAI AA, Young RJ, Bressel M, Angel C, et al
Comprehensive profiling identifies tumour and immune-microenvironmental differences in clinical subsets of cutaneous squamous cell carcinoma.
Br J Dermatol. 2023 Jul 20:ljad250. doi: 10.1093.
PubMed Abstract available

FAVARO R, Formai A, Pavia G, Gargiulo L, et al
The impact of biologic therapy for moderate-to-severe psoriasis on the immune responses to SARS-CoV2 infection and vaccination.
Br J Dermatol. 2023 Jul 18:ljad242. doi: 10.1093.
PubMed

WEIDINGER S, Bieber T, Cork MJ, Reich A, et al
Safety and efficacy of amlitelimab, a fully human, non-depleting, non-cytotoxic anti-OX40Ligand monoclonal antibody, in atopic dermatitis: results of a phase IIa randomised placebo-controlled trial.
Br J Dermatol. 2023 Jul 18:ljad240. doi: 10.1093.
PubMed Abstract available

SMAK GREGOOR AM, van Egmond S, Nijsten TEC, Wakkee M, et al
Time to reconsider skin cancer related follow-up visits.
Br J Dermatol. 2023 Jul 18:ljad241. doi: 10.1093.
PubMed

VIKSTROM S, Mikiver R, Lapins J, Nielsen K, et al
Increasing melanoma incidence and survival trend shifts with improved melanoma-specific survival between 1990 and 2020 in Sweden.
Br J Dermatol. 2023 Jul 18:ljad244. doi: 10.1093.
PubMed Abstract available

Benefits of treatment with dupilumab for children aged 6-11 years with severe atopic dermatitis.
Br J Dermatol. 2023;189:e39.
PubMed

The impact of weekly eczema symptom assessments on patient outcomes.
Br J Dermatol. 2023;189:e38.
PubMed

Imsidolimab for the treatment of generalized pustular psoriasis.
Br J Dermatol. 2023;189:e37.
PubMed

A review of genetic hair disorders.
Br J Dermatol. 2023;189:e36.
PubMed

LOFVENDAHL S, Norlin JM, Schmitt-Egenolf M
Comorbidities in palmoplantar pustulosis: a Swedish population-based register study.
Br J Dermatol. 2023;189:230-232.
PubMed

BAKER A, Mitchell EJ, Partlett C, Thomas KS, et al
Evaluating the effect of weekly patient-reported symptom monitoring on trial outcomes: results of the Eczema Monitoring Online randomized controlled trial.
Br J Dermatol. 2023;189:180-187.
PubMed Abstract available

MOGHADAM P, Tancrede E, Bouaziz JD, Kallout J, et al
Efficacy and safety of dupilumab in bullous pemphigoid: a retrospective multicentric study of 36 patients.
Br J Dermatol. 2023;189:244-246.
PubMed

SCHULTHEIS M, Staubach P, Nikolakis G, Schollenberger L, et al
A centre-based ambulatory care concept for hidradenitis suppurativa improves disease activity, disease burden and patient satisfaction: results from the randomized controlled EsmAiL trial.
Br J Dermatol. 2023;189:170-179.
PubMed Abstract available

YOTSU RR, Vagamon B, Almamy D, Aka N, et al
Buruli ulcer: application of thermography for remote diagnosis of a neglected tropical disease.
Br J Dermatol. 2023;189:236-238.
PubMed

CHORAGUDI S, Yosipovitch G
Prurigo nodularis is highly linked with neural sensitization disorders of pain among hospitalized adults in the United States - National Inpatient Sample 2016-2019.
Br J Dermatol. 2023;189:240-242.
PubMed

ASFOUR L, Bokhari L, Bhoyrul B, Eisman S, et al
Treatment of moderate-to-severe alopecia areata with baricitinib in preadolescent children.
Br J Dermatol. 2023;189:248-250.
PubMed

SOKOLOFF A, Dykman M, Sokoloff G, Vellody K, et al
If my hidradenitis had a voice, this is what it would say: the perspective of a young woman with Down syndrome and hidradenitis suppurativa.
Br J Dermatol. 2023;189:221-222.
PubMed

MERHI S, Salameh P, Abboud M, Seneschal J, et al
Facial involvement is reflective of patients' global perception of vitiligo extent.
Br J Dermatol. 2023;189:188-194.
PubMed Abstract available

KIRBY JS, Martorell A, Sayed CJ, Alarcon I, et al
Understanding the real-world patient journey and unmet needs of people with hidradenitis suppurativa through social media research.
Br J Dermatol. 2023;189:228-230.
PubMed

ADAMSON SR, Higgins CL, Veysey E
Hailey-Hailey disease (benign familial pemphigus) responsive to treatment with ocrelizumab for multiple sclerosis.
Br J Dermatol. 2023;189:232-234.
PubMed

LAM M, Spuls PI, Leshem YA, Gerbens LAA, et al
Reporting of Harmonising Outcome Measures for Eczema (HOME) Core Outcome Set Instruments in randomized clinical trials for systemic treatments in Atopic Dermatitis.
Br J Dermatol. 2023 Jul 12:ljad237. doi: 10.1093.
PubMed

KEARNEY N, Kirby B
The expanding psoriasis therapeutic landscape - reading and understanding clinical trials.
Br J Dermatol. 2023 Jul 12:ljad238. doi: 10.1093.
PubMed

CHIU YM, Chiu HY
Lifetime risk, life expectancy, loss-of-life expectancy, and lifetime healthcare expenditure for Stevens-Johnson syndrome/toxic epidermal necrolysis in Taiwan: follow-up of a nationwide cohort from 2008 to 2019.
Br J Dermatol. 2023 Jul 10:ljad234. doi: 10.1093.
PubMed Abstract available

THOMAS SE, van den Reek JMPA
Should we prefer biologics over non-biologic agents in psoriasis?
Br J Dermatol. 2023 Jul 9:ljad231. doi: 10.1093.
PubMed

Creating the Scale of Alopecia Areata Distress to measure a wide range of negative emotional, social and relationship disease consequences in adults.
Br J Dermatol. 2023;189:e31.
PubMed

Safety of treatment with guselkumab in clinical trials for up to 5 years in patients with moderate-to-severe plaque psoriasis.
Br J Dermatol. 2023;189:e29.
PubMed

An oncogene-targeted therapy for Merkel cell carcinoma.
Br J Dermatol. 2023;189:e33.
PubMed

The use of biosimilars for psoriasis in the UK and Ireland.
Br J Dermatol. 2023;189:e30.
PubMed

Better understand about circulating biomarkers and disease severity of chronic hand eczema and atopic dermatitis.
Br J Dermatol. 2023;189:e34.
PubMed

Finding treatments to reduce scaling in ichthyosis.
Br J Dermatol. 2023;189:e32.
PubMed

WAN J, Shin DB, Syed MN, Abuabara K, et al
Malignancy risk in patients with atopic dermatitis: a population-based cohort study.
Br J Dermatol. 2023;189:53-61.
PubMed Abstract available

Review of treatments for toenail onychomycosis caused by dermatophytes.
Br J Dermatol. 2023;189:e28.
PubMed

GORBATENKO-ROTH K, Wood S, Johnson M, Wallander I, et al
Beyond health-related quality of life: initial psychometric validation of a new scale for addressing the gap in assessing the full range of alopecia areata psychosocial burden.
Br J Dermatol. 2023;189:71-79.
PubMed Abstract available

GUPTA AK, Venkataraman M, Bamimore MA
Relative impact of traditional vs. newer oral antifungals for dermatophyte toenail onychomycosis: a network meta-analysis study.
Br J Dermatol. 2023;189:12-22.
PubMed Abstract available

LLOYD-LAVERY A
Further evidence for the long-term safety of guselkumab.
Br J Dermatol. 2023;189:10-11.
PubMed

ITO T, Kageyama R
Is the Scale of Alopecia Areata Distress a new method of assessing the psychological burden of alopecia areata?
Br J Dermatol. 2023;189:8.
PubMed

KERVARREC T
From genetic characterization to new potential therapeutic options: targeting Bcl-xL in Merkel carcinoma.
Br J Dermatol. 2023;189:7.
PubMed

ZIEGLER A, Ebstein F, Shamseldin H, Prouteau C, et al
Gain-of-function variants in the KDF1 gene cause hidradenitis suppurativa associated with ectodermal dysplasia by stabilizing IkappaB kinase alpha.
Br J Dermatol. 2023;189:131-132.
PubMed

HENNIES HC
Does the understanding of signalling pathways pave the way to therapies for keratinization disorders?
Br J Dermatol. 2023;189:5-6.
PubMed

KORTE EWH, Welponer T, Kottner J, van der Werf S, et al
Heterogeneity of reported outcomes in epidermolysis bullosa clinical research: a scoping review as a first step towards outcome harmonization.
Br J Dermatol. 2023;189:80-90.
PubMed Abstract available

PETROF G, Martinez AE
Epidermolysis bullosa: time to come together for better outcomes.
Br J Dermatol. 2023;189:5.
PubMed

BURGESS IF, Brunton ER
Head lice: evidence that resistance to physically acting treatments is developing.
Br J Dermatol. 2023;189:144-145.
PubMed

CONNOLLY A, Walsh S, Philippidou M, Salisbury J, et al
Acute hepatic failure in trimethoprim-induced drug rash with eosinophilia and systemic symptoms (DRESS).
Br J Dermatol. 2023;189:140-141.
PubMed

CROWDER D, Herbert S, Haughton R
Psychosocial impact of pyoderma gangrenosum: a patient perspective.
Br J Dermatol. 2023;189:125-128.
PubMed

WARREN RB, Basey V, Lynam A, Curtis C, et al
The risk of venous thromboembolism in atopic dermatitis: A matched cohort analysis in UK primary care.
Br J Dermatol. 2023 Jul 7:ljad212. doi: 10.1093.
PubMed Abstract available

YEN H, Chiu YE
More than skin deep: Getting on the same page for mental health in children and young people with skin conditions.
Br J Dermatol. 2023 Jul 7:ljad232. doi: 10.1093.
PubMed

KWIATKOWSKA D, Reich A
Seeking new topical therapies in psoriasis.
Br J Dermatol. 2023 Jul 7:ljad233. doi: 10.1093.
PubMed

ERTUS C, Scailteux LM, Lescoat A, Berthe P, et al
Major adverse cardiovascular events in patients treated with oral Janus kinase inhibitors for atopic dermatitis: a systematic review and meta-analysis.
Br J Dermatol. 2023 Jul 6:ljad229. doi: 10.1093.
PubMed Abstract available

GOLLINS CE, Coates LC
Validation of a new measure of patient global assessment in psoriasis.
Br J Dermatol. 2023 Jul 6:ljad228. doi: 10.1093.
PubMed

TSAI YC, Schlaepfer T, Ignatova D, Chang YT, et al
Boost of innate immunity cytokines as biomarkers of response to extracorporeal photopheresis in leukaemic cutaneous T-cell lymphoma patients.
Br J Dermatol. 2023 Jul 6:ljad220. doi: 10.1093.
PubMed Abstract available

GIUFFRIDA R, Zanin Poletto G, Guarneri F, Conforti C, et al
Nevus count on the face for the identification of patients with higher risk of melanoma.
Br J Dermatol. 2023 Jul 6:ljad216. doi: 10.1093.
PubMed

OLLECH A, Lefferdink R, Sheth A, Blumstein A, et al
Systemic Immunosuppressive Therapies for Children with Refractory Atopic Dermatitis: A Large Real-Life Cohort Study.
Br J Dermatol. 2023 Jul 5:ljad222. doi: 10.1093.
PubMed

HONG CH, Lee CH
A nationwide UK cohort study reveals an association between atopic dermatitis and venous thromboembolism.
Br J Dermatol. 2023 Jul 5:ljad221. doi: 10.1093.
PubMed

JUNEJO MH, Wolfe I, Patel J, Duus E, et al
Use of the Dermatology Life Quality Index suite of patient reported outcome measures in skin neglected tropical diseases.
Br J Dermatol. 2023 Jul 3:ljad217. doi: 10.1093.
PubMed

RIBERO S, Quaglino P, Roccuzzo G
Predicting progression in very thin melanoma: the challenge of the next decade?
Br J Dermatol. 2023 Jul 3:ljad218. doi: 10.1093.
PubMed

June 2023

TSAI TF
Heterogeneity of generalized pustular psoriasis in multi-ethnic Johor Bahru, Malaysia.
Br J Dermatol. 2023 Jun 28:ljad197. doi: 10.1093.
PubMed

BARRABES-TORRELLA C, Arandes-Marcocci J, Armillas-Lliteras L, Posada-Caez RA, et al
Sarcomatoid transformation of a basal cell carcinoma following treatment with hedgehog inhibitors.
Br J Dermatol. 2023 Jun 28:ljad206. doi: 10.1093.
PubMed

LUO M, Zhu C, Lin J, Lin L, et al
Bidirectional Mendelian randomization analysis did not indicate a causal relationship between atopic dermatitis and COVID-19.
Br J Dermatol. 2023 Jun 27:ljad208. doi: 10.1093.
PubMed

OGAWA-MOMOHARA M, Muro Y, Murase C, Taki T, et al
Allergen-specific IgG4 increase in atopic dermatitis with long-term dupilumab use.
Br J Dermatol. 2023 Jun 27:ljad207. doi: 10.1093.
PubMed

HAN JH, Ju HJ, Kang H, Lee JH, et al
Autoimmune, Inflammatory, Allergic, and Neuropsychiatric Outcomes of Offspring Born to Mothers with Vitiligo: A Nationwide Population-based Birth Cohort Study of Korea.
Br J Dermatol. 2023 Jun 19:ljad196. doi: 10.1093.
PubMed

YU N, Peng C, Zhou J, Gu J, et al
Measurement properties of the Patient Global Assessment numerical rating scale in moderate-to-severe psoriasis.
Br J Dermatol. 2023 Jun 13:ljad188. doi: 10.1093.
PubMed Abstract available

MCPHERSON T, Ravenscroft J, Ali R, Barlow R, et al
British Society for Paediatric and Adolescent Dermatology (BSPAD) assessment and support of mental health in children and young people (CYP) with skin conditions: A multi-disciplinary expert consensus statement and recommendations.
Br J Dermatol. 2023 Jun 9:ljad193. doi: 10.1093.
PubMed Abstract available

KAKISH H, Sun J, Zheng DX, Ali Ahmed F, et al
Predictors of Sentinel Lymph Node Metastasis in Very Thin Invasive Melanomas.
Br J Dermatol. 2023 Jun 8:ljad195. doi: 10.1093.
PubMed Abstract available

AKIYAMA M
Cathepsin and cutaneous disorders of cornification and inflammation: Their close links.
Br J Dermatol. 2023 Jun 8:ljad190. doi: 10.1093.
PubMed

LAX SJ, Roberts A, Cliffe E, Ramesh G, et al
Public views are needed for skin colour scales.
Br J Dermatol. 2023 Jun 8:ljad189. doi: 10.1093.
PubMed

AGUILAR-CALDERON PE, Reyes-Soto MA, Sanchez-Meza E, Brown-Herrera A, et al
Melanonychia as a manifestation of chronic lead poisoning.
Br J Dermatol. 2023 Jun 7:ljad194. doi: 10.1093.
PubMed

KIRCIK LH, Alonso-Llamazares J, Bhatia N, Bukhalo M, et al
Once-daily roflumilast foam 0.3% for scalp and body psoriasis: A randomized, double-blind, vehicle-controlled phase 2b study.
Br J Dermatol. 2023 Jun 5:ljad182. doi: 10.1093.
PubMed Abstract available

VERGARA IA, Stark MS
One Step Closer to Improving Melanoma Diagnosis and Prognosis with Liquid Biopsies.
Br J Dermatol. 2023 Jun 3:ljad185. doi: 10.1093.
PubMed

May 2023

MORAN B, Smith CM, Zabarowski A, Ryan M, et al
Targeting the NLRP3 inflammasome reduces inflammation in hidradenitis suppurativa skin.
Br J Dermatol. 2023 May 27:ljad184. doi: 10.1093.
PubMed Abstract available

MUTO Y, Kambayashi Y, Kato H, Fukushima S, et al
Postoperative adjuvant therapy for120 melanoma patients, including acral and mucosal subtypes: A multicenter, observational study of two-year follow-up results.
Br J Dermatol. 2023 May 27:ljad183. doi: 10.1093.
PubMed

LAWSON A, Wininger M, Wang M, Steger M, et al
Premenarchal Lichen Sclerosus: A Multicenter Examination of the Novel Diagnostic Tool, the SWIFT Model.
Br J Dermatol. 2023 May 26:ljad180. doi: 10.1093.
PubMed

ALABAS OA, Mason KJ, Yiu ZZN, Warren RB, et al
Effectiveness and survival of methotrexate versus adalimumab in patients with moderate-to-severe psoriasis: A cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR).
Br J Dermatol. 2023 May 25:ljad179. doi: 10.1093.
PubMed Abstract available

Results from 1 year of treatment with lebrikizumab for atopic dermatitis.
Br J Dermatol. 2023;188:e43.
PubMed

Skin cancer incidence and survival rates in England, 2013-2019.
Br J Dermatol. 2023;188:e45.
PubMed

Atopic eczema: palmar patterns associated with filaggrin variants, disease severity and barrier function in a South Asian population.
Br J Dermatol. 2023;188:e46.
PubMed

Atopic dermatitis across the globe: differences in prevalence and access to treatments.
Br J Dermatol. 2023;188:e42.
PubMed

PANDYA R, Kleitsch J, Werth VP
Trial of intravenous immunoglobulin in dermatomyositis: a critically appraised research paper.
Br J Dermatol. 2023;188:738-739.
PubMed

GARG A, Rawal S, Akilov O, Alavi A, et al
Factors associated with disease-specific life impact in patients with hidradenitis suppurativa: results from the Global VOICE project.
Br J Dermatol. 2023;188:808-810.
PubMed

ALONSO-ALONSO R, Rodriguez M, Garcia-Diaz N, Tomas-Roca L, et al
NanoString analysis of mycosis fungoides reveals individual molecular identity.
Br J Dermatol. 2023;188:812-814.
PubMed

O'CONNELL KA, Schaefer M, Atzmony L, Vleugels RA, et al
Clinical features in adults with acquired cutis laxa: a retrospective review.
Br J Dermatol. 2023;188:800-816.
PubMed

THOMAS BR, Tan XL, Van Duijvenboden S, Hogan SC, et al
Deep palmar phenotyping in atopic eczema: patterns associated with filaggrin variants, disease severity and barrier function in a South Asian population.
Br J Dermatol. 2023;188:785-792.
PubMed Abstract available

CHOSIDOW O, Chang AY
The skin of people experiencing homelessness: more (known) is less (neglected).
Br J Dermatol. 2023;188:694-695.
PubMed

Two melanoma genes (MITF and MC1R) interact to cause different risks.
Br J Dermatol. 2023;188:e44.
PubMed

BECHMAN K, Hayes JF, Mathewman J, Henderson A, et al
Electronic screening for mental illness in patients with psoriasis.
Br J Dermatol. 2023 May 24:ljad141. doi: 10.1093.
PubMed

HIJNEN D, Olydam J
Prediction of response to dupilumab treatment.
Br J Dermatol. 2023;188:e41.
PubMed

POGORZELSKA-DYRBUS J, Szepietowski JC
Melanoma cells in optical super-high magnification dermoscopy.
Br J Dermatol. 2023 May 22:ljad168. doi: 10.1093.
PubMed

Correction to: 319 Effects of omega-3 fatty acid supplementation on atopic dermatitis.
Br J Dermatol. 2023 May 22:ljad154. doi: 10.1093.
PubMed

TAKEICHI T, Ito Y, Lee JYW, Murase C, et al
KLK11 ichthyosis: large truncal hyperkeratotic pigmented plaques underscore a distinct autosomal dominant disorder of cornification.
Br J Dermatol. 2023 May 22:ljad082. doi: 10.1093.
PubMed

VROOM IR, Hulshof MA, Schelhaas W, Koning SN, et al
Differences and similarities in teledermatological primary care case histories between people with skin of color and White skin.
Br J Dermatol. 2023 May 20:ljad164. doi: 10.1093.
PubMed

ROMITI R, Martins LPF, Santana YRT, Timbo RV, et al
Prevalence of psoriasis and other autoimmune skin diseases in a recently contacted Amerindian community in the Auaris region, Yanomami territory, Brazil.
Br J Dermatol. 2023 May 20:ljad165. doi: 10.1093.
PubMed

SPEKHORST LS, Boesjes CM, Loman L, Zuithoff NPA, et al
Successful tapering of dupilumab in atopic dermatitis patients with low disease activity: a large pragmatic daily practice study from the BioDay registry.
Br J Dermatol. 2023 May 13:ljad159. doi: 10.1093.
PubMed Abstract available

PETERKNECHT E, Scarisbrick J
Skin Swabs in the Skin Lymphoma Clinic - From Swab to Treatment.
Br J Dermatol. 2023 May 13:ljad160. doi: 10.1093.
PubMed

CHOON SE, Wright AK, Griffiths CEM, Wong KW, et al
Incidence and prevalence of generalised pustular psoriasis in multi-ethnic Johor Bahru, Malaysia: a population-based cohort study using routinely captured electronic health records in Teleprimary Care (TPC(R)) clinical information system from 2010 to
Br J Dermatol. 2023 May 10:ljad158. doi: 10.1093.
PubMed Abstract available

CRANWELL WC, Sinclair RD
Can brepocitinib be formulated into an effective topical therapy to treat mild-to-moderate chronic plaque psoriasis?
Br J Dermatol. 2023 May 8:ljad157. doi: 10.1093.
PubMed

DAN J, Sprow G, Concha J, Patel J, et al
A comparison of the efficacy of Skindex-16 and Skindex-29 in dermatomyositis.
Br J Dermatol. 2023 May 5:ljad133. doi: 10.1093.
PubMed

VAN LAAR R, Latif B, King S, Love C, et al
Validation of microRNA Liquid Biopsy for Diagnosis and Risk Stratification of Invasive Cutaneous Melanoma.
Br J Dermatol. 2023 May 5:ljad137. doi: 10.1093.
PubMed Abstract available

BZIOUECHE H, Boniface K, Drullion C, Marchetti S, et al
Impact of House-Dust-Mite in Vitiligo Skin: Environmental Contribution to Increased Cutaneous Immunity and Melanocyte Detachment.
Br J Dermatol. 2023 May 4:ljad148. doi: 10.1093.
PubMed Abstract available

FREEMAN EE, Garcia-Doval I, Naldi L, Hay RJ, et al
COVID-19 and the skin, three years on: long term impacts, emerging trends and clinical practice.
Br J Dermatol. 2023 May 3:ljad131. doi: 10.1093.
PubMed

PATRA S, Karat TP, Kaur M
Buried dermal interrupted or vertical mattress: what to prefer for dermal layer suturing of surgical skin wounds?
Br J Dermatol. 2023 May 3:ljad132. doi: 10.1093.
PubMed

Correction to: Local cutaneous refractoriness to sun exposure following omalizumab injections in solar urticaria.
Br J Dermatol. 2023 May 2:ljad130. doi: 10.1093.
PubMed

April 2023

FLOHR C, Irvine AD, Cork MJ, Simpson EL, et al
Dupilumab improves patient-reported symptoms and health-related quality of life in children aged 6-11 years with severe atopic dermatitis.
Br J Dermatol. 2023 Apr 30:ljad124. doi: 10.1093.
PubMed

WARREN RB, Reich A, Kaszuba A, Placek W, et al
Imsidolimab, an Anti-IL-36 Receptor Monoclonal Antibody for the Treatment of Generalised Pustular Psoriasis: Results from the Phase 2 GALLOP Trial.
Br J Dermatol. 2023 Apr 30:ljad083. doi: 10.1093.
PubMed Abstract available

ARENTS BWM
Intriguing findings on lebrikizumab for treating moderate-to-severe atopic dermatitis.
Br J Dermatol. 2023 Apr 24:ljad068. doi: 10.1093.
PubMed

BAO C, Xu Q, Xiao Z, Wang H, et al
Abrocitinib as a novel treatment for lichen sclerosus.
Br J Dermatol. 2023 Apr 24:ljad129. doi: 10.1093.
PubMed

GLEESON D, Mahil SK
Imsidolimab: an emerging biologic therapy for generalised pustular psoriasis.
Br J Dermatol. 2023 Apr 20:ljad128. doi: 10.1093.
PubMed

Immunity 6 months after COVID-19 vaccination in patients with psoriasis treated with immunomodulatory drugs.
Br J Dermatol. 2023;188:e38.
PubMed

Serum biomarker analysis to identify subtypes of atopic dermatitis in China and to help with predicting the effectiveness of treatment with dupilumab.
Br J Dermatol. 2023;188:e37.
PubMed

The real-world effectiveness and persistence of acitretin, ciclosporin, fumaric acid esters and methotrexate for treating moderate-to-severe psoriasis.
Br J Dermatol. 2023;188:e35.
PubMed

Neutrophil migration in hidradenitis suppurativa.
Br J Dermatol. 2023;188:e36.
PubMed

WOLK K
Hope for a new therapy for hidradenitis suppurativa: blocking of granulocyte colony-stimulating factor receptor.
Br J Dermatol. 2023;188:590.
PubMed

DUDINK K, Bouwman K, Chen Y, DePrimo SE, et al
Guselkumab for hidradenitis suppurativa: a phase II, open-label, mode-of-action study.
Br J Dermatol. 2023;188:601-609.
PubMed Abstract available

STARRETT GJ, Lee JW, Chatterjee S, Jedrych JJ, et al
Detection of extensive host-virus DNA hybrids in human polyomavirus 7-associated pruritic rash.
Br J Dermatol. 2023;188:675-677.
PubMed

MENDES-BASTOS P, Martorell A, Bettoli V, Matos AP, et al
The use of ultrasound and magnetic resonance imaging in the management of hidradenitis suppurativa: a narrative review.
Br J Dermatol. 2023;188:591-600.
PubMed Abstract available

WARK KJL, Der Sarkissian SA, Tatian A, Woods J, et al
The association between pilonidal sinus disease and hidradenitis suppurativa: a systematic review and meta-analysis.
Br J Dermatol. 2023;188:673-675.
PubMed

SCHUSTER B, Gallinger J, Philipp-Dormston WG, Vasel M, et al
Less confident, successful and happy: patients with post-acne hyperpigmentation are stigmatized.
Br J Dermatol. 2023;188:682-684.
PubMed

FREW JW
In search of therapeutic biomarkers to interleukin-23 antagonism in hidradenitis suppurativa.
Br J Dermatol. 2023;188:588-589.
PubMed

SANTOS LL, Zhu Z, Brown K, Kirby JS, et al
Initial validation of the Hidradenitis Suppurativa Quality of Life tool in a clinical trial setting.
Br J Dermatol. 2023;188:672-673.
PubMed

GAMELL C, Bankovacki A, Scalzo-Inguanti K, Sedgmen B, et al
CSL324, a granulocyte colony-stimulating factor receptor antagonist, blocks neutrophil migration markers that are upregulated in hidradenitis suppurativa.
Br J Dermatol. 2023;188:636-648.
PubMed Abstract available

VALENTI M, Costanzo A
Nonadherence to immune-modifying therapies during the COVID-19 pandemic: the crucial role of doctor-patient communication in avoiding drug discontinuation.
Br J Dermatol. 2023;188:586-590.
PubMed

BURDEN AD, Bachelez H, Choon SE, Marrakchi S, et al
The Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) score: online assessment and validation study of a specific measure of GPP disease activity.
Br J Dermatol. 2023 Apr 19:ljad071. doi: 10.1093.
PubMed

BEN ABDALLAH H, Johansen C
Transmembrane protein 232 (TMEM232) regulates inflammation in experimental models of atopic dermatitis.
Br J Dermatol. 2023 Apr 17:ljad127. doi: 10.1093.
PubMed

TAKEICHI T, Muro Y, Akiyama M
Ichthyotic skin phenotype induced by the chronic activation of Toll-like receptor 2, and autoinflammation.
Br J Dermatol. 2023 Apr 17:ljad122. doi: 10.1093.
PubMed

LALLAS A
Which melanoma patients are at priority for monitoring to detect new primary melanoma?
Br J Dermatol. 2023 Apr 17:ljad125. doi: 10.1093.
PubMed

SBIDIAN E
A multistep approach from scoping review to strong evidence: biomarkers in psoriasis.
Br J Dermatol. 2023 Apr 13:ljac101. doi: 10.1093.
PubMed

QUAADE AS, Wang X, Solberg JBK, Ulrich NH, et al
Circulating biomarkers are associated with disease severity of chronic hand eczema and atopic dermatitis.
Br J Dermatol. 2023 Apr 13:ljad110. doi: 10.1093.
PubMed Abstract available

DESCATHA A, Ezzedine K, Le Roux G
A case of Paederus Dermatitis in Western Europe: a signal for One Health -One World concept for the dermatologist.
Br J Dermatol. 2023 Apr 13:ljad103. doi: 10.1093.
PubMed

KELLY L, Coote L, Dinnes J, Fleming C, et al
Key issues when considering adopting a skin cancer diagnostic tool which uses artificial intelligence.
Br J Dermatol. 2023 Apr 12:ljad080. doi: 10.1093.
PubMed

VITTRUP I
Malignancy risk in atopic dermatitis: heterogenous effects and perspectives.
Br J Dermatol. 2023 Apr 11:ljad119. doi: 10.1093.
PubMed

IBRAHIM LS, Venables ZC, McPhail S, Levell NJ, et al
Missing melanomas in England during the COVID-19 pandemic: 2,485 fewer melanoma diagnoses in 2020 than in 2019.
Br J Dermatol. 2023 Apr 10:ljad117. doi: 10.1093.
PubMed

GRIFFIN L, O'Reilly P, Murphy M, Prendergast G, et al
Photoprotection and Skin Cancer Education - the Experiences of Renal Transplant Recipients, a qualitative study. Why the 'personal touch' is important.
Br J Dermatol. 2023 Apr 6:ljad116. doi: 10.1093.
PubMed

LEBWOHL MG, Merola JF, Rowland K, Miller M, et al
Safety of Guselkumab Treatment for up to 5 Years in Patients With Moderate-to-Severe Psoriasis: Pooled Analyses Across Seven Clinical Trials With Greater Than 8600 Patient-Years of Exposure.
Br J Dermatol. 2023 Apr 6:ljad115. doi: 10.1093.
PubMed Abstract available

FUJISAWA Y, Namikawa K, Yoshino K, Kiniwa Y, et al
Combined use of nivolumab and ipilimumab among Japanese melanoma patients: Multi-center, retrospective study of 111 cases.
Br J Dermatol. 2023 Apr 5:ljad114. doi: 10.1093.
PubMed

PHAN DB, Bewley AP, Smith CH, Mackenzie T, et al
Uptake of tumour necrosis factor-alpha inhibitor biosimilars for psoriasis: A drug utilisation study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR).
Br J Dermatol. 2023 Apr 5:ljad107. doi: 10.1093.
PubMed Abstract available

SPELMAN L
Safety and longevity of biologic treatment in the setting of moderate to severe psoriasis - enhancing the body of evidence.
Br J Dermatol. 2023 Apr 3:ljad112. doi: 10.1093.
PubMed

GUNTHER C
Rapid response of cutaneous lupus erythematosus to treatment with the type I interferon receptor antagonist anifrolumab.
Br J Dermatol. 2023 Apr 1:ljad111. doi: 10.1093.
PubMed

March 2023

TORRELO A, Rewerska B, Galimberti M, Paller A, et al
Efficacy and safety of baricitinib in combination with topical corticosteroids in pediatric patients with moderate-to-severe atopic dermatitis with inadequate response to topical corticosteroids: results from a phase 3, randomized, double-blind, place
Br J Dermatol. 2023 Mar 31:ljad096. doi: 10.1093.
PubMed Abstract available

Factors associated with mental illness in adults with atopic eczema or psoriasis.
Br J Dermatol. 2023;188:e27.
PubMed

Quality of life of Bangladeshi children and young adults with atopic eczema and their families in East London.
Br J Dermatol. 2023;188:e33.
PubMed

Parent and child experiences of skin conditions and views on mindfulness-based support.
Br J Dermatol. 2023;188:e32.
PubMed

Effects of air pollution on psoriasis in Wuhan, China.
Br J Dermatol. 2023;188:e30.
PubMed

Use of proton pump inhibitors in people taking BRAF/MEK inhibitors for metastatic melanoma.
Br J Dermatol. 2023;188:e29.
PubMed

What do parents/carers of children with eczema and young people with eczema think of two websites to help them to manage eczema?
Br J Dermatol. 2023;188:e31.
PubMed

KRIDIN K, Mruwat N, Amber KT, Ludwig RJ, et al
Risk of infections in patients with pemphigus treated with rituximab vs. azathioprine or mycophenolate mofetil: a large-scale global cohort study.
Br J Dermatol. 2023;188:499-505.
PubMed Abstract available

BOZONNAT A, Polivka L, Leclerc-Mercier S, Luscan R, et al
Severe tracheal involvement in type XVII collagen junctional epidermolysis bullosa.
Br J Dermatol. 2023;188:564-566.
PubMed

DRUMM C, Chawla S, Kravvas G, Spencer A, et al
Representation of genital dermatoses in dermatological literature.
Br J Dermatol. 2023;188:563-564.
PubMed

PIMENTEL MA, Li MM, Noe MH, Latour E, et al
Features that define clinical severity of ulcerative pyoderma gangrenosum: a Delphi consensus study of experts and patients on behalf of the US Medical Dermatology Society.
Br J Dermatol. 2023;188:566-568.
PubMed

GREENWELL K, Sivyer K, Howells L, Steele M, et al
'Eczema shouldn't control you; you should control eczema': qualitative process evaluation of online behavioural interventions to support young people and parents/carers of children with eczema.
Br J Dermatol. 2023;188:506-513.
PubMed Abstract available

TAWFIK SS, Thomas BR, Kelsell DP, Grigg J, et al
Dermatology Quality of Life Index scores in Bangladeshi patients with atopic eczema and their families in East London.
Br J Dermatol. 2023;188:524-532.
PubMed Abstract available

STEYN M, Ayis S, O'Connor J, Lakhan MK, et al
Dapsone therapy for hidradenitis suppurativa: a retrospective review of characteristics and treatment outcomes in a cohort of 122 patients in a tertiary dermatology setting.
Br J Dermatol. 2023;188:573-574.
PubMed

CAZZANIGA S, Naldi L, Borradori L
Rituximab and risk of infections in patients with pemphigus: answers from a global population-based cohort study.
Br J Dermatol. 2023;188:454-455.
PubMed

MAGIN P, Fisher K
Online behavioural interventions for children and young people with atopic eczema: refining the way forward.
Br J Dermatol. 2023;188:453.
PubMed

GLEESON D, Barker JNWN, Capon F, Pink AE, et al
Are Janus kinase inhibitors an effective treatment for palmoplantar pustulosis? A critically appraised topic.
Br J Dermatol. 2023;188:471-473.
PubMed

JIANG SW, Petty AJ, Jacobs JL, Robinson C, et al
Association between age at symptom onset and disease severity in older patients with hidradenitis suppurativa.
Br J Dermatol. 2023;188:555-576.
PubMed

BELZER A, Leasure AC, Damsky W, Cohen JM, et al
The association of anxiety with granuloma annulare: a case-control study of the National Institutes of Health 'All of Us' research programme.
Br J Dermatol. 2023;188:558-560.
PubMed Abstract available

VANCE TM, Li T, Cho E, Drucker AM, et al
Prenatal antibiotic use and subsequent risk of atopic eczema.
Br J Dermatol. 2023;188:561-563.
PubMed

CAPOZZA K
Lost in translation: understanding the experience of atopic eczema among non-English-speaking families.
Br J Dermatol. 2023;188:456-457.
PubMed

DIFFEY BL
Sun protection: false beliefs and misguided advocacy.
Br J Dermatol. 2023;188:552-554.
PubMed

BLAUVELT A, Thyssen JP, Guttman-Yassky E, Bieber T, et al
Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials.
Br J Dermatol. 2023 Mar 30:ljad022. doi: 10.1093.
PubMed Abstract available

Potential new solution to reduce skin complications and improve quality of life in people living with a stoma.
Br J Dermatol. 2023;188:e28.
PubMed

ASCOTT A, van Bodegraven B, Vernon S, Orteu CH, et al
The geographical variation of melanoma, basal and squamous cell carcinoma in England.
Br J Dermatol. 2023 Mar 30:ljad100. doi: 10.1093.
PubMed

FAN K, Srinivas N, Kubat L, Gravemeyer J, et al
B-cell lymphoma extra-large (Bcl-xL) is a promising drug target in Merkel cell carcinoma.
Br J Dermatol. 2023 Mar 30:ljad099. doi: 10.1093.
PubMed Abstract available

DOOLAN BJ, Rayinda T, Chiu FP, McGrath JA, et al
A review of genotrichoses and hair pathology associated with inherited skin diseases.
Br J Dermatol. 2023 Mar 29:ljad102. doi: 10.1093.
PubMed Abstract available

BRUNO W
Joint contribution of MC1R and MITF alleles to melanoma risk in the age of polygenic risk scores.
Br J Dermatol. 2023 Mar 28:ljad097. doi: 10.1093.
PubMed

TAGOE H, Hassan S, Youssef G, Heywood W, et al
Chronic activation of Toll-like receptor 2 induces an ichthyotic skin phenotype.
Br J Dermatol. 2023 Mar 27:ljad095. doi: 10.1093.
PubMed Abstract available

LANDIS MN, Smith SR, Berstein G, Fetterly G, et al
Efficacy and safety of topical brepocitinib cream for mild-to-moderate chronic plaque psoriasis: a phase IIb, randomised, double-blind, vehicle-controlled, parallel-group study.
Br J Dermatol. 2023 Mar 27:ljad098. doi: 10.1093.
PubMed Abstract available

STROBER B, Tada Y, Mrowietz U, Lebwohl M, et al
Bimekizumab maintenance of response through three years in patients with moderate to severe plaque psoriasis: Results from the BE BRIGHT open-label extension trial.
Br J Dermatol. 2023 Mar 27:ljad035. doi: 10.1093.
PubMed Abstract available

NI Y, Watts CG, Scolyer RA, Madronio C, et al
Risk of developing a second primary melanoma after a first primary melanoma in a population-based Australian cohort.
Br J Dermatol. 2023 Mar 22:ljad076. doi: 10.1093.
PubMed

SINIKUMPU SP, Jokelainen J, Huilaja L
The association between atopic dermatitis and acne: a retrospective Finnish nationwide registry study.
Br J Dermatol. 2023 Mar 22:ljad086. doi: 10.1093.
PubMed

RAGAMIN A, Tupker RA, de Graaf M, Rustemeyer T, et al
Investigator Global Assessment for impetiginization in Atopic Dermatitis (IGA impetiginization): Development and initial reliability testing.
Br J Dermatol. 2023 Mar 22:ljad085. doi: 10.1093.
PubMed

CARTER LM, Wigston Z, Laws P, Vital EM, et al
Rapid efficacy of anifrolumab across multiple subtypes of recalcitrant cutaneous lupus erythematosus parallels changes in discrete subsets of blood transcriptomic and cellular biomarkers.
Br J Dermatol. 2023 Mar 22:ljad089. doi: 10.1093.
PubMed Abstract available

BLAUVELT A, Thaci D, Papp KA, Ho V, et al
Safety of guselkumab in patients with psoriasis with a history of malignancy: 5-year results from the VOYAGE 1 and VOYAGE 2 trials.
Br J Dermatol. 2023 Mar 22:ljad081. doi: 10.1093.
PubMed

PATHMARAJAH P, Corso R, Salam A, Shah G, et al
Neutropenia in patients on dupilumab for atopic dermatitis: a case series and review of trial data.
Br J Dermatol. 2023 Mar 17:ljad038. doi: 10.1093.
PubMed

HAN J, Cai X, Qin S, Zhang Z, et al
TMEM232 Promotes the Inflammatory Response in Atopic Dermatitis via NF-kappaB and STAT3 Signaling Pathways.
Br J Dermatol. 2023 Mar 17:ljad078. doi: 10.1093.
PubMed Abstract available

SINGH N, Schikowski T
Skin diseases and emerging determinants: the need for interactive research.
Br J Dermatol. 2023 Mar 14:ljad008. doi: 10.1093.
PubMed

DE VRIES E
The important but difficult exercise of getting valid descriptive skin cancer data.
Br J Dermatol. 2023 Mar 10:ljad065. doi: 10.1093.
PubMed

DRAELOS ZD, Adam DN, Hong CH, Lebwohl MG, et al
Efficacy and safety of roflumilast cream for chronic plaque psoriasis with facial/neck and intertriginous area involvement: a post hoc analysis from a randomized controlled trial.
Br J Dermatol. 2023 Mar 9:ljad060. doi: 10.1093.
PubMed

MOSAM A, Todd G
Global epidemiology and disparities in atopic dermatitis.
Br J Dermatol. 2023 Mar 7:ljad042. doi: 10.1093.
PubMed Abstract available

WALLINGFORD CK, Demeshko A, Krishnankutty Krishnakripa A, Smit DJ, et al
MC1R 'r' allele does not increase melanoma risk in MITF E318K carriers.
Br J Dermatol. 2023 Mar 5:ljad041. doi: 10.1093.
PubMed Abstract available

DE DIOS MA, Arroyo-Andres J, Rubio-Muniz C, Concepcion Garrido M, et al
Cutaneous features at injection sites of intravenous mephedrone.
Br J Dermatol. 2023 Mar 5:ljad064. doi: 10.1093.
PubMed

OLSEN CM, Gordon LG, Carter SM, Whiteman DC, et al
The ethical implications of opportunistic detection of melanoma in clinical care.
Br J Dermatol. 2023 Mar 3:ljad055. doi: 10.1093.
PubMed

GHIASVAND R, Berge LAM, Andreassen BK, Green AC, et al
Statin use and risk of cutaneous melanoma: A nationwide nested case-control study.
Br J Dermatol. 2023 Mar 3:ljad057. doi: 10.1093.
PubMed

DRUCKER AM
Atopic dermatitis in 2023 and beyond.
Br J Dermatol. 2023 Mar 2:ljad053. doi: 10.1093.
PubMed

February 2023

VAN BODEGRAVEN B, Vernon S, Eversfield C, Board R, et al
"Get Data Out" Skin: national cancer registry incidence and survival rates for all registered skin tumour groups for 2013-2019 in England.
Br J Dermatol. 2023 Feb 23:ljad033. doi: 10.1093.
PubMed Abstract available

Greater understanding about other diseases that are closely linked to having a diagnosis of psoriasis.
Br J Dermatol. 2023;188:e23.
PubMed

Atopic dermatitis and school performance in children and young adults.
Br J Dermatol. 2023;188:e21.
PubMed

New findings about what drives inflammation in hidradenitis suppurativa may lead to new treatments.
Br J Dermatol. 2023;188:e24.
PubMed

Skin cancer and ultraviolet-radiation exposure in different jobs.
Br J Dermatol. 2023;188:e22.
PubMed

JAYASINGHE D, Koh U, Plasmeijer EI, Menzies SW, et al
The dynamic nature of naevi in adulthood: prospective population-based study using three-dimensional total-body photography.
Br J Dermatol. 2023;188:437-439.
PubMed

FAN B, Wang M
Tofacitinib in recalcitrant bullous pemphigoid: a report of seven cases.
Br J Dermatol. 2023;188:432-434.
PubMed

NILSSON SF, Ali Z, Laursen TM, Thyssen JP, et al
Association of homelessness and skin conditions: A Danish population-based cohort study.
Br J Dermatol. 2023 Feb 22:ljad040. doi: 10.1093.
PubMed Abstract available

VALENTI M, Costanzo A
Efficacy and safety of switching psoriatic patients to bimekizumab: new evidence from clinical trials.
Br J Dermatol. 2023;188:316-317.
PubMed

EADIE E, Josso M, Touti R, Renoux P, et al
Commercial visible-light protecting sunscreens for photosensitive individuals.
Br J Dermatol. 2023;188:445-447.
PubMed

SUN X, Sheng A, Xu AE
Successful treatment of vitiligo with crisaborole ointment: a report of two cases.
Br J Dermatol. 2023;188:436-437.
PubMed

LI HO, Bailey AMJ, Pastukhova E, Tan MG, et al
Comorbid diagnosis of systemic lupus erythematosus in vitiligo: a systematic review and meta-analysis.
Br J Dermatol. 2023;188:440-441.
PubMed

FAGAN N, Doherty GA, Meah N, Sinclair R, et al
Cross-specialty identification of the JAK1 inhibitor trial agent filgotinib as a potential therapy for alopecia areata.
Br J Dermatol. 2023;188:442-443.
PubMed

BHATE K, Mansfield KE, Sinnott SJ, Margolis DJ, et al
Long-term oral antibiotic use in people with acne vulgaris in UK primary care: a drug utilization study.
Br J Dermatol. 2023;188:361-371.
PubMed Abstract available

GIAMARELLOS-BOURBOULIS EJ
Keratinocytes as drivers of hidradenitis suppurativa inflammation: need for priming.
Br J Dermatol. 2023;188:318-319.
PubMed

KRAJEWSKI PK, Matusiak L, Szepietowski JC
Adipokines as an important link between hidradenitis suppurativa and obesity: a narrative review.
Br J Dermatol. 2023;188:320-327.
PubMed Abstract available

AGARWALA S, Mata DA, Safeer LZ, Hafeez F, et al
Proliferative actinic keratoses are associated with adverse clinical outcomes relative to actinic keratoses without a proliferative growth pattern.
Br J Dermatol. 2023;188:439-440.
PubMed

COLLINS MS, Ali S, Wiss IP, Senna MM, et al
Retrospective analysis of the risk of hyperkalaemia in women older than 65 years of age prescribed spironolactone for female-pattern hair loss.
Br J Dermatol. 2023;188:429-447.
PubMed

SMITH H, Hussain W
Is it time we changed the way we manage melanoma in situ of the trunk and limbs?
Br J Dermatol. 2023 Feb 18:ljad031. doi: 10.1093.
PubMed

VON KOBYLETZKI L
Which patients with atopic eczema and psoriasis develop depression, anxiety, and severe mental illness: is the evidence clear?
Br J Dermatol. 2023 Feb 15:ljad009. doi: 10.1093.
PubMed

OLSEN CM, Pandeya N, Whiteman DC
The rise in thick melanomas: can early detection reduce the burden?
Br J Dermatol. 2023 Feb 15:ljad034. doi: 10.1093.
PubMed

PUIG L
Psoriasis treatment does not impair the immunogenicity of ChAOx1-S[recombinant] COVID-19 vaccination.
Br J Dermatol. 2023;188:163-165.
PubMed

Responses to AstraZeneca COVID-19 vaccines in patients with immune-mediated skin diseases.
Br J Dermatol. 2023;188:e19.
PubMed

Photodamage and photoprotection in populations with skin of colour.
Br J Dermatol. 2023;188:e11.
PubMed

Greater understanding about a rare inherited skin disorder from a study of NLRP1 in two sisters with different severity of disease.
Br J Dermatol. 2023;188:e18.
PubMed

A review of the role of four types of epidermal cells in messaging between the skin, nervous system and immune system.
Br J Dermatol. 2023;188:e12.
PubMed

Patients successfully treated with baricitinib for atopic dermatitis: what happens if they lower their dose or stop treatment?
Br J Dermatol. 2023;188:e14.
PubMed

REICH K, Simpson E, Wollenberg A, Bissonnette R, et al
Efficacy of downtitration or treatment withdrawal compared with continuous dosing after successful treatment with baricitinib in patients with moderate-to-severe atopic dermatitis in a randomized substudy from the long-term extension study BREEZE-AD3.
Br J Dermatol. 2023;188:208-217.
PubMed Abstract available

KRUTMANN J, Piquero-Casals J, Morgado-Carrasco D, Granger C, et al
Photoprotection for people with skin of colour: needs and strategies.
Br J Dermatol. 2023;188:168-175.
PubMed Abstract available

TALAGAS M
Anatomical contacts between sensory neurons and epidermal cells: an unrecognized anatomical network for neuro-immuno-cutaneous crosstalk.
Br J Dermatol. 2023;188:176-185.
PubMed Abstract available

SHARMA A, Birnie AJ, Bordea C, Cheung ST, et al
British Association of Dermatologists guidelines for the management of people with cutaneous squamous cell carcinoma in situ (Bowen disease) 2022.
Br J Dermatol. 2023;188:186-194.
PubMed

KHAN SS, Ashcroft DM, Dlova N, Kini LC, et al
A skin disease survey of the Maasai in North Eastern Tanzania.
Br J Dermatol. 2023;188:303-304.
PubMed

ZAGONA-PRIZIO C, Khan S, Yee DK, Khan S, et al
Psoriasis and fatigue: a cross-sectional population study of psoriasis patients in the United States using the Medical Expenditure Panel Surveys.
Br J Dermatol. 2023;188:301-303.
PubMed

YANG DD, Borsky K, Jani C, Crowley C, et al
Trends in keratinocyte skin cancer incidence, mortality and burden of disease in 33 countries between 1990 and 2017.
Br J Dermatol. 2023;188:237-246.
PubMed Abstract available

ADAMS L, Nakafero G, Grainge MJ, Card T, et al
Is vaccination against COVID-19 associated with psoriasis or eczema flare? Self-controlled case series analysis using data from the Clinical Practice Research Datalink (Aurum).
Br J Dermatol. 2023;188:297-299.
PubMed

LANGLEY RG, Sofen H, Dei-Cas I, Reich K, et al
Secukinumab long-term efficacy and safety in psoriasis through to year 5 of treatment: results of a randomized extension of the phase III ERASURE and FIXTURE trials.
Br J Dermatol. 2023;188:198-207.
PubMed Abstract available

GILL K, Xu J, Kozera E, Stewart T, et al
Strongyloides screening prior to dupilumab therapy in atopic dermatitis: a retrospective cohort study evaluating screening utility.
Br J Dermatol. 2023;188:294-295.
PubMed

CARRASCOSA JM
Conventional therapy in psoriasis. Lost in translation?
Br J Dermatol. 2023 Feb 10:ljad030. doi: 10.1093.
PubMed

POIZEAU F, Balusson F, Lemaitre F, Tron C, et al
The concomitant use of proton pump inhibitors and BRAF/MEK inhibitors in metastatic melanoma.
Br J Dermatol. 2023 Feb 10:ljac085. doi: 10.1093.
PubMed Abstract available

COWDELL F
Living with hidradenitis suppurativa: managing the pain.
Br J Dermatol. 2023;188:e10.
PubMed

Safety of baricitinib in adults with severe alopecia areata.
Br J Dermatol. 2023;188:e15.
PubMed

Guidelines from the British Association of Dermatologists for the management of people with squamous cell carcinoma in situ (Bowen disease).
Br J Dermatol. 2023;188:e13.
PubMed

Small particles of cobalt cause eczema in people with allergies.
Br J Dermatol. 2023;188:e20.
PubMed

Merkel cell carcinoma: changes in the number of people affected, treatment and survival between 2004 and 2018.
Br J Dermatol. 2023;188:e16.
PubMed

A review of the outcome measures used in clinical trials for vitiligo.
Br J Dermatol. 2023;188:e17.
PubMed

MISTRY K, Levell NJ, Hollestein L, Wakkee M, et al
Trends in incidence, treatment and survival of Merkel cell carcinoma in England 2004-2018: a cohort study.
Br J Dermatol. 2023;188:228-236.
PubMed Abstract available

GJERSVIK P
Merkel cell carcinoma: aggressive, rare and on the rise.
Br J Dermatol. 2023;188:162.
PubMed

KING B, Mostaghimi A, Shimomura Y, Zlotogorski A, et al
Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials.
Br J Dermatol. 2023;188:218-227.
PubMed Abstract available

SMITH CM, Hambly R, Gatault S, Iglesias-Martinez LF, et al
B-cell-derived transforming growth factor-beta may drive the activation of inflammatory macrophages and contribute to scarring in hidradenitis suppurativa.
Br J Dermatol. 2023;188:290-310.
PubMed

SANZ J, Gao JL, King DS, Modest AM, et al
Prevalence of rosacea in transgender and gender-diverse populations: a retrospective cohort study.
Br J Dermatol. 2023;188:304-306.
PubMed

BISSONNETTE R
Safety of baricitinib in patients with alopecia areata.
Br J Dermatol. 2023;188:163.
PubMed

GOVENDER K, Sibanda W, Lenzy Y, Dlova NC, et al
The efficacy of learning programmes on hairstylists and barbers in the early detection of alopecia and scalp disorders in South Africa.
Br J Dermatol. 2023;188:308-309.
PubMed

STEELE L, Innes S, Oldham J, Cunningham M, et al
Safety outcomes for topical corticosteroid use in eczema herpeticum: a single-centre retrospective cohort study.
Br J Dermatol. 2023;188:295-297.
PubMed

ALHEGGI A, McGrath JA, Hubbard L, Greenblatt DT, et al
Treatment of multifactorial anaemia in adults with severe epidermolysis bullosa using intravenous ferric carboxymaltose: a single institution, observational, retrospective study.
Br J Dermatol. 2023;188:306-307.
PubMed

ELEFTHERIADOU V, Bergqvist C, Kechichian E, Shourick J, et al
Has the core outcome (domain) set for vitiligo been implemented? An updated systematic review on outcomes and outcome measures in vitiligo randomized clinical trials.
Br J Dermatol. 2023;188:247-258.
PubMed Abstract available

BROWN-KORSAH JB, Omar D, Wang X, Taylor SC, et al
Factors contributing to time to chemotherapy, immunotherapy and radiation for patients with mycosis fungoides in the United States National Cancer Database.
Br J Dermatol. 2023;188:299-301.
PubMed

MCSWEENEY SM, Rayinda T, McGrath JA, Tziotzios C, et al
Two phase III trials of baricitinib for alopecia areata: a critically appraised research paper.
Br J Dermatol. 2023;188:195-197.
PubMed

CHEN ML, Rotemberg V, Lester JC, Novoa RA, et al
Evaluation of diagnosis diversity in artificial intelligence datasets: a scoping review.
Br J Dermatol. 2023;188:292-294.
PubMed

SYMANZIK C, John SM
Occupational exposure to cobalt nanoparticles: potential implications on risk assessment and preventive measures.
Br J Dermatol. 2023;188:161-162.
PubMed

BERKING C
Update on the management of Bowen disease with a focus on patients' needs.
Br J Dermatol. 2023;188:166.
PubMed

CHANPRAPAPH K, Seree-Aphinan C, Rattanakaemakorn P, Pomsoong C, et al
A real-world prospective cohort study of immunogenicity and reactogenicity of ChAdOx1-S[recombinant] among patients with immune-mediated dermatological diseases.
Br J Dermatol. 2023;188:268-277.
PubMed Abstract available

BELLEFEUILLE G, Paiewonsky B, Khalid B, Freese RL, et al
Inflammatory induration in hidradenitis suppurativa and application to severity assessment.
Br J Dermatol. 2023;188:309-310.
PubMed

WU Y, Gu C, Wang S, Yin H, et al
Serum biomarker-based endotypes of atopic dermatitis in China and prediction for efficacy of dupilumab.
Br J Dermatol. 2023 Feb 9:ljad032. doi: 10.1093.
PubMed Abstract available

BORGHI A, D'Abundo L, Bassi C, Lupini L, et al
A microRNA signature to predict risk progression of vulvar lichen sclerosus to squamous cell carcinoma.
Br J Dermatol. 2023 Feb 4:ljad024. doi: 10.1093.
PubMed

January 2023

THORLACIUS L, Alam M
A milestone reached for lichen sclerosus trial outcome standardisation.
Br J Dermatol. 2023 Jan 27:ljad025. doi: 10.1093.
PubMed

MCSWEENEY SM, Bintcliffe K, Fassihi H, Sarkany R, et al
Local cutaneous refractoriness to sun exposure following omalizumab injections in solar urticaria.
Br J Dermatol. 2023 Jan 27:ljad012. doi: 10.1093.
PubMed

KVIST-HANSEN A, Perez-Alos L, Al-Sofi RF, Heftdal LD, et al
Waning humoral and cellular immunity after COVID-19 vaccination in patients with psoriasis treated with methotrexate and biologics: a cohort study.
Br J Dermatol. 2023 Jan 27:ljad023. doi: 10.1093.
PubMed Abstract available

SIMPSON RC, Kirtschig G, Selk A, von Seitzberg S, et al
Core outcome domains for lichen sclerosus: a CORALS initiative consensus statement.
Br J Dermatol. 2023 Jan 26:ljac145. doi: 10.1093.
PubMed Abstract available

SIMPSON RC
Safety of tralokinumab in atopic dermatitis.
Br J Dermatol. 2023 Jan 26:ljad007. doi: 10.1093.
PubMed

GROLLEAU C, Le Cleach L, Shourick J, Sbidian E, et al
Long-term clinical trials of biologics in plaque psoriasis demonstrate heterogeneous study designs.
Br J Dermatol. 2023 Jan 26:ljac142. doi: 10.1093.
PubMed

A new genetic cause for woolly hair and skin fragility.
Br J Dermatol. 2023;188:e8.
PubMed

Clinical trial of Oleogel-S10 (birch bark extract gel) in epidermolysis bullosa.
Br J Dermatol. 2023;188:e4.
PubMed

Lived experiences of patients with hidradenitis suppurativa-related pain.
Br J Dermatol. 2023;188:e6.
PubMed

Providing new insights into the causes of large-to-giant congenital melanocytic naevi.
Br J Dermatol. 2023;188:e7.
PubMed

KOGAME T, Yonekura S, Lovato P, Hirata M, et al
Interleukin-13 inhibition by tralokinumab reduces inducible T-cell costimulator-positive innate lymphoid cells in skin lesions of atopic dermatitis.
Br J Dermatol. 2023;188:146-148.
PubMed

STARK MS
Deficiencies in mismatch DNA repair: providing the soil for large-to-giant congenital melanocytic naevus development.
Br J Dermatol. 2023;188:5.
PubMed

BERTOLD C, Martel P, Passeron T, Bahadoran P, et al
Pigmented demodicosis presenting as lentigo maligna diagnosed by reflectance confocal microscopy.
Br J Dermatol. 2023;188:149-150.
PubMed

WANG H, Lin Z
Identification of the underlying gene for Flegel disease: another 'two-hit' genodermatosis?
Br J Dermatol. 2023;188:7-8.
PubMed

MELLERIO JE
EASE-y does it: Oleogel-S10 for epidermolysis bullosa wounds.
Br J Dermatol. 2023;188:10-11.
PubMed

OKUN MM
The promise of personalized medicine for hidradenitis suppurativa.
Br J Dermatol. 2023;188:3.
PubMed

JACKSON A, Moss C, Chandler KE, Balboa PL, et al
Biallelic TUFT1 variants cause woolly hair, superficial skin fragility and desmosomal defects.
Br J Dermatol. 2023;188:75-83.
PubMed Abstract available

ORENSTEIN LAV, Salame N, Siira MR, Urbanski M, et al
Pain experiences among those living with hidradenitis suppurativa: a qualitative study.
Br J Dermatol. 2023;188:41-51.
PubMed Abstract available

MOSS C, Roked F, Davis PJ, Khan M, et al
Birth incidence and outcome of harlequin ichthyosis and collodion membrane in the UK and Ireland: a national 2-year prospective surveillance study.
Br J Dermatol. 2023;188:139-140.
PubMed

KEARNEY N, Kirby B
The devastating impact of hidradenitis suppurativa on employment.
Br J Dermatol. 2023;188:9-10.
PubMed

THACI D, Vender R, de Rie MA, Conrad C, et al
Safety and efficacy of bimekizumab through 2 years in patients with moderate-to-severe plaque psoriasis: longer-term results from the BE SURE randomized controlled trial and the open-label extension from the BE BRIGHT trial.
Br J Dermatol. 2023;188:22-31.
PubMed Abstract available

MIRALI S, Yeung J
Does bimekizumab stand the test of time for psoriasis?
Br J Dermatol. 2023;188:5-6.
PubMed

SCHNEIDER-BURRUS S, Kalus S, Fritz B, Wolk K, et al
The impact of hidradenitis suppurativa on professional life.
Br J Dermatol. 2023;188:122-130.
PubMed Abstract available

ZHANG J, Schuttelaar MLA
Water and adult eczema: the hard truth?
Br J Dermatol. 2023;188:e1.
PubMed

AUBERT H, Arlegui H, De Rycke Y, Bachelez H, et al
Biologic tapering for patients with psoriasis with low disease activity: data from the French PsoBioTeq Registry.
Br J Dermatol. 2023;188:150-152.
PubMed

WEI B, Gu J, Gao B, Bao Y, et al
Deficient mismatch repair is detected in large-to-giant congenital melanocytic naevi: providing new insight into aetiology and diagnosis.
Br J Dermatol. 2023;188:64-74.
PubMed Abstract available

YUMICEBA V, Spielmann M
When too much is too much: noncoding duplications in skin disorders.
Br J Dermatol. 2023;188:e2-e3.
PubMed

JAGLE S, Hsu HH, Juratli HA, Zimmer AD, et al
Pathogenic variants in the SPTLC1 gene cause hyperkeratosis lenticularis perstans.
Br J Dermatol. 2023;188:94-99.
PubMed Abstract available

BROWN AC, Earp EM, Veitch D, Wernham A, et al
The top 10 research priorities for skin cancer surgery in the UK: results of a James Lind Alliance Priority Setting Partnership.
Br J Dermatol. 2023;188:141-142.
PubMed

VINCENT R, Ormerod E, Gollins CE, Rai N, et al
Semi-virtual patch testing: the future?
Br J Dermatol. 2023;188:137-139.
PubMed

OYMANNS M, Daum-Marzian M, Bellm A, Elsayad K, et al
Near complete responses to concurrent brentuximab vedotin and ultra-hypofractionated low-dose total skin electron beam radiation in advanced cutaneous T-cell lymphoma.
Br J Dermatol. 2023;188:145-146.
PubMed

GABES M, Donhauser T, Kann G, Masur C, et al
Burden of disease: assessing quality-of-life impacts in hyperhidrosis.
Br J Dermatol. 2023;188:143-145.
PubMed

SHIONOYA A, Yoto Y, Hida T, Ishikawa A, et al
Bacillus Calmette-Guerin-induced lupus vulgaris in a patient with Mendelian susceptibility to mycobacterial disease caused by a novel STAT1 variation.
Br J Dermatol. 2023;188:142-143.
PubMed

HAMBLY R, Gatault S, Smith CM, Iglesias-Martinez LF, et al
B-cell and complement signature in severe hidradenitis suppurativa that does not respond to adalimumab.
Br J Dermatol. 2023;188:52-63.
PubMed Abstract available

ZHOU L, Shao L, Gao S, Cui C, et al
Impact of response patterns for patients with advanced acral melanoma treated with anti-programmed death-1 monotherapy.
Br J Dermatol. 2023;188:112-121.
PubMed Abstract available

CLARK A, Murphy MJ, King B, Cohen JM, et al
Patient perspectives on the lived experience of granuloma annulare.
Br J Dermatol. 2023;188:134-136.
PubMed

KRAKOWSKI I, Habel H, Nielsen K, Ingvar C, et al
Association of metformin use and survival in patients with cutaneous melanoma and diabetes.
Br J Dermatol. 2023;188:32-40.
PubMed Abstract available

VAN EGMOND S, de Vere Hunt I, Cai ZR, Rizk N, et al
The perspectives of 606 US dermatologists on active surveillance for low-risk basal cell carcinoma.
Br J Dermatol. 2023;188:136-137.
PubMed

KERN JS, Sprecher E, Fernandez MF, Schauer F, et al
Efficacy and safety of Oleogel-S10 (birch triterpenes) for epidermolysis bullosa: results from the phase III randomized double-blind phase of the EASE study.
Br J Dermatol. 2023;188:12-21.
PubMed Abstract available

Patients with melanoma and diabetes benefit from metformin treatment.
Br J Dermatol. 2023;188:e5.
PubMed

FISCHER J, Alter S
Adding up the desmosomal genes causing syndromes with hair and skin involvement: identification of TUFT1 by state-of-the-art whole-genome sequencing.
Br J Dermatol. 2023;188:8-9.
PubMed

ARDERN-JONES MR, Buchanan EE, Njungu S, O'Driscoll D, et al
Successful Dose Reduction of Dupilumab in Atopic Dermatitis.
Br J Dermatol. 2023 Jan 20:ljad011. doi: 10.1093.
PubMed

PADOVESE V, Fuller LC, Griffiths CEM, Maurer T, et al
Migrant skin health - Perspectives from the Migrant Health Summit, Malta, 2022.
Br J Dermatol. 2023 Jan 19:ljad001. doi: 10.1093.
PubMed

MAUL JT, Frohlich F, Maul LV, Stunnenberg R, et al
Access to psoriasis treatment in Brazil and Chile: A cross-sectional multi-centre ;Global Healthcare Study on Psoriasis.
Br J Dermatol. 2023 Jan 19:ljac128. doi: 10.1093.
PubMed Abstract available

BRAVO FG
Assessing the use of biologic therapy for psoriasis in Latin America.
Br J Dermatol. 2023 Jan 13:ljad003. doi: 10.1093.
PubMed

FOSTIER W, Holt G, Sampson J, Rajan N, et al
Folliculin inactivation and cutaneous leiomyosarcoma in Birt-Hogg-Dube syndrome.
Br J Dermatol. 2023 Jan 11:ljac138. doi: 10.1093.
PubMed

SWIFT T
Peristomal Skin Complications: New Materials Needed to Ease the Ostomy Care Market.
Br J Dermatol. 2023 Jan 11:ljad006. doi: 10.1093.
PubMed

ALABAS OA, Mason KJ, Yiu ZZN, Hampton PJ, et al
Effectiveness and persistence of acitretin, ciclosporin, fumaric acid esters and methotrexate for patients with moderate-to-severe psoriasis: a cohort study from BADBIR.
Br J Dermatol. 2023 Jan 6:ljad004. doi: 10.1093.
PubMed Abstract available

YEW YW, Apfelbacher CJ
Validation of novel diagnostic criteria for atopic dermatitis in an adult and elderly Chinese population.
Br J Dermatol. 2023 Jan 5:ljac143. doi: 10.1093.
PubMed

December 2022

QUIRKE-MCFARLANE S, Weinman J, Cook ES, Yiu ZZN, et al
Non-adherence to systemic immune-modifying therapy in people with psoriasis during the COVID-19 pandemic: findings from a global cross-sectional survey.
Br J Dermatol. 2022 Dec 23:ljac144. doi: 10.1093.
PubMed Abstract available

SO C, McCarthy D, Watts CG, Kearney C, et al
Diagnostic biopsies of suspected skin cancer in general practice from 2010 to 2017 in Victoria, Australia.
Br J Dermatol. 2022 Dec 22:ljac111. doi: 10.1093.
PubMed

CICHY J
Compartmentalized response of the human epidermis to staphylococci.
Br J Dermatol. 2022 Dec 21:ljac125. doi: 10.1093.
PubMed

VEGAS LP, Claudepierre P
Trajectories of comorbidities in patients with psoriasis: a question to be answered.
Br J Dermatol. 2022 Dec 21:ljac126. doi: 10.1093.
PubMed

PERRIER F, Robsahm TE, Ghiasvand R, Borch KB, et al
No association between physical activity and primary melanoma thickness in a cohort of Norwegian women.
Br J Dermatol. 2022 Dec 21:ljac136. doi: 10.1093.
PubMed

LAN J, Huang Q, Yang L, Li Y, et al
Effects of ambient air pollution on outpatient visits for psoriasis in Wuhan, China: a time-series analysis.
Br J Dermatol. 2022 Dec 19:ljac124. doi: 10.1093.
PubMed Abstract available

ADESANYA EI, Matthewman J, Schonmann Y, Hayes JF, et al
Factors associated with depression, anxiety and severe mental illness among adults with atopic eczema or psoriasis: a systematic review and meta-analysis.
Br J Dermatol. 2022 Dec 19:ljac132. doi: 10.1093.
PubMed Abstract available

HUGHES O, Shelton KH, Penny H, Thompson AR, et al
Parent and child experience of skin conditions: Relevance for the provision of mindfulness-based interventions.
Br J Dermatol. 2022 Dec 15:ljac129. doi: 10.1093.
PubMed Abstract available

KEZIC S, van der Molen HF
Occupational skin cancer: measurements of ultraviolet radiation exposure bring knowledge for prevention.
Br J Dermatol. 2022 Dec 14:ljac127. doi: 10.1093.
PubMed

YUE W, Cheng D, Sun Z, Shen Y, et al
Validation of diagnostic criteria for atopic dermatitis and proposal of novel diagnostic criteria for adult and elderly Chinese populations: a multicentre, prospective, clinical setting-based study.
Br J Dermatol. 2022 Dec 12:ljac097. doi: 10.1093.
PubMed Abstract available

SAETRE R, Gotfredsen JL, Nonboe P, Hansen HD, et al
An ostomy baseplate with a skin-protection technology reduces peristomal skin complications: a randomized controlled trial (the ATTRACT study).
Br J Dermatol. 2022 Dec 8:ljac122. doi: 10.1093.
PubMed Abstract available

FLOHR C
How we treat atopic dermatitis now and how that will change over the next 5 years.
Br J Dermatol. 2022 Dec 7:ljac116. doi: 10.1093.
PubMed Abstract available

PLATAIS C, Lalagianni N, Momen S, Ormond M, et al
Efficacy of hydroxychloroquine in oral lichen planus: a retrospective review.
Br J Dermatol. 2022 Dec 3:ljac113. doi: 10.1093.
PubMed

MROWIETZ U, Augustin M
Using the upgrade criteria of the European Psoriasis Consensus is best practice care according to the people-centred healthcare concept of the World Health Organization.
Br J Dermatol. 2022;187:1007-1008.
PubMed

A review of how pain is measured in painful skin conditions and rheumatoid arthritis studies, to determine pain measurement in future hidradenitis suppurativa trials.
Br J Dermatol. 2022;187:e196-e221.
PubMed

PHILPOTT M
Transcriptomic analysis identifies regulators of the Wnt signalling and hypoxia-inducible factor pathways as possible mediators of androgenetic alopecia.
Br J Dermatol. 2022;187:845.
PubMed

LAX SJ, Drucker AM
How will brepocitinib cream compare with established treatments for mild-to-moderate eczema?
Br J Dermatol. 2022;187:838.
PubMed

KRIDIN K, Hammers CM
Atypical clinical manifestation and protracted latency are observed in the emerging variant of checkpoint inhibitor-associated bullous pemphigoid.
Br J Dermatol. 2022;187:843-844.
PubMed

EDEN M, Hainsworth R, Gordon LG, Epton T, et al
On the potential beneficial effects of indoor tanning: reply from the authors.
Br J Dermatol. 2022;187:1057-1058.
PubMed

MIDGETTE B, Strunk A, Akilov O, Alavi A, et al
Factors associated with treatment satisfaction in patients with hidradenitis suppurativa: results from the Global VOICE project.
Br J Dermatol. 2022;187:927-935.
PubMed Abstract available

CAPOZZA K, Vastrup A, Proctor A, Roberts A, et al
The sound of silence: where are the voices of patients in eczema guideline development?
Br J Dermatol. 2022;187:1005-1006.
PubMed

REHMAN R, Haque M, Ceresnie M, Hamzavi IH, et al
Dermatological considerations and culturally sensitive recommendations for women who wear the hijab.
Br J Dermatol. 2022;187:1003-1004.
PubMed Abstract available

LIU J, Chen Z, Hu L, Song Z, et al
Three new founder mutations in Chinese patients with Nagashima-type palmoplantar keratoderma.
Br J Dermatol. 2022;187:1043-1045.
PubMed

VERMEER MCSC, Al-Shinnag M, Sillje HHW, Gaytan AE, et al
A translation re-initiation variant in KLHL24 also causes epidermolysis bullosa simplex and dilated cardiomyopathy via intermediate filament degradation.
Br J Dermatol. 2022;187:1045-1048.
PubMed Abstract available

SILVERTHORNE CA, Bowen C, Lord J, McHugh N, et al
A qualitative study of patients' experiences of screening for psoriatic arthritis.
Br J Dermatol. 2022;187:1035-1037.
PubMed

LINDQVIST PG, Epstein E, Landin-Olsson M
On the potential beneficial effects of indoor tanning.
Br J Dermatol. 2022;187:1057.
PubMed

MOSTMANS Y, Smith V, Cutolo M, Melsens K, et al
Nailfold videocapillaroscopy and serum vascular endothelial growth factor in probable COVID-19-induced chilblains: a cross-sectional study to assess microvascular impairment.
Br J Dermatol. 2022;187:1017-1019.
PubMed

MATARD B, Bourrat E, Cavalie M, Chiaverini C, et al
Folliculitis decalvans and dystrophic epidermolysis bullosa: a significant association.
Br J Dermatol. 2022;187:1026-1028.
PubMed Abstract available

JI-XU A, Lei DK, Worswick S, Maloney NJ, et al
Patient and disease characteristics associated with psychiatric symptoms and impaired quality of life in pityriasis rubra pilaris.
Br J Dermatol. 2022;187:1024-1026.
PubMed

KOPTYEV J, Strunk A, Garg A
Low predictive value of questionnaire-based diagnosis of hidradenitis suppurativa.
Br J Dermatol. 2022;187:1015-1017.
PubMed

COOK MK, Perche PO, White JC, Feldman SR, et al
Psychosocial burden of frontal fibrosing alopecia: a qualitative interview study.
Br J Dermatol. 2022;187:1013-1015.
PubMed

LIU Q, Tang Y, Huang Y, Wang J, et al
Insights into male androgenetic alopecia using comparative transcriptome profiling: hypoxia-inducible factor-1 and Wnt/beta-catenin signalling pathways.
Br J Dermatol. 2022;187:936-947.
PubMed Abstract available

GABES M, Ragamin A, Baker A, Kann G, et al
Content validity of the Recap of atopic eczema (RECAP) instrument in Dutch, English and German to measure eczema control in young people with atopic eczema: a cognitive interview study.
Br J Dermatol. 2022;187:919-926.
PubMed Abstract available

November 2022

HU C, Jansen PW
Do adolescents with atopic dermatitis have lower cognitive function and school performance than their peers without atopic dermatitis?
Br J Dermatol. 2022 Nov 29:ljac105. doi: 10.1093.
PubMed

KOKOLAKIS G, Warren RB, Strober B, Blauvelt A, et al
Bimekizumab efficacy and safety in patients with moderate-to-severe plaque psoriasis who switched from adalimumab, ustekinumab or secukinumab: results from phase III/IIIb trials.
Br J Dermatol. 2022 Nov 29:ljac089. doi: 10.1093.
PubMed Abstract available

ABUABARA K, Langan SM
Atopic dermatitis across the life course.
Br J Dermatol. 2022 Nov 18:ljac072. doi: 10.1093.
PubMed Abstract available

TRIER AM, Kim BS
Insights into atopic dermatitis pathogenesis lead to newly approved systemic therapies.
Br J Dermatol. 2022 Nov 18:ljac016. doi: 10.1093.
PubMed Abstract available

CLAYTON K, Holbrook DJ, Vallejo A, Porter G, et al
Skin programming of inflammatory responses to Staphylococcus aureus is compartmentalized according to epidermal keratinocyte differentiation status.
Br J Dermatol. 2022 Nov 17:ljac088. doi: 10.1093.
PubMed Abstract available

SCHELL SL, Cong Z, Sennett ML, Gettle SL, et al
Keratinocytes and immune cells in the epidermis are key drivers of inflammation in hidradenitis suppurativa providing a rationale for novel topical therapies.
Br J Dermatol. 2022 Nov 17:ljac096. doi: 10.1093.
PubMed Abstract available

IBRAHIM N, Jovic M, Ali S, Williams N, et al
The epidemiology, healthcare and societal burden of basal cell carcinoma in Wales 2000-2018: a retrospective nationwide analysis.
Br J Dermatol. 2022 Nov 17:ljac090. doi: 10.1093.
PubMed Abstract available

WEISSHAAR E, Bentz P, Haufe E, Heinrich L, et al
Itching and treatments in atopic dermatitis (AD): results from the German AD registry TREATgermany.
Br J Dermatol. 2022 Nov 17:ljac070. doi: 10.1093.
PubMed

GRINNELL M, Concha J, Feng R, Keyes E, et al
Clinical research: photo validation study using Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) scores in patients with dermatomyositis.
Br J Dermatol. 2022 Nov 17:ljac091. doi: 10.1093.
PubMed

ROSENO NAL, Lorup EH, Richardson C, Alarcon I, et al
Exploring disease comorbidities and temporal disease progression of psoriasis: an observational, retrospective, multi-database, cohort study.
Br J Dermatol. 2022 Nov 11:ljac086. doi: 10.1093.
PubMed Abstract available

WITTLICH M, Westerhausen S, Strehl B, Versteeg H, et al
The GENESIS-UV study on ultraviolet radiation exposure levels in 250 occupations to foster epidemiological and legislative efforts to combat nonmelanoma skin cancer.
Br J Dermatol. 2022 Nov 11:ljac093. doi: 10.1093.
PubMed Abstract available

HE X, Shi H
How does acral melanoma respond to immunotherapy?
Br J Dermatol. 2022 Nov 10:ljac035. doi: 10.1093.
PubMed

VITTRUP I, Andersen YMF, Skov L, Wu JJ, et al
The association between atopic dermatitis, cognitive function and school performance in children and young adults.
Br J Dermatol. 2022 Nov 3:ljac058. doi: 10.1093.
PubMed Abstract available

Measuring the effects of treatments for capillary malformations (vascular birthmarks).
Br J Dermatol. 2022;187:e173-e192.
PubMed

EVRENOGLOU T
Stratification according to disease severity can better reveal the relative effectiveness of treatments for acne vulgaris.
Br J Dermatol. 2022;187:637-638.
PubMed

FLEDDERUS AC, Gout HA
A core outcome set for pressure ulcers: an important step towards standardized outcome reporting of prevention strategies.
Br J Dermatol. 2022;187:634-635.
PubMed

FROELUNDE AS, Vestergaard C
Prurigo nodularis: the epidemiology of an under-recognized disease.
Br J Dermatol. 2022;187:e171-e172.
PubMed

GIAMARELLOS-BOURBOULIS EJ
Modulation of keratin deposition and pathogenesis of hidradenitis suppurativa: evidence coming from pachyonychia congenita.
Br J Dermatol. 2022;187:e170-e171.
PubMed

ORCHARD D
Preventing atopic eczema: vitamin D supplementation another piece of the puzzle?
Br J Dermatol. 2022;187:630-631.
PubMed

HARRS C, van den Akker PC, Baardman R, Duipmans JC, et al
The aggressive behaviour of squamous cell carcinoma in epidermolysis bullosa: analysis of clinical outcomes and tumour characteristics in the Dutch EB Registry.
Br J Dermatol. 2022;187:824-826.
PubMed

CHOSIDOW O, Beylot-Barry M, Corgibet F, Jouan N, et al
Isotretinoin: reasserting its public health value at the population level, addressing potential neuropsychiatric risk at the individual level.
Br J Dermatol. 2022;187:831-832.
PubMed

LOPEZ DJ, Singh A, Waidyatillake NT, Su JC, et al
The association between domestic hard water and eczema in adults from the UK Biobank cohort study.
Br J Dermatol. 2022;187:704-712.
PubMed Abstract available

MALOVITSKI K, Meijers O, Cohen-Barak E, Bergman J, et al
Heterozygous variants in the integrin subunit beta 4 gene (ITGB4) cause autosomal dominant nail dystrophy.
Br J Dermatol. 2022;187:826-828.
PubMed

BONTOUX C, de Masson A, Thonnart N, Ram-Wolff C, et al
Large-cell transformation is an independent poor prognostic factor in Sezary syndrome: analysis of 117 cases.
Br J Dermatol. 2022;187:815-817.
PubMed

RING HC, Egeberg A, Zachariae C, Thomsen SF, et al
Considerable improvement in hidradenitis suppurativa with oral roflumilast therapy.
Br J Dermatol. 2022;187:813-815.
PubMed

MAVRANEZOULI I, Daly CH, Welton NJ, Deshpande S, et al
A systematic review and network meta-analysis of topical pharmacological, oral pharmacological, physical and combined treatments for acne vulgaris.
Br J Dermatol. 2022;187:639-649.
PubMed Abstract available

ALI S, Pham H, Waterhouse M, Baxter C, et al
The effect of vitamin D supplementation on risk of keratinocyte cancer: an exploratory analysis of the D-Health randomized controlled trial.
Br J Dermatol. 2022;187:667-675.
PubMed Abstract available

LECHNER A, Coleman S, Balzer K, Kirkham JJ, et al
Core outcomes for pressure ulcer prevention trials: results of an international consensus study: Classification: Outcomes and qualitative research.
Br J Dermatol. 2022;187:743-752.
PubMed Abstract available

MARANGA A, Roche FC, Alausa M, McWilliams T, et al
Quality of life in patients with central centrifugal cicatricial alopecia: a preliminary study.
Br J Dermatol. 2022;187:802-804.
PubMed Abstract available

BATAILLE P, Layese R, Claudepierre P, Paris N, et al
Paradoxical reactions and biologic agents: a French cohort study of 9303 patients.
Br J Dermatol. 2022;187:676-683.
PubMed Abstract available

EL-HEIS S, D'Angelo S, Curtis EM, Healy E, et al
Maternal antenatal vitamin D supplementation and offspring risk of atopic eczema in the first 4 years of life: evidence from a randomized controlled trial.
Br J Dermatol. 2022;187:659-666.
PubMed Abstract available

GREENBLATT DT, Hubbard L, Bloor C, Card D, et al
Vitamin C concentrations in patients with epidermolysis bullosa.
Br J Dermatol. 2022;187:808-810.
PubMed

HUGHES O
The need for psychological support in routine dermatological care across the UK.
Br J Dermatol. 2022;187:778-779.
PubMed Abstract available

GAMBICHLER T, Abu Rached N, Susok L, Becker JC, et al
Serum neuron-specific enolase independently predicts outcomes of patients with Merkel cell carcinoma.
Br J Dermatol. 2022;187:806-808.
PubMed

SARASWAT N, Kumar S, Tripathy DM, Gopal MM, et al
COVID-19-associated necrolytic acral erythema with postvaccination exacerbation in a seronegative patient.
Br J Dermatol. 2022;187:e169.
PubMed

BOUDREAUX BW, Pincelli TP, Bhullar PK, Patel MH, et al
Secukinumab for the treatment of adult-onset pityriasis rubra pilaris: a single-arm clinical trial with transcriptomic analysis.
Br J Dermatol. 2022;187:650-658.
PubMed Abstract available

SANGHVI AP, Miles JA, Sayed C
Clostridium difficile infection risk in patients with hidradenitis suppurativa.
Br J Dermatol. 2022;187:800-802.
PubMed Abstract available

MERVIS JS, Maeng MM, Kirsner RS, Wester ST, et al
Teprotumumab as a novel treatment for pretibial myxoedema.
Br J Dermatol. 2022;187:795-797.
PubMed

SINGH R, Balogh EA, Senthilnathan A, Richardson IM, et al
Fear of negative evaluation in patients with hidradenitis suppurativa is correlated with worse quality of life: an observational study.
Br J Dermatol. 2022;187:788-790.
PubMed

BONDS PD, Huang J, Ike J, Mukherjee E, et al
International Classification of Diseases codes do not capture all cases of hidradenitis suppurativa in the electronic health record: a retrospective cohort.
Br J Dermatol. 2022;187:787-788.
PubMed

BELZER A, Silber A, Mehra S, Gilani S, et al
Mucosal haemangioma in the setting of treatment with trastuzumab emtansine (T-DM1).
Br J Dermatol. 2022;187:e168.
PubMed

LEWITT TM, Mammis-Gierbolini A, Parnell M, Sarfo A, et al
International consensus definition of disease flare in hidradenitis suppurativa.
Br J Dermatol. 2022;187:785-787.
PubMed

October 2022

MIDANDER K, Werner P, Isaksson M, Wisgrill L, et al
Cobalt nanoparticles cause allergic contact dermatitis in humans.
Br J Dermatol. 2022 Oct 28:ljac043. doi: 10.1093.
PubMed Abstract available

TURNER CT, Zeglinski MR, Boivin W, Zhao H, et al
Granzyme K contributes to endothelial microvascular damage and leakage during skin inflammation.
Br J Dermatol. 2022 Oct 23:ljac017. doi: 10.1093.
PubMed Abstract available

ALI F, Smith CH, Mahil SK
Spesolimab in the treatment of generalized pustular psoriasis: a critically appraised research paper.
Br J Dermatol. 2022 Oct 23:ljac049. doi: 10.1093.
PubMed

YOTSU RR, Fuller LC, Murdoch ME, Revankar C, et al
World Health Organization strategic framework for integrated control and management of skin-related neglected tropical diseases: what does this mean for dermatologists?
Br J Dermatol. 2022 Oct 20:ljac031. doi: 10.1093.
PubMed

The search for measurable predictors linked with negative health complications in psoriasis.
Br J Dermatol. 2022;187:e158-e167.
PubMed

TZELLOS T
Implementing evidence-based strategies to optimize the journey of patients with hidradenitis suppurativa.
Br J Dermatol. 2022;187:462-463.
PubMed

PANDYA AG, Ezzedine K
Noticeability of vitiligo is in the eye of the beholder.
Br J Dermatol. 2022;187:461-462.
PubMed

DESSINIOTI C
Advances in acne clinical research: a new class of topical treatment for moderate-to-severe facial acne.
Br J Dermatol. 2022;187:455-456.
PubMed

CUCKA B, Biglione B, Zhou L, Phillips EJ, et al
Drug reaction with eosinophilia and systemic symptoms in patients hospitalized with COVID-19: a case series from a large US healthcare system.
Br J Dermatol. 2022;187:619-622.
PubMed

MISERY L
Chronic prurigo.
Br J Dermatol. 2022;187:464-471.
PubMed Abstract available

RENERT-YUVAL Y, Correa da Rosa J, Garcet S, Pavel AB, et al
Analysis of alopecia areata surveys suggests a threshold for improved patient-reported outcomes.
Br J Dermatol. 2022;187:539-547.
PubMed Abstract available

DARRIGADE AS, Oules B, Sohier P, Jullie ML, et al
Sweet-like syndrome and multiple COVID arm syndrome following COVID-19 vaccines: 'specific' patterns in a series of 192 patients.
Br J Dermatol. 2022;187:615-617.
PubMed Abstract available

POTTIER C, Eymieux S, Blanchard-Laumonnier E, Robert J, et al
Loose anagen hair syndrome: take a closer look!
Br J Dermatol. 2022;187:e156.
PubMed

YUKSEL YT, Edslev SM, Janstrup AK, Goldeman MS, et al
Colonization with Staphylococcus aureus in healthcare workers: consequences of hand eczema.
Br J Dermatol. 2022;187:609-611.
PubMed

TAYLOR MT, Bordeaux ZA, Deng J, Parthasarathy V, et al
Association between prurigo nodularis and substance use disorders.
Br J Dermatol. 2022;187:608-609.
PubMed

RING HC, Yao Y, Maul JT, Ingram JR, et al
The road to biologics in patients with hidradenitis suppurativa: a nationwide drug utilization study.
Br J Dermatol. 2022;187:523-530.
PubMed Abstract available

BATCHELOR JM, Gran S, Leighton P, Howells L, et al
Using the Vitiligo Noticeability Scale in clinical trials: construct validity, interpretability, reliability and acceptability.
Br J Dermatol. 2022;187:548-556.
PubMed Abstract available

DANIEL SR, Gandhi K, Anastassopoulos KP, Pandya AG, et al
Impact of nonsegmental vitiligo on patients' health-related quality of life in the United States.
Br J Dermatol. 2022;187:603-606.
PubMed

KLEIN EJ, Shapiro J, Piraccini B, Cummins D, et al
Giving a voice: dermatologists' legislative advocacy for patients with hair loss.
Br J Dermatol. 2022;187:582-583.
PubMed

PICARDO M, Cardinali C, La Placa M, Lewartowska-Bialek A, et al
Efficacy and safety of N-acetyl-GED-0507-34-LEVO gel in patients with moderate-to severe facial acne vulgaris: a phase IIb randomized double-blind, vehicle-controlled trial.
Br J Dermatol. 2022;187:507-514.
PubMed Abstract available

HAGAN PG, Bouazzi D, Nyarko G, Dartey ES, et al
Prevalence of Hidradenitis Suppurativa in Berekum, Ghana.
Br J Dermatol. 2022;187:586-587.
PubMed

September 2022

GRAU-PEREZ M, Garcia-Doval I
Differences in cutaneous manifestations of COVID-19 during the Delta and Omicron waves revealed using the ZOE app.
Br J Dermatol. 2022 Sep 23. doi: 10.1111/bjd.21868.
PubMed

SIMPSON EL, Merola JF, Silverberg JI, Reich K, et al
Safety of Tralokinumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis: Pooled Analysis of Five Randomized, Double-blind, Placebo-controlled Phase 2 and Phase 3 Trials.
Br J Dermatol. 2022 Sep 9. doi: 10.1111/bjd.21867.
PubMed Abstract available

PUIG L
Psoriasis treatment: no more room on the summit?
Br J Dermatol. 2022 Sep 5. doi: 10.1111/bjd.21848.
PubMed

KIM RW, Barta K, Begolka WS, Capozza K, et al
The quantitative impact of atopic dermatitis on caregivers across multiple life domains.
Br J Dermatol. 2022 Sep 3. doi: 10.1111/bjd.21855.
PubMed

SIVALINGAM V, Tamber K
Understanding the impact of life with vulval lichen sclerosus.
Br J Dermatol. 2022 Sep 2. doi: 10.1111/bjd.21846.
PubMed

LEE H, Kwon O
Immune checkpoint inhibitor-induced cutaneous toxicities: they are not just random.
Br J Dermatol. 2022 Sep 2. doi: 10.1111/bjd.21838.
PubMed

Revolutionizing Atopic Dermatitis, 9-11 April 2022.
Br J Dermatol. 2022;187:e80-e155.
PubMed

WILSON BN, Shah R, Menzer C, Aleisa A, et al
Consensus on the Clinical Management of Chronic Radiation Dermatitis and Radiation Fibrosis: A Delphi Survey.
Br J Dermatol. 2022 Sep 1. doi: 10.1111/bjd.21852.
PubMed

APFELBACHER C
Closing a gap: an investigator global assessment for use in hidradenitis suppurativa clinical trials.
Br J Dermatol. 2022;187:e79.
PubMed

PAVLOVSKY M, Peled A, Sarig O, Astman N, et al
Coexistence of pachyonychia congenita and hidradenitis suppurativa: more than a coincidence.
Br J Dermatol. 2022;187:392-400.
PubMed Abstract available

GOULDEN V, Ling TC, Babakinejad P, Dawe R, et al
British Association of Dermatologists and British Photodermatology Group guidelines for narrowband ultraviolet B phototherapy 2022.
Br J Dermatol. 2022;187:295-308.
PubMed

AARTS P, van der Zee HH
Damage in hidradenitis suppurativa: receiving the deserved attention.
Br J Dermatol. 2022;187:282-283.
PubMed

FAZEL S, Paljarvi T
Response to 'Isotretinoin and adverse neuropsychiatric outcomes: retrospective cohort study using routine data': reply from authors.
Br J Dermatol. 2022;187:450-451.
PubMed

CHANG R, Lai CC, Hung YM, Wang SI, et al
Response to 'Isotretinoin and adverse neuropsychiatric outcomes: retrospective cohort study using routine data'.
Br J Dermatol. 2022;187:450.
PubMed

GARG A, Krueger JG
Raising the bar for efficacy in hidradenitis suppurativa: a rationale for combination targeted therapies.
Br J Dermatol. 2022;187:414-415.
PubMed Abstract available

DI CESARE A, Nikolakis G, Kanni T, Giamarellos-Bourboulis EJ, et al
Identification of clinical features affecting diagnostic delay in paediatric hidradenitis suppurativa: results from a multicentre observational study.
Br J Dermatol. 2022;187:428-430.
PubMed

PENNITZ A, Kinberger M, Avila Valle G, Passeron T, et al
Self-applied topical interventions for melasma: a systematic review and meta-analysis of data from randomized, investigator-blinded clinical trials.
Br J Dermatol. 2022;187:309-317.
PubMed Abstract available

MERHI R, Canu D, Barnetche T, Duchez E, et al
Assessment of Vitiligo Area Scoring Index (VASI), Facial-VASI and Vitiligo Extent Score using standardized photography of patients with vitiligo.
Br J Dermatol. 2022;187:422-424.
PubMed

KLEIN B, Treudler R, Dumann K, Boldt A, et al
Clinical response of CARD14-associated papulosquamous eruption to an anti-interleukin-17A antibody.
Br J Dermatol. 2022;187:419-422.
PubMed Abstract available

GRINNELL M, Keyes E, Diaz D, Vazquez T, et al
Mycophenolate mofetil and methotrexate efficacy in dermatomyositis.
Br J Dermatol. 2022;187:437-438.
PubMed

JIANG SW, Kwock JT, Liu B, Petty AJ, et al
High-dose, high-frequency ustekinumab therapy for patients with severe hidradenitis suppurativa.
Br J Dermatol. 2022;187:417-419.
PubMed Abstract available

CHEN F, Deng D, Pan C, Yao Z, et al
Detection and characterization of low-level mosaicism among clinically unaffected parents of 'sporadic' epidermolysis bullosa simplex cases.
Br J Dermatol. 2022;187:441-443.
PubMed Abstract available

FRITSCHE M, Okun M, Kirby JS
Damage in hidradenitis suppurativa: a narrative review emphasizing the need for a novel outcome measure.
Br J Dermatol. 2022;187:288-294.
PubMed Abstract available

HASAN ZU, Ahmed I, Matin RN, Homer V, et al
Topical treatment of actinic keratoses in organ transplant recipients: a feasibility study for SPOT (Squamous cell carcinoma Prevention in Organ transplant recipients using Topical treatments).
Br J Dermatol. 2022;187:324-337.
PubMed Abstract available

August 2022

KEMPF W
Follicular T helper cells and cutaneous T-cell lymphomas.
Br J Dermatol. 2022 Aug 31. doi: 10.1111/bjd.21839.
PubMed

MOLHO-PESSACH V, Hartshtark S, Merims S, Lotem M, et al
Giant congenital melanocytic nevus with a novel CUX1-BRAF fusion mutation treated with trametinib.
Br J Dermatol. 2022 Aug 28. doi: 10.1111/bjd.21851.
PubMed

BALAK DMW, Rissmann R
Anti-interleukin-17A for pityriasis rubra pilaris: catching the psoriasis biologic wave.
Br J Dermatol. 2022 Aug 22. doi: 10.1111/bjd.21813.
PubMed

NALDI L, Cazzaniga S
The chicken or the egg: disentangling the relationship between smoking, alcohol consumption and psoriasis using Mendelian randomization.
Br J Dermatol. 2022 Aug 21. doi: 10.1111/bjd.21805.
PubMed

LIU Y, Banka S, Huang Y, Hardman-Smart J, et al
Germline intergenic duplications at Xq26.1 underlie Bazex-Dupre-Christol basal cell carcinoma susceptibility syndrome.
Br J Dermatol. 2022 Aug 20. doi: 10.1111/bjd.21842.
PubMed Abstract available

LANDIS MN, Arya M, Smith S, Draelos Z, et al
Efficacy and safety of topical brepocitinib for the treatment of mild-to-moderate atopic dermatitis: a phase IIb, randomised, double-blind, vehicle-controlled, dose-ranging, and parallel-group study.
Br J Dermatol. 2022 Aug 20. doi: 10.1111/bjd.21826.
PubMed Abstract available

KAWSAR A, Edwards C, Patel P, Heywood RM, et al
Checkpoint inhibitor associated bullous cutaneous immune related adverse events: a multi-centre observational study.
Br J Dermatol. 2022 Aug 17. doi: 10.1111/bjd.21836.
PubMed Abstract available

LEVIN NA, Rashighi M
Psoriasis and hidradenitis suppurativa are associated with inflammatory bowel disease: a growing body of evidence.
Br J Dermatol. 2022 Aug 17. doi: 10.1111/bjd.21808.
PubMed

MCCOY K, DeSimone J
Progression of in situ and early invasive cutaneous squamous cell carcinomas concurrent with successful target tumor response to PD-1 inhibitor.
Br J Dermatol. 2022 Aug 17. doi: 10.1111/bjd.21831.
PubMed

CHRISTIANSEN AG, Carstensen O, Sommerlund M, Clausen PA, et al
Prevalence of skin sensitisation and dermatitis among epoxy-exposed workers in the wind turbine industry.
Br J Dermatol. 2022 Aug 16. doi: 10.1111/bjd.21830.
PubMed Abstract available

KIM RW, Barta K, Begolka WS, Capozza K, et al
Qualitative analysis of the impact of atopic dermatitis on caregivers and the quantitative impact of atopic dermatitis on caregivers across multiple life domains.
Br J Dermatol. 2022 Aug 16. doi: 10.1111/bjd.21828.
PubMed

HASAN SB, Gendra R, James J, Morris D, et al
Pain measurement in painful skin conditions and rheumatoid arthritis randomized controlled trials: A scoping review to inform pain measurement in hidradenitis suppurativa.
Br J Dermatol. 2022 Aug 12. doi: 10.1111/bjd.21821.
PubMed Abstract available

RANUM A, Freese R, Ramesh V, Pearson DR, et al
Lichen sclerosus in female patients is associated with an increased risk of metabolic syndrome and cardiovascular comorbidities: A retrospective cohort review.
Br J Dermatol. 2022 Aug 10. doi: 10.1111/bjd.21811.
PubMed

BELL KJL, Nijsten T
Melanoma overdiagnosis: why it matters and what can be done about it.
Br J Dermatol. 2022 Aug 5. doi: 10.1111/bjd.21750.
PubMed

CATALA A, Clavo Escribano P, Riera J, Martin-Ezquerra G, et al
Monkeypox outbreak in Spain: clinical and epidemiological findings in a prospective cross-sectional study of 185 cases.
Br J Dermatol. 2022 Aug 2. doi: 10.1111/bjd.21790.
PubMed Abstract available

FENG Y, Lu Y, Wang H
Leucoderma secondary to wig wearing.
Br J Dermatol. 2022;187:e64.
PubMed Abstract available

Better understanding about the severity of disease in cutaneous T-cell lymphoma from studying immune checkpoint receptors.
Br J Dermatol. 2022;187:e69-e76.
PubMed

GARG A, Zema C, Kim K, Gao W, et al
Development and initial validation of the HS-IGA: a novel hidradenitis suppurativa-specific investigator global assessment for use in interventional trials.
Br J Dermatol. 2022;187:203-210.
PubMed Abstract available

BIRABAHARAN M, Kaelber DC, Orme CM, Paravar T, et al
Evaluating risk of bullous pemphigoid after mRNA COVID-19 vaccination.
Br J Dermatol. 2022;187:271-273.
PubMed

LIU Y, Tan Y, Liu J, Song Z, et al
Novel and founder variants of SERPINA12 in Chinese patients with autosomal recessive palmoplantar keratoderma.
Br J Dermatol. 2022;187:267-270.
PubMed Abstract available

DI RAIMONDO C, Rubio-Gonzalez B, Palmer J, Weisenburger DD, et al
Expression of immune checkpoint molecules programmed death protein 1, programmed death-ligand 1 and inducible T-cell co-stimulator in mycosis fungoides and Sezary syndrome: association with disease stage and clinical outcome.
Br J Dermatol. 2022;187:234-243.
PubMed Abstract available

JIANG TT, Kruglov O, Geskin L, Akilov OE, et al
Repetitive expanded T-cell receptor clonotypes impart the classic T helper 2 Sezary cell phenotype.
Br J Dermatol. 2022;187:265-267.
PubMed Abstract available

BAE JM, Kim M, Han JH, Lee S, et al
Preventive effect of levodopa on vitiligo development: a nationwide case-control study.
Br J Dermatol. 2022;187:259-261.
PubMed

RING HC, Thomsen SF
The impact of Janus kinase 1 inhibitors on quality of life in patients with hidradenitis suppurativa.
Br J Dermatol. 2022;187:274.
PubMed

YUKSEL YT, Ibler K, Agner T, Ofenloch R, et al
Validation of the Danish version of the Quality of Life in Hand Eczema Questionnaire (QOLHEQ).
Br J Dermatol. 2022;187:256-258.
PubMed

DE VERE HUNT I, Halley M, Sum K, Yekrang K, et al
A qualitative exploration of the experiences of itch for adults living with epidermolysis bullosa.
Br J Dermatol. 2022;187:261-263.
PubMed

BUECHLER CR, Sagher E, Tisack A, Jacobsen G, et al
Demographic factors and disparate outcomes in mycosis fungoides: retrospective analysis of a racially diverse 440-patient cohort from Detroit, Michigan, USA.
Br J Dermatol. 2022;187:246-248.
PubMed

SINGH R, Mohammed A, Senthilnathan A, Feldman SR, et al
Hidradenitis suppurativa may impact clothing patterns even in patients with mild disease and symptoms: an observational study.
Br J Dermatol. 2022;187:250-251.
PubMed

MORGAN CL, Thomas M, Stander S, Jabbar-Lopez ZK, et al
Epidemiology of prurigo nodularis in England: a retrospective database analysis.
Br J Dermatol. 2022;187:188-195.
PubMed Abstract available

July 2022

SCHNEIDER AM, Nelson AM
Impaired epidermal barriers in congenital ichthyoses house a changing microbial landscape.
Br J Dermatol. 2022 Jul 29. doi: 10.1111/bjd.21746.
PubMed

VAN DER SCHOOT LS, Atalay S, Otero ME, Kievit W, et al
Regaining adequate treatment responses in patients with psoriasis who discontinued dose reduction of adalimumab, etanercept or ustekinumab.
Br J Dermatol. 2022 Jul 27. doi: 10.1111/bjd.21797.
PubMed

WANG L, Rocas D, Dalle S, Sako N, et al
Primary cutaneous peripheral T-cell lymphomas with a T follicular helper phenotype: An integrative clinical, pathological, and molecular case series study.
Br J Dermatol. 2022 Jul 27. doi: 10.1111/bjd.21791.
PubMed Abstract available

SHARIATMADARI I, Matteucci P, Barreda A, O'Toole L, et al
Response to 'British Association of Dermatologists guidelines for the management of adults with basal cell carcinoma 2021': Vismodegib and indications for its use.
Br J Dermatol. 2022 Jul 23. doi: 10.1111/bjd.21788.
PubMed

ORMEROD AD
Predicting the outcome of psoriasis treatment.
Br J Dermatol. 2022 Jul 22. doi: 10.1111/bjd.21747.
PubMed

VISCONTI A, Murray B, Rossi N, Wolf J, et al
Cutaneous Manifestations of SARS-CoV-2 infection during the Delta and Omicron waves in 348,691 UK users of the UK ZOE COVID Study App.
Br J Dermatol. 2022 Jul 22. doi: 10.1111/bjd.21784.
PubMed Abstract available

LAURENT C, Lefevre G, Kahn JE, Staumont-Salle D, et al
Cutaneous manifestations of lymphoid-variant hypereosinophilic syndrome.
Br J Dermatol. 2022 Jul 21. doi: 10.1111/bjd.21782.
PubMed

NIKOLAOU V, Apalla Z, Carrera C, Fattore D, et al
Clinical associations and classification of immune checkpoint inhibitors-induced cutaneous toxicities: A multicentric study from the EADV-Task Force of Dermatology for Cancer Patients.
Br J Dermatol. 2022 Jul 21. doi: 10.1111/bjd.21781.
PubMed Abstract available

CHOON SE, Wright AK, Griffiths CEM, Tey KE, et al
Incidence and prevalence of psoriasis in multi-ethnic Johor Bahru, Malaysia: a population-based cohort study using electronic health data routinely captured in Teleprimary Care (TPC(R)) clinical information system from 2010 to 2020.
Br J Dermatol. 2022 Jul 13. doi: 10.1111/bjd.21768.
PubMed Abstract available

NAGTZAAM IF, van Leersum FS, Kouwenberg LCM, Blok MJ, et al
STS pathogenic variants in a Dutch patient cohort clinically suspected for X-linked ichthyosis shows genetic heterogeneity.
Br J Dermatol. 2022 Jul 13. doi: 10.1111/bjd.21775.
PubMed

MOHAMAD J, Sarig O, Beattie P, Malovitski K, et al
A unique skin phenotype resulting from a large heterozygous deletion spanning six keratin genes.
Br J Dermatol. 2022 Jul 13. doi: 10.1111/bjd.21766.
PubMed Abstract available

YANG N, Chen L, Shao J, Jiang F, et al
Dupilumab with concomitant JAK inhibitor: A novel treatment strategy for atopic dermatitis with poor response to dupilumab.
Br J Dermatol. 2022 Jul 13. doi: 10.1111/bjd.21776.
PubMed

ROCCUZZO G, Fava P, Avallone G, Aquino C, et al
Time to next treatment and safety assessment in Cutaneous-T-cell lymphomas: a retrospective analysis on patients treated with bexarotene and acitretin.
Br J Dermatol. 2022 Jul 13. doi: 10.1111/bjd.21772.
PubMed

ARNOLD S, Fernando S, Rees S
Living with Vulval Lichen Sclerosus: a qualitative interview study.
Br J Dermatol. 2022 Jul 13. doi: 10.1111/bjd.21777.
PubMed Abstract available

FROMME M, Schneider CV, Schlapbach C, Cazzaniga S, et al
Comorbidities in lichen planus by phenome-wide association study in two biobank population cohorts.
Br J Dermatol. 2022 Jul 12. doi: 10.1111/bjd.21762.
PubMed Abstract available

RUIZ GENAO DP, Carretero G, Rivera-Diaz R, Carrascosa JM, et al
Differences in epidemiology, comorbidities and treatment choice between plaque psoriasis and pustular psoriasis: results from the Biobadaderm registry.
Br J Dermatol. 2022 Jul 12. doi: 10.1111/bjd.21763.
PubMed

BLAUVELT A, Kimball AB, Augustin M, Okubo Y, et al
Efficacy and Safety of Mirikizumab in Psoriasis: Results from a 52-Week, Double-Blinded, Placebo-Controlled, Randomised Withdrawal, Phase III Trial (OASIS-1).
Br J Dermatol. 2022 Jul 6. doi: 10.1111/bjd.21743.
PubMed Abstract available

British Society for Investigative Dermatology Virtual Annual Meeting, 29-31 March 2021.
Br J Dermatol. 2022;187:e1-e63.
PubMed

HUNT N
Identity and psychological distress in alopecia areata.
Br J Dermatol. 2022;187:9-10.
PubMed

SCHUTTELAAR MLA
A new avenue for treatment of chronic hand eczema.
Br J Dermatol. 2022;187:7-8.
PubMed

RAVENCROFT J, Eichenfield L
Isotretinoin does not contribute to increased neuropsychiatric risk in the overall acne population, but risk management during treatment remains essential.
Br J Dermatol. 2022;187:8-9.
PubMed

PALJARVI T, McPherson T, Luciano S, Herttua K, et al
Isotretinoin and adverse neuropsychiatric outcomes: retrospective cohort study using routine data.
Br J Dermatol. 2022;187:64-72.
PubMed Abstract available

MACBETH AE, Holmes S, Harries M, Chiu WS, et al
The associated burden of mental health conditions in alopecia areata: a population-based study in UK primary care.
Br J Dermatol. 2022;187:73-81.
PubMed Abstract available

WORM M, Thyssen JP, Schliemann S, Bauer A, et al
The pan-JAK inhibitor delgocitinib in a cream formulation demonstrates dose response in chronic hand eczema in a 16-week randomized phase IIb trial.
Br J Dermatol. 2022;187:42-51.
PubMed Abstract available

WANG J, Ram-Wolff C, Dobos G, Al Hage J, et al
Head and neck granulomatous rash associated with mogamulizumab mimicking mycosis fungoides.
Br J Dermatol. 2022;187:129-131.
PubMed

HEWITT RM, Bundy C, Newi AL, Chachos E, et al
How do dermatologists' personal models inform a patient-centred approach to management: a qualitative study using the example of prescribing a new treatment (Apremilast).
Br J Dermatol. 2022;187:82-88.
PubMed Abstract available

Eumelanin Human Skin Colour Scale: proof-of-concept study.
Br J Dermatol. 2022;187:vi.
PubMed

June 2022

WEI J, Zhu J, Xu H, Zhou D, et al
Alcohol consumption and smoking in relation to psoriasis: a Mendelian randomization study.
Br J Dermatol. 2022 Jun 28. doi: 10.1111/bjd.21718.
PubMed Abstract available

SANTANDREA G, Valli R, Ragazzi M, Castagnetti F, et al
Clinically unquestionable but histologically deceptive melanomas in acral skin grafts: PRAME confirms its role.
Br J Dermatol. 2022 Jun 28. doi: 10.1111/bjd.21715.
PubMed

VONK J, de Wit JG, Voskuil FJ, Koldijk M, et al
Fluorescence molecular imaging using cetuximab-800CW in cutaneous squamous cell carcinoma surgery: a proof-of-concept study.
Br J Dermatol. 2022 Jun 28. doi: 10.1111/bjd.21722.
PubMed

SCHNEEWEISS MC, Kirchgesner J, Wyss R, Jin Y, et al
Occurrence of inflammatory bowel disease in patients with chronic inflammatory skin diseases: a cohort study.
Br J Dermatol. 2022 Jun 19. doi: 10.1111/bjd.21704.
PubMed Abstract available

CALBET-LLOPART N, Combalia M, Kiroglu A, Potrony M, et al
Common genetic variants associated with melanoma risk or naevus count in wild-type MC1R melanoma patients.
Br J Dermatol. 2022 Jun 14. doi: 10.1111/bjd.21707.
PubMed Abstract available

AGUILAR-DURAN S, Mee J, Popat S, Heelan K, et al
Atezolizumab-induced linear IgA bullous dermatosis.
Br J Dermatol. 2022 Jun 7. doi: 10.1111/bjd.21653.
PubMed

FAN R, Leasure AC, Maisha FI, Little AJ, et al
Thyroid disorders associated with lichen sclerosus: A case-control study in the All of Us research program.
Br J Dermatol. 2022 Jun 6. doi: 10.1111/bjd.21702.
PubMed

BATTESTI G, Ram-Wolff C, Dobos G, Aubin F, et al
Granulomatous slack skin: clinical characteristics, prognosis, and response to therapy. A study from the Cutaneous Lymphoma French Study Group.
Br J Dermatol. 2022 Jun 6. doi: 10.1111/bjd.21699.
PubMed

ITO M, Kamata M, Uchida H, Egawa S, et al
Ixekizumab rapidly improves inflammatory markers in patients with generalized pustular psoriasis.
Br J Dermatol. 2022 Jun 6. doi: 10.1111/bjd.21701.
PubMed

PENG C, Jian X, Xie Y, Li L, et al
Genomic alterations of dermatofibrosarcoma protuberans revealed by whole-genome sequencing.
Br J Dermatol. 2022;186:997-1009.
PubMed Abstract available

OFENLOCH R, Grochulska K, Mettang T, Weisshaar E, et al
The incidence of chronic itch in patients on haemodialysis and associated factors.
Br J Dermatol. 2022;186:1052-1054.
PubMed

ROELENS M, de Masson A, Andrillon A, Ram-Wolff C, et al
Mogamulizumab induces long-term immune restoration and reshapes tumour heterogeneity in Sezary syndrome.
Br J Dermatol. 2022;186:1010-1025.
PubMed Abstract available

BETTUZZI T, Hua C, Diaz E, Colin A, et al
Epidermal necrolysis: characterization of different phenotypes using an unsupervised clustering analysis.
Br J Dermatol. 2022;186:1037-1039.
PubMed

MIN MS, Kus K, Wei N, Kassamali B, et al
Evaluating the role of histopathology in diagnosing pyoderma gangrenosum using Delphi and PARACELSUS criteria: a multicentre, retrospective cohort study.
Br J Dermatol. 2022;186:1035-1037.
PubMed

May 2022

THAM KC, Lefferdink R, Duan K, Lim SS, et al
Distinct skin microbiome community structures in congenital ichthyosis.
Br J Dermatol. 2022 May 28. doi: 10.1111/bjd.21687.
PubMed Abstract available

SINGAL A, Mehta S
Eumelanin Human Skin Colour Scale: a novel concept with potential for further refinement.
Br J Dermatol. 2022 May 28. doi: 10.1111/bjd.21652.
PubMed

MIURA H, Fujiwara S
Successful treatment of severe subcorneal pustular dermatosis with the 308-nm ultraviolet B excimer laser.
Br J Dermatol. 2022 May 28. doi: 10.1111/bjd.21633.
PubMed

RICCI F, Abeni D
Heterogeneity of reports about the impact of the COVID-19 pandemic on melanoma diagnosis.
Br J Dermatol. 2022 May 24. doi: 10.1111/bjd.21598.
PubMed

OLSEN CM
International surveillance of trends in melanoma survival: the impact of morphology.
Br J Dermatol. 2022 May 24. doi: 10.1111/bjd.21651.
PubMed

HAN J, O'Neal S, Gravely A, Linos E, et al
United States Academic Dermatologists' Attitudes Towards Active Surveillance for Basal Cell Carcinoma.
Br J Dermatol. 2022 May 23. doi: 10.1111/bjd.21675.
PubMed

MARTIN-MORO F, Martin-Rubio I, Garcia-Vela JA
TRBC1 expression assessed by flow cytometry as a novel marker of clonality in cutaneous alphabeta T-cell lymphomas with peripheral blood involvement.
Br J Dermatol. 2022 May 23. doi: 10.1111/bjd.21678.
PubMed

CORBETT M, Ramessur R, Marshall D, Acencio ML, et al
Biomarkers of systemic treatment response in people with psoriasis: a scoping review.
Br J Dermatol. 2022 May 23. doi: 10.1111/bjd.21677.
PubMed Abstract available

KAMMINGA NCW, van der Veldt AAM, Joosen MCW, de Joode K, et al
Experiences of resuming life after immunotherapy and associated survivorship care needs: a qualitative study among patients with metastatic melanoma.
Br J Dermatol. 2022 May 21. doi: 10.1111/bjd.21670.
PubMed Abstract available

LANGAN EA, Kunstner A
The gastrointestinal microbiome and psoriasis: more food for thought.
Br J Dermatol. 2022 May 20. doi: 10.1111/bjd.21618.
PubMed

BALAK DMW, Lambert J
Weighing in on weight-based secukinumab dosing for psoriasis.
Br J Dermatol. 2022 May 16. doi: 10.1111/bjd.21607.
PubMed

PONTES FSC, Pereira GG, da Silva Santos PS, Pontes HAR, et al
Isotretinoin and herpes simplex virus infection.
Br J Dermatol. 2022 May 11. doi: 10.1111/bjd.21610.
PubMed

SCHEEL CH, Rached NA, Gambichler T
Interleukin-17RA blockade by brodalumab decreases inflammatory pathways in hidradenitis suppurativa skin and serum.
Br J Dermatol. 2022 May 9. doi: 10.1111/bjd.21591.
PubMed

WHITEMAN DC, Olsen CM, MacGregor S, Law MH, et al
The effect of screening on melanoma incidence and biopsy rates.
Br J Dermatol. 2022 May 9. doi: 10.1111/bjd.21649.
PubMed Abstract available

COLE EF, Mustin DE, Feldman RJ
The Effect of Race and Fitzpatrick Skin Type on Bullous Pemphigoid Disease Area Index (BPDAI) Scores.
Br J Dermatol. 2022 May 9. doi: 10.1111/bjd.21648.
PubMed

CAPON F
New genetic and clinical features of neonatal inflammatory skin and bowel disease 1.
Br J Dermatol. 2022 May 6. doi: 10.1111/bjd.21589.
PubMed

DISSEMOND J, Romanelli M
Inflammatory skin diseases and wounds.
Br J Dermatol. 2022 May 6. doi: 10.1111/bjd.21619.
PubMed Abstract available

SCHUMMER P, Schilling B
How representative are data from global trials on programmed death-1 blockade in melanoma?
Br J Dermatol. 2022 May 4. doi: 10.1111/bjd.21621.
PubMed

LEONARDI-BEE J, Drucker AM
Systemic treatments for psoriasis: not another network meta-analysis!
Br J Dermatol. 2022 May 3. doi: 10.1111/bjd.21601.
PubMed

MAGIN P, Fisher K
Body dysmorphic disorder, skin diseases and psychological morbidity: common and complex.
Br J Dermatol. 2022 May 3. doi: 10.1111/bjd.21586.
PubMed

CARRERA C, Podlipnik S
Does acral melanoma need a distinctive prognostic staging system?
Br J Dermatol. 2022 May 3. doi: 10.1111/bjd.21585.
PubMed

BACHELEZ H
Is heat shock protein 90 inhibition a relevant treatment strategy for psoriasis?
Br J Dermatol. 2022;186:771-772.
PubMed

BAARDMAN R, Bolling MC
The importance of accurate epidemiological data of epidermolysis bullosa.
Br J Dermatol. 2022;186:765-766.
PubMed

KLEIN TM
Content validity of five single-item instruments in adolescents with alopecia areata.
Br J Dermatol. 2022;186:763-764.
PubMed

Findings from a survey about hidradenitis suppurativa in the Netherlands.
Br J Dermatol. 2022;186:e200-e219.
PubMed Abstract available

KEARNEY N, Kirby B
The prevalence of hidradenitis suppurativa outside the hospital setting: the impact of the undiagnosed.
Br J Dermatol. 2022;186:767-768.
PubMed

SIBBALD C, Alhusayen R
Janus kinase inhibitors for hidradenitis suppurativa: expanding the therapeutic toolbox.
Br J Dermatol. 2022;186:768-769.
PubMed

ALAVI A, Hamzavi I, Brown K, Santos LL, et al
Janus kinase 1 inhibitor INCB054707 for patients with moderate-to-severe hidradenitis suppurativa: results from two phase II studies.
Br J Dermatol. 2022;186:803-813.
PubMed Abstract available

CHEN CW, Wei JC
Response to 'Validation of generalized drug-related rash diagnoses using International Classification of Diseases 9th and 10th Revision codes'.
Br J Dermatol. 2022;186:910-911.
PubMed

GOLDENBERG M, Krishna SG, Milani-Nejad N, Trinidad JC, et al
Response to: 'Validation of generalized drug-related rash diagnoses using International Classification of Diseases 9(th) and 10(th) Revision codes': reply from the authors.
Br J Dermatol. 2022;186:911.
PubMed

WONGVIBULSIN S, Parthasarathy V, Pahalyants V, Murphy W, et al
Latent class analysis identification of prurigo nodularis comorbidity phenotypes.
Br J Dermatol. 2022;186:903-905.
PubMed

PETROF G, Papanikolaou M, Martinez AE, Mellerio JE, et al
The epidemiology of epidermolysis bullosa in England and Wales: data from the national epidermolysis bullosa database.
Br J Dermatol. 2022;186:843-848.
PubMed Abstract available

BARRANCA A, Debarbieux S, Tancrede-Bohin E, Saillard C, et al
A nationwide study evaluating the association of autoimmune bullous diseases and acquired haemophilia: description of clinical and prognostic features.
Br J Dermatol. 2022;186:899-902.
PubMed

YATSUZUKA K, Murakami M
Response to 'Anakinra for palmoplantar pustulosis: results from a randomized, double-blind, multicentre, two-staged, adaptive placebo-controlled trial (APRICOT)'.
Br J Dermatol. 2022;186:908.
PubMed

CRO S, Smith CH
Response to: 'Anakinra for palmoplantar pustulosis: results from a randomized, double-blind, multicentre, two-staged, adaptive placebo-controlled trial (APRICOT)': reply from the authors.
Br J Dermatol. 2022;186:909-910.
PubMed Abstract available

MACEY J, Kitchen H, Aldhouse NVJ, Edson-Heredia E, et al
A qualitative interview study to explore adolescents' experience of alopecia areata and the content validity of sign/symptom patient-reported outcome measures.
Br J Dermatol. 2022;186:849-860.
PubMed Abstract available

WAKKEE M
Polygenic risk scores for melanoma: a stepwise process towards clinical implementation.
Br J Dermatol. 2022;186:768.
PubMed

April 2022

FLOREZ ID
Clinical practice guidelines for psoriasis: which ones are the best?
Br J Dermatol. 2022 Apr 29. doi: 10.1111/bjd.21605.
PubMed

SAMIMI M
Is 5-fluorouracil the best candidate for topical chemoprevention of skin cancers in organ transplant recipients?
Br J Dermatol. 2022 Apr 28. doi: 10.1111/bjd.21602.
PubMed

ZHUANG K, Ran Y
Primary cutaneous nocardiosis caused by a novel Nocardia species.
Br J Dermatol. 2022 Apr 28. doi: 10.1111/bjd.21599.
PubMed

CHOON SE, Bachelez H
Time to accurately determine the burden of generalized pustular psoriasis at the population level.
Br J Dermatol. 2022 Apr 28. doi: 10.1111/bjd.21588.
PubMed

LEMMENS VEPP, Louwman MWJ
Basal cell carcinoma, an often unjustly overlooked healthcare challenge.
Br J Dermatol. 2022 Apr 28. doi: 10.1111/bjd.21587.
PubMed

BIEBER T, Reich K, Paul C, Tsunemi Y, et al
Efficacy and Safety of Baricitinib in Combination With Topical Corticosteroids in Patients With Moderate-to-Severe Atopic Dermatitis With Inadequate Response, Intolerance, or Contraindication to Cyclosporine: Results From a Randomized, Placebo-Control
Br J Dermatol. 2022 Apr 28. doi: 10.1111/bjd.21630.
PubMed Abstract available

RAMESSUR R, Corbett M, Marshall D, Acencio ML, et al
Biomarkers of disease progression in people with psoriasis: a scoping review.
Br J Dermatol. 2022 Apr 28. doi: 10.1111/bjd.21627.
PubMed Abstract available

LAQUER V, Parra V, Lacour JP, Takahashi H, et al
IL-33 antibody failed to demonstrate benefit in a phase 2 double-blind, randomised placebo-controlled study in adult patients with moderate-to-severe atopic dermatitis.
Br J Dermatol. 2022 Apr 28. doi: 10.1111/bjd.21631.
PubMed

JENDOUBI F, Shourik J, Seneschal J, Giordano-Labadie F, et al
Longer Dupilumab Dosing Intervals in Adult Patients with Atopic Dermatitis: Experience from a French Multicentre Retrospective Cohort Study.
Br J Dermatol. 2022 Apr 28. doi: 10.1111/bjd.21628.
PubMed

KWAN Z, Anand RL, Mallipeddi R, Ali FR, et al
The utility of negative histopathological analysis of debulk specimens during Mohs micrographic surgery for basal cell carcinoma.
Br J Dermatol. 2022 Apr 20. doi: 10.1111/bjd.21613.
PubMed

GRIFFIN LR, Ryan S, Ramsay B
Response to 'Patients with nodular prurigo commonly have pre-existing psychological disease that requires treatment concomitant with cutaneous therapies'.
Br J Dermatol. 2022 Apr 20. doi: 10.1111/bjd.21616.
PubMed

REICH K, Cullen E, Weinberg M
Maintenance of response in moderate-to-severe psoriasis after withdrawal of the IL-17A and IL-17F nanobody sonelokimab - Is there a role for IL-17F in disease reoccurrence?
Br J Dermatol. 2022 Apr 20. doi: 10.1111/bjd.21617.
PubMed

SIMPSON EL, Bissonnette R, Paller AS, King B, et al
The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD): A Clinical Outcome Measure for the Severity of Atopic Dermatitis.
Br J Dermatol. 2022 Apr 20. doi: 10.1111/bjd.21615.
PubMed Abstract available

SOLIMAN YS, Mieczkowska K, Zhu TR, Hossain O, et al
Characterizing Basal Cell Carcinoma in Hispanic Individuals Undergoing Mohs Micrographic Surgery: A 7-year Retrospective Review at an Academic Institution in the Bronx.
Br J Dermatol. 2022 Apr 20. doi: 10.1111/bjd.21614.
PubMed

MANOLACHE L, Finlay AY
Should self-help interventions become routine in psoriasis therapy?
Br J Dermatol. 2022 Apr 19. doi: 10.1111/bjd.21584.
PubMed

MAKINO T, Sugiyama H, Oshima M, Mizawa M, et al
Cutaneous gnathostomiasis caused by Gnathostoma spinigerum.
Br J Dermatol. 2022 Apr 15. doi: 10.1111/bjd.21007.
PubMed

HARVIMA IT, Harvima RJ
Survival from cutaneous malignant melanoma is improving, but is it because of a trend in decreasing melanoma thickness or the advent of new 'revolutionary' therapeutics?
Br J Dermatol. 2022 Apr 12. doi: 10.1111/bjd.21583.
PubMed

GJERSVIK P
The future is hard to predict, even for patients with cutaneous squamous cell carcinoma.
Br J Dermatol. 2022 Apr 12. doi: 10.1111/bjd.21291.
PubMed

BLOME C, von Stulpnagel CC, Augustin M, Mrowietz U, et al
Measuring patient-relevant benefits in psoriasis with the Patient Benefit Index: Development and preliminary validation of a 10-item short form.
Br J Dermatol. 2022 Apr 5. doi: 10.1111/bjd.21593.
PubMed

NIELSEN ML, Nymand LK, Thomsen SF, Thyssen JP, et al
Delay in diagnosis and treatment of patients with psoriasis - a population-based cross-sectional study.
Br J Dermatol. 2022 Apr 5. doi: 10.1111/bjd.21594.
PubMed

LOFT N, Skov L, Richardson C, Trivedi V, et al
A nationwide population-based cohort study of the incidence of severe and rare infections among adults with psoriasis in Denmark.
Br J Dermatol. 2022 Apr 5. doi: 10.1111/bjd.21595.
PubMed Abstract available

NALDI L
Going global with assessing the acne burden: is the evidence worth the effort?
Br J Dermatol. 2022;186:605.
PubMed

Revolutionizing Atopic Dermatitis, 11-13 December 2021.
Br J Dermatol. 2022;186:e135-e185.
PubMed

BARBAROT S
Targeting the itch-scratch vicious circle in atopic eczema.
Br J Dermatol. 2022;186:608.
PubMed

SUBRAMANIAM KS, Antoniou MN, McGrath JA, Lwin SM, et al
The potential of gene therapy for recessive dystrophic epidermolysis bullosa.
Br J Dermatol. 2022;186:609-619.
PubMed Abstract available

KASPERKIEWICZ M, Strong R, Mead K, Yale M, et al
COVID-19 vaccine acceptance and hesitancy in patients with immunobullous diseases: a cross-sectional study of the International Pemphigus and Pemphigoid Foundation.
Br J Dermatol. 2022;186:737-739.
PubMed

LUCKY AW, Pope E
Pregnancy in epidermolysis bullosa: long-awaited guidelines of care.
Br J Dermatol. 2022;186:602-603.
PubMed

SARKANY RPE, Canfield M, Morgan M, Foster L, et al
Ultraviolet radiation exposure to the face in patients with xeroderma pigmentosum and healthy controls: applying a novel methodology to define photoprotection behaviour.
Br J Dermatol. 2022;186:713-720.
PubMed Abstract available

GAMBICHLER T, Hamdani N, Budde H, Sieme M, et al
Bullous pemphigoid after SARS-CoV-2 vaccination: spike-protein-directed immunofluorescence confocal microscopy and T-cell-receptor studies.
Br J Dermatol. 2022;186:728-731.
PubMed

CHEN H, Zhang TC, Yin XL, Man JY, et al
Magnitude and temporal trend of acne vulgaris burden in 204 countries and territories from 1990 to 2019: an analysis from the Global Burden of Disease Study 2019.
Br J Dermatol. 2022;186:673-683.
PubMed Abstract available

RAMIREZ-GARCIALUNA JL, Wang SC, Yangzom T, Piguet V, et al
Use of thermal imaging and a dedicated wound-imaging smartphone app as an adjunct to staging hidradenitis suppurativa.
Br J Dermatol. 2022;186:723-726.
PubMed

RASHID H, Meijer JM, Bolling MC, Horvath B, et al
Clinical response to rituximab and improvement in quality of life in patients with bullous pemphigoid and mucous membrane pemphigoid.
Br J Dermatol. 2022;186:721-723.
PubMed

CHEN XQ, Zheng DY, Xiao YY, Dong BL, et al
Aetiology of tinea capitis in China: a multicentre prospective study.
Br J Dermatol. 2022;186:705-712.
PubMed Abstract available

GREENBLATT DT, Pillay E, Snelson K, Saad R, et al
Recommendations on pregnancy, childbirth and aftercare in epidermolysis bullosa: a consensus-based guideline.
Br J Dermatol. 2022;186:620-632.
PubMed

March 2022

DADZIE OE, Sturm RA, Fajuyigbe D, Petit A, et al
The Eumelanin Human Skin Colour Scale: A Proof-of-Concept Study.
Br J Dermatol. 2022 Mar 29. doi: 10.1111/bjd.21277.
PubMed Abstract available

KATO J, Namikawa K, Uehara J, Nomura M, et al
Prognoses of melanoma patients who continue/discontinue anti-programmed death-1 therapy after achieving a complete response in a real-world setting: A multicenter retrospective study.
Br J Dermatol. 2022 Mar 29. doi: 10.1111/bjd.21276.
PubMed

DI CARLO V, Stiller CA, Eisemann N, Bordoni A, et al
Does the morphology of cutaneous melanoma help explain the international differences in survival? Results from 1,578,482 adults diagnosed during 2000-2014 in 59 countries (CONCORD-3).
Br J Dermatol. 2022 Mar 29. doi: 10.1111/bjd.21274.
PubMed Abstract available

SOWTER P, Santibanez-Koref M, Jackson MS, Borthwick GM, et al
Response to 'Cutaneous squamous cell carcinoma is associated with Lynch syndrome: widening the spectrum of Lynch syndrome-associated tumours'.
Br J Dermatol. 2022 Mar 24. doi: 10.1111/bjd.20970.
PubMed

FISCHER K, Aringer M, Steininger J, Heil J, et al
Improvement of cutaneous inflammation and panniculitis in dermatomyositis patients by the JAK-inhibitor baricitinib.
Br J Dermatol. 2022 Mar 23. doi: 10.1111/bjd.21252.
PubMed

KURTANSKY NR, Manci RN, Bello DM, Adamson AS, et al
Risk of non-acral cutaneous melanoma after the diagnosis of acral melanoma.
Br J Dermatol. 2022 Mar 23. doi: 10.1111/bjd.21251.
PubMed

STEFANOVIC N, Fitzmaurice CJ, Ormond P, Irvine AD, et al
Risk Factors for Distant Metastasis in Cutaneous Squamous Cell Carcinoma.
Br J Dermatol. 2022 Mar 22. doi: 10.1111/bjd.21250.
PubMed

BAI X, Shoushtari AN, Betof Warner A, Si L, et al
Benefit and Toxicity to PD-1 Blockade Varies by Ethnicity in Patients with Advanced Melanoma: An International Multicenter Observational Study.
Br J Dermatol. 2022 Mar 16. doi: 10.1111/bjd.21241.
PubMed Abstract available

JACOBY TV, Otto TS, Asdourian MS, Shah N, et al
Association of preexisting drug allergies with cutaneous immune related adverse events among patients on immune checkpoint inhibitor therapy.
Br J Dermatol. 2022 Mar 15. doi: 10.1111/bjd.21243.
PubMed

TODBERG T, Egeberg A, Zachariae C, Sorensen N, et al
Patients with psoriasis have a dysbiotic taxonomic and functional gut microbiota.
Br J Dermatol. 2022 Mar 15. doi: 10.1111/bjd.21245.
PubMed Abstract available

REID C, Welsh C, Martin-Smith H, Dharmaprasad S, et al
A Rapid Access Clinic for Psoriasis - First Experiences.
Br J Dermatol. 2022 Mar 15. doi: 10.1111/bjd.21242.
PubMed

PENNY CL, Quow K, Rundle CW, Al-Rohil RN, et al
Response to 'Clinical and direct immunofluorescence characteristics of cutaneous toxicity associated with enfortumab vedotin' :reply from authors.
Br J Dermatol. 2022 Mar 10. doi: 10.1111/bjd.21239.
PubMed

OYA K, Nakamura Y, Fujisawa Y, Nomura T, et al
Response to 'Clinical and direct immunofluorescence characteristics of cutaneous toxicity associated with enfortumab vedotin'.
Br J Dermatol. 2022 Mar 9. doi: 10.1111/bjd.21230.
PubMed

KOREN J, Mburu S, Trigos D, Damiani G, et al
Generalised pustular psoriasis: the case for rare disease and orphan designation.
Br J Dermatol. 2022 Mar 8. doi: 10.1111/bjd.21231.
PubMed

REICH K, Baraliakos X, Coates LC, Elewski B, et al
Secukinumab demonstrates high and sustained efficacy in nail psoriasis: Post hoc analysis from phase 3 trials in patients with psoriatic arthritis.
Br J Dermatol. 2022 Mar 8. doi: 10.1111/bjd.21233.
PubMed

XIA P, Pasquali L, Gao C, Srivastava A, et al
miR-378a regulates keratinocyte responsiveness to IL-17A in psoriasis.
Br J Dermatol. 2022 Mar 8. doi: 10.1111/bjd.21232.
PubMed

ZAMAGNI F, Bucchi L, Mancini S, Crocetti E, et al
The relative contribution of the decreasing tumour thickness trend to the 2010s increase in net survival from cutaneous malignant melanoma in Italy: a population-based investigation.
Br J Dermatol. 2022 Mar 6. doi: 10.1111/bjd.21051.
PubMed Abstract available

NOVAK N, Cabanillas B
Herpesvirus, serious and opportunistic infections associated with atopic dermatitis.
Br J Dermatol. 2022 Mar 6. doi: 10.1111/bjd.20982.
PubMed

PARAGH G
Epidermal melanoma prognostic factors: a link to paracrine transforming growth factor-beta signalling.
Br J Dermatol. 2022 Mar 2. doi: 10.1111/bjd.20981.
PubMed

ZAGAR T, Hlaca N, Brajac I, Prpic-Massari L, et al
Bullous Sweet syndrome following SARS-CoV-2 Oxford AstraZeneca vaccine.
Br J Dermatol. 2022;186:e110.
PubMed

A comparison of the different questionnaires used to measure health-related quality of life in patients with dermatological conditions.
Br J Dermatol. 2022;186:e111-e133.
PubMed Abstract available

CONCHA JSS, Afarideh M, Werth VP
Postinflammatory hyperpigmentation and erythema: new insights into the pathogenesis.
Br J Dermatol. 2022;186:390-391.
PubMed

LAYTON AM, McDonald BS, Mohd Mustapa MF, Levell NJ, et al
National Institute for Health and Care Excellence (NICE) acne guideline: what's the latest for dermatologists?
Br J Dermatol. 2022;186:426-428.
PubMed

DOBOS G, Assaf C
Transcriptomic changes during stage progression of mycosis fungoides: from translational analyses to their potential clinical implications.
Br J Dermatol. 2022;186:387-388.
PubMed

AOKI V, Miyamoto D
Unfolding the worldwide incidence of bullous pemphigoid: what are we missing?
Br J Dermatol. 2022;186:386-387.
PubMed

SABROE RA, Lawlor F, Grattan CEH, Ardern-Jones MR, et al
British Association of Dermatologists guidelines for the management of people with chronic urticaria 2021.
Br J Dermatol. 2022;186:398-413.
PubMed

GOLDENBERG M, Amigo M, Krishna SG, Milani-Nejad N, et al
Validation of generalized drug-related rash diagnoses using International Classification of Diseases 9th and 10th Revision codes.
Br J Dermatol. 2022;186:583-585.
PubMed

TISACK A, Fotouhi A, Fidai C, Friedman BJ, et al
Response to 'A clinical and biological review of keratoacanthoma': reply from authors.
Br J Dermatol. 2022;186:592-593.
PubMed

MAZZONI D, Muir J
Considerations in the management of keratoacanthoma.
Br J Dermatol. 2022;186:592.
PubMed

SIMPSON K, Low ZM, Yap T, Kern JS, et al
Ultralow-dose rituximab in pemphigus: a single-centre experience.
Br J Dermatol. 2022;186:581-583.
PubMed

VELLAICHAMY G, Kohli I, Zubair R, Yin C, et al
An in vivo model of postinflammatory hyperpigmentation and erythema: clinical, colorimetric and molecular characteristics.
Br J Dermatol. 2022;186:508-519.
PubMed Abstract available

BAILEY AMJ, Li HO, Burns K, Cheng W, et al
Targeting the opioid pathway for the treatment of chronic kidney disease-associated pruritus: a systematic review and meta-analysis of randomized controlled trials.
Br J Dermatol. 2022;186:575-577.
PubMed

XIAO MZX, Hennessey D, Iyer A, O'Keefe S, et al
Transcriptomic changes during stage progression of mycosis fungoides.
Br J Dermatol. 2022;186:520-531.
PubMed Abstract available

PERSSON MSM, Begum N, Grainge MJ, Harman KE, et al
The global incidence of bullous pemphigoid: a systematic review and meta-analysis.
Br J Dermatol. 2022;186:414-425.
PubMed Abstract available

February 2022

LEE A, Stanley G, Gardiner MD, Batchelor JM, et al
An international clinician survey CompAring Non-Absorbable Versus Absorbable sutures for Skin surgery: the CANVAS Study.
Br J Dermatol. 2022 Feb 22. doi: 10.1111/bjd.21062.
PubMed

NAVRAZHINA K, Frew JW, Grand D, Williams SC, et al
IL-17RA blockade by brodalumab decreases inflammatory pathways in hidradenitis suppurativa skin and serum.
Br J Dermatol. 2022 Feb 22. doi: 10.1111/bjd.21060.
PubMed Abstract available

MIRALI S, Fabusiwa K, Linos E
Safety in numbers: risankizumab for moderate-to-severe psoriasis.
Br J Dermatol. 2022 Feb 20. doi: 10.1111/bjd.20947.
PubMed

NGUYEN R
Ocular conjunctivitis in biological therapies for atopic dermatitis.
Br J Dermatol. 2022 Feb 16. doi: 10.1111/bjd.20945.
PubMed

HAN J, O'Neal S, Gravely A, Gupta R, et al
Patients' attitudes towards active surveillance for basal cell carcinoma.
Br J Dermatol. 2022 Feb 15. doi: 10.1111/bjd.21058.
PubMed

TANNENBAUM R, Strunk A, Garg A
Age- and Sex- Adjusted Prevalence Estimates Among Pediatric Patients with Psoriasis in the United States.
Br J Dermatol. 2022 Feb 14. doi: 10.1111/bjd.21057.
PubMed

VERMEER MH, Moins-Teisserenc H, Bagot M, Quaglino P, et al
Flow cytometry for the assessment of blood tumour burden in cutaneous T-cell lymphoma: towards a standardised approach.
Br J Dermatol. 2022 Feb 14. doi: 10.1111/bjd.21053.
PubMed Abstract available

VAN COILE L, Verhaeghe E, Ongenae K, Brochez L, et al
Basal cell carcinoma in older adults: how to decide when active surveillance or watchful waiting are appropriate?
Br J Dermatol. 2022 Feb 14. doi: 10.1111/bjd.21056.
PubMed

YEN H, Huang CH, Huang IH, Hung WK, et al
Systematic review and critical appraisal of psoriasis clinical practice guidelines: a Global Guidelines in Dermatology Mapping Project (GUIDEMAP).
Br J Dermatol. 2022 Feb 13. doi: 10.1111/bjd.21047.
PubMed Abstract available

SANGERS TE, Wakkee M, Kramer-Noels EC, Nijsten T, et al
Limited impact of COVID-19 related diagnostic delay on cutaneous melanoma and squamous cell carcinoma tumor characteristics: A nationwide pathology registry analysis.
Br J Dermatol. 2022 Feb 10. doi: 10.1111/bjd.21050.
PubMed Abstract available

MASTORINO L, Roccuzzo G, Dapavo P, Siliquini N, et al
Patients with psoriasis resistant to multiple biologic therapies: characteristics and definition of a difficult-to-treat population.
Br J Dermatol. 2022 Feb 10. doi: 10.1111/bjd.21048.
PubMed

EDEN M, Hainsworth R, Gordon LG, Epton T, et al
Cost-effectiveness of a policy-based intervention to reduce melanoma and other skin cancers associated with indoor tanning.
Br J Dermatol. 2022 Feb 10. doi: 10.1111/bjd.21046.
PubMed Abstract available

FUTAMURA M
Easy assessment tool for disease severity of atopic dermatitis in clinical practice.
Br J Dermatol. 2022 Feb 6. doi: 10.1111/bjd.20951.
PubMed

MARGOLIS DJ
Atopic dermatitis: filaggrin and skin barrier dysfunction.
Br J Dermatol. 2022 Feb 6. doi: 10.1111/bjd.20946.
PubMed

BECHMAN K, Cook ES, Dand N, Yiu ZZN, et al
Vaccine hesitancy and access to psoriasis care in the COVID-19 pandemic: findings from a global patient-reported cross-sectional survey.
Br J Dermatol. 2022 Feb 1. doi: 10.1111/bjd.21042.
PubMed

GAO JM, Goiriz R, Rajpopat S, Goldsmith P, et al
Occupational dermatoses during the second wave of the COVID-19 pandemic: a UK prospective study of 805 healthcare workers.
Br J Dermatol. 2022;186:374-376.
PubMed

Different ways of estimating the amount of individual sun exposure.
Br J Dermatol. 2022;186:e84-e109.
PubMed Abstract available

LEIENDECKER L, Jung PS, Obenauf AC
Targeting CD56 with an antibody-drug conjugate in Merkel cell carcinoma.
Br J Dermatol. 2022;186:209-210.
PubMed

SCHELL SL, Nelson AM
Are antimicrobial peptides a double-edged sword in hidradenitis suppurativa pathophysiology?
Br J Dermatol. 2022;186:204-205.
PubMed

SINCLAIR R
Alopecia areata: progress, but who pays?
Br J Dermatol. 2022;186:206-207.
PubMed

VAN DER ZEE HH, van de Bunte M, van Straalen KR
Management of mild hidradenitis suppurativa: our greatest challenge yet.
Br J Dermatol. 2022;186:355-356.
PubMed

GLEESON D, Cliff S, Das M
Eruptive keratoacanthomas associated with dupilumab therapy.
Br J Dermatol. 2022;186:376-377.
PubMed Abstract available

NAGOBA BS, Rayate AS, Patil NR, Gavkare AM, et al
Citric acid treatment of infected venous eczema refractory to conventional treatment: a novel approach.
Br J Dermatol. 2022;186:377-379.
PubMed

LEUS AJG, Horvath B, Terra JB, Diercks GFH, et al
Eligibility criteria for programmed death receptor 1 inhibitors vs. real-world advice: a retrospective analysis of 69 patients with advanced cutaneous squamous cell carcinoma of the head and neck.
Br J Dermatol. 2022;186:371-372.
PubMed

GAUDIN O, Milpied B, Papouin B, Hue S, et al
Lupus erythematosus and epidermal necrolysis: a case series of 16 patients.
Br J Dermatol. 2022;186:372-374.
PubMed

CARTER C, Martin K, Gordon C, Goulding JMR, et al
Exploring the lived experience of women with rosacea: visible difference and psychological impact.
Br J Dermatol. 2022;186:366-367.
PubMed

ESNAULT C, Leblond V, Martin C, Desgranges A, et al
Adcitmer((R)) , a new CD56-targeting monomethyl auristatin E-conjugated antibody, is a potential therapeutic approach in Merkel cell carcinoma.
Br J Dermatol. 2022;186:295-306.
PubMed Abstract available

FALKENHAIN-LOPEZ D, Fulgencio-Barbarin J, Puerta-Pena M, Montero-Menarguez J, et al
Single-centre experience of using pegylated liposomal doxorubicin as maintenance treatment in mycosis fungoides.
Br J Dermatol. 2022;186:363-365.
PubMed

HASANAJ A, Zaki F, Harman KE, Grindlay D, et al
Cause-specific mortality in people with bullous pemphigoid and pemphigus vulgaris: a systematic review and meta-analysis.
Br J Dermatol. 2022;186:359-361.
PubMed

YAO Y, Frew JW, Thomsen SF, Ring HC, et al
Antimicrobial peptides in hidradenitis suppurativa: a systematic review.
Br J Dermatol. 2022;186:236-244.
PubMed Abstract available

SOUEID L, Triguero-Mas M, Dalmau A, Barrera-Gomez J, et al
Estimating personal solar ultraviolet radiation exposure through time spent outdoors, ambient levels and modelling approaches.
Br J Dermatol. 2022;186:266-273.
PubMed Abstract available

HARRIES M, Macbeth AE, Holmes S, Chiu WS, et al
The epidemiology of alopecia areata: a population-based cohort study in UK primary care.
Br J Dermatol. 2022;186:257-265.
PubMed Abstract available

January 2022

PAKHCHANIAN H, Raiker R, Wolf M, Trotter SC, et al
Examining the Risk of Breakthrough Infection and COVID-19 Vaccination Safety in Atopic Dermatitis Patients.
Br J Dermatol. 2022 Jan 27. doi: 10.1111/bjd.21038.
PubMed

LAM M, Monaghan C, Chan AW, Drucker AM, et al
Characterization of discontinuation and nonpublication of phase 3 randomized clinical trials for psoriasis.
Br J Dermatol. 2022 Jan 21. doi: 10.1111/bjd.21025.
PubMed

GEALE K, Schmitt-Egenolf M
Severity of psoriasis - Time to disentangle severity from symptom control.
Br J Dermatol. 2022 Jan 19. doi: 10.1111/bjd.21023.
PubMed

PENNY CL, Quow K, Rundle CW, Al-Rohil RN, et al
Clinical and direct immunofluorescence characteristics of cutaneous toxicity associated with enfortumab vedotin.
Br J Dermatol. 2022 Jan 19. doi: 10.1111/bjd.21022.
PubMed

EBATA T
Dose flexibility of oral Janus kinase inhibitors for long-term control of atopic dermatitis.
Br J Dermatol. 2022 Jan 19:ljac082. doi: 10.1093.
PubMed

WEI X, Wu D, Chen Y, Li H, et al
Prognostic value of ulceration varies across Breslow thicknesses and clinical stages in acral melanoma: a retrospective study.
Br J Dermatol. 2022 Jan 18. doi: 10.1111/bjd.21026.
PubMed Abstract available

MUFTIN Z, Gilbert P, Thompson AR
A Randomised Controlled Feasibility Trial of Online Compassion-focused Self-Help for Psoriasis.
Br J Dermatol. 2022 Jan 18. doi: 10.1111/bjd.21020.
PubMed Abstract available

KOZERA E, Stewart T, Gill K, De La Vega MA, et al
Dupilumab Associated Head and Neck Dermatitis is Associated with Elevated Pre-Treatment Serum Malassezia-Specific Immunoglobulin E: A Multicenter, Prospective Cohort Study.
Br J Dermatol. 2022 Jan 18. doi: 10.1111/bjd.21019.
PubMed

YOSIPOVITCH G, Papp K, Forman S, Han G, et al
The contribution of itch and skin severity improvements to the Dermatology Life Quality Index in patients with atopic dermatitis in baricitinib phase 3 trials.
Br J Dermatol. 2022 Jan 18. doi: 10.1111/bjd.21015.
PubMed

SCHUT C, Dalgard FJ, Bewley A, Evers AWM, et al
Body dysmorphia in common skin diseases: Results of an observational, cross-sectional multi-centre study among dermatological out-patients in 17 European countries.
Br J Dermatol. 2022 Jan 18. doi: 10.1111/bjd.21021.
PubMed Abstract available

SORENSEN ST, Nagy D, Lindahl LM, Farkas DK, et al
Risk of Cancer in Patients with Psoriasis and Venous Thromboembolism: a Danish Population-based Cohort study 1996-2018.
Br J Dermatol. 2022 Jan 18. doi: 10.1111/bjd.21016.
PubMed

SEMSARIAN CR, Ma T, Nickel B, Scolyer RA, et al
Do we need to rethink the diagnoses melanoma in situ and severely dysplastic naevus?
Br J Dermatol. 2022 Jan 10. doi: 10.1111/bjd.21010.
PubMed

HALLE A, De Becdelievre A, Funalot B, Labreze C, et al
SCN10A variants associated with congenital Harlequin Syndrome.
Br J Dermatol. 2022 Jan 10. doi: 10.1111/bjd.21011.
PubMed

KODAMA S, Gupta D, Sullivan E, Rosenwasser N, et al
Paradoxical psoriasis after exposure to tumor necrosis factor inhibitors in children-A retrospective cohort study.
Br J Dermatol. 2022 Jan 7. doi: 10.1111/bjd.20980.
PubMed

KEZIC S, McAleer MA, Jakasa I, Goorden SMI, et al
Children with atopic dermatitis show increased activity of beta- glucocerebrosidase and stratum corneum levels of glucosylcholesterol that are strongly related to local cytokine milieu.
Br J Dermatol. 2022 Jan 7. doi: 10.1111/bjd.20979.
PubMed Abstract available

SAMUELOV L, Sarig O, Malovitski K, Bergson S, et al
Neonatal inflammatory skin and bowel disease type 1 caused by a complex genetic defect and responsive to combined anti-TNF-alpha and IL-12/23 blockade.
Br J Dermatol. 2022 Jan 6. doi: 10.1111/bjd.20978.
PubMed Abstract available

GINDL A, Schotta AM, Berent S, Markowicz M, et al
Persistent Lyme disease with cutaneous borrelia biofilm formation.
Br J Dermatol. 2022 Jan 6. doi: 10.1111/bjd.20977.
PubMed

CALABRESE L, Fiocco Z, Satoh TK, Peris K, et al
Therapeutic potential of targeting IL-1 family cytokines in chronic inflammatory skin diseases.
Br J Dermatol. 2022 Jan 6. doi: 10.1111/bjd.20975.
PubMed Abstract available

KEMPF W, Petrella T, Willemze R, Jansen P, et al
Clinical, histopathological and prognostic features of primary cutaneous acral CD8+ T-cell lymphoma and other dermal CD8+ cutaneous lymphoproliferations - Results of an EORTC Cutaneous Lymphoma Group Workshop.
Br J Dermatol. 2022 Jan 5. doi: 10.1111/bjd.20973.
PubMed Abstract available

ARENTS BWM, Zuuren EJV, Vermeulen S, Schoones JW, et al
Global Guidelines in Dermatology Mapping Project (GUIDEMAP) - a systematic review of atopic dermatitis clinical practice guidelines: are they clear, unbiased, trustworthy and evidence based (CUTE)?
Br J Dermatol. 2022 Jan 4. doi: 10.1111/bjd.20972.
PubMed Abstract available

ORMOND M, McParland H, Thakrar P, Donaldson A, et al
Validation of an Oral Disease Severity Score for use in oral lichen planus.
Br J Dermatol. 2022 Jan 4. doi: 10.1111/bjd.20968.
PubMed

AUGUSTIN M, Reich K, Yamauchi P, Pinter A, et al
Secukinumab dosing every two weeks demonstrated superior efficacy compared with dosing every four weeks in patients with psoriasis weighing 90 kg or more: Results of a randomised controlled trial.
Br J Dermatol. 2022 Jan 4. doi: 10.1111/bjd.20971.
PubMed Abstract available

LOFVENDAHL S, Norlin JM, Schmitt-Egenolf M
Prevalence and incidence of generalised pustular psoriasis in Sweden - a population-based register study.
Br J Dermatol. 2022 Jan 2. doi: 10.1111/bjd.20966.
PubMed Abstract available

MAGIN PJ, Tng ETV
Specialists and generalists in skin disease management: educational, clinical and research imperatives.
Br J Dermatol. 2022;186:1-2.
PubMed

BLANCHARD G, Guenova E
Mogamulizumab-associated rash (MAR) mars its efficacy in the treatment of cutaneous lymphoma.
Br J Dermatol. 2022;186:15-16.
PubMed

Psoriasis: From Gene to Clinic, 9(th) International Congress The Queen Elizabeth II Conference Centre, London, UK 9(th) -11(th) December 2021.
Br J Dermatol. 2022;186:e2-e82.
PubMed

NATSUGA K
Prevention of chemotherapy-induced hair loss by peroxisome proliferator-activated receptor-gamma modulation.
Br J Dermatol. 2022;186:14-15.
PubMed

EZZEDINE K, Pandya AG
British Association of Dermatologist guidelines: a lighthouse to help guide clinicians and researchers planning future clinical trials for vitiligo.
Br J Dermatol. 2022;186:3-4.
PubMed

FLEMING P
Risankizumab vs. fumaric acid esters: a direct comparison.
Br J Dermatol. 2022;186:4-5.
PubMed

VAN STRAALEN KR, Gulliver W
The expected missing heritability of hidradenitis suppurativa in perspective.
Br J Dermatol. 2022;186:9-10.
PubMed

HUGHES M, Denton CP
The critical need for patient-reported outcome measures to assess the severity and impact of systemic sclerosis.
Br J Dermatol. 2022;186:11-12.
PubMed

GABES M
The 'Chronic Itch Burden Scale': giving patients with chronic pruritus a voice.
Br J Dermatol. 2022;186:10-11.
PubMed

ABBAS LF, Joseph AK, Prasad S, Zhu JL, et al
Revealing novel, latent subsets of patients with morphoea through principal component analysis.
Br J Dermatol. 2022;186:193-195.
PubMed

JABBOUR AJ, van Straalen KR, Colvin A, Prens EP, et al
Clinical translation of hidradenitis suppurativa genetic studies requires global collaboration.
Br J Dermatol. 2022;186:183-185.
PubMed

RAYINDA T, McSweeney SM, Dand N, Fenton DA, et al
Clinical characteristics of male frontal fibrosing alopecia: a single-centre case series from London, UK.
Br J Dermatol. 2022;186:195-197.
PubMed

SIBEONI J, Dunogue B, Dupont A, Haiddar D, et al
Development and validation of a patient-reported outcome in systemic sclerosis: the Hand scleroDerma lived Experience (HAnDE) scale.
Br J Dermatol. 2022;186:96-105.
PubMed Abstract available

KJAERSGAARD ANDERSEN R, Clemmensen SB, Larsen LA, Hjelmborg JVB, et al
Evidence of gene-gene interaction in hidradenitis suppurativa: a nationwide registry study of Danish twins.
Br J Dermatol. 2022;186:78-85.
PubMed Abstract available

ELEFTHERIADOU V, Atkar R, Batchelor J, McDonald B, et al
British Association of Dermatologists guidelines for the management of people with vitiligo 2021.
Br J Dermatol. 2022;186:18-29.
PubMed

THEUNIS J, Nordon C, Falissard B, Orri M, et al
Development and preliminary validation of the patient-reported Chronic Itch Burden Scale assessing health-related quality of life in chronic pruritus.
Br J Dermatol. 2022;186:86-95.
PubMed Abstract available

December 2021

MICEVIC G, Lo SN, Rajan N
Targeting the neonatal Fc receptor in pemphigus: safety first.
Br J Dermatol. 2021 Dec 27. doi: 10.1111/bjd.20939.
PubMed

KAPPELIN J, Green AC, Ingvar A, Ahnlide I, et al
Incidence and trends of basal cell carcinoma in Sweden: A population-based registry study.
Br J Dermatol. 2021 Dec 23. doi: 10.1111/bjd.20964.
PubMed Abstract available

LOBATO-BEREZO A, Gonzalez-Farre M, Pujol RM
Pustular frontal fibrosing alopecia: a new variant within the folliculitis decalvans and lichen planopilaris phenotypic spectrum?
Br J Dermatol. 2021 Dec 23. doi: 10.1111/bjd.20962.
PubMed

PUIG L, Costanzo A, Munoz-Elias EJ, Jazra M, et al
The biological basis of disease recurrence in psoriasis: a historical perspective and current models.
Br J Dermatol. 2021 Dec 23. doi: 10.1111/bjd.20963.
PubMed Abstract available

STEINBERG J, Iles MM, Lee JY, Wang X, et al
Independent evaluation of melanoma polygenic risk scores in UK and Australian prospective cohorts.
Br J Dermatol. 2021 Dec 18. doi: 10.1111/bjd.20956.
PubMed Abstract available

DANBY SG, Andrew PV, Kay LJ, Pinnock A, et al
Enhancement of stratum corneum lipid structure improves skin barrier function and protects against irritation in adults with dry, eczema-prone, skin.
Br J Dermatol. 2021 Dec 18. doi: 10.1111/bjd.20955.
PubMed Abstract available

PRENS LM, Bouwman K, Troelstra LD, Prens EP, et al
New Insights in Hidradenitis Suppurativa from a Population-based Dutch Cohort: Prevalence, Smoking Behaviour, Socioeconomic Status and Comorbidities.
Br J Dermatol. 2021 Dec 18. doi: 10.1111/bjd.20954.
PubMed Abstract available

THOMSON J, Hogan S, Leonardi-Bee J, Williams HC, et al
Response to 'Interventions for basal cell carcinoma: abridged Cochrane systematic review and GRADE assessments': reply from the authors.
Br J Dermatol. 2021 Dec 17. doi: 10.1111/bjd.20950.
PubMed

VINERETSKY KA, Domingo-Musibay E, Karagas MR, Lazovich D, et al
A functional variant in the immune signalling receptor NKG2D alters skin cancer risk.
Br J Dermatol. 2021 Dec 8. doi: 10.1111/bjd.20943.
PubMed

LUENGAS-MARTINEZ A, Paus R, Young HS
A novel personalised treatment approach for psoriasis: anti-VEGF-A therapy.
Br J Dermatol. 2021 Dec 8. doi: 10.1111/bjd.20940.
PubMed Abstract available

VENABLES ZC, Tokez S, Hollestein LM, Mooyaart AL, et al
Validation of Four Cutaneous Squamous Cell Carcinoma Staging Systems Using Nationwide Data.
Br J Dermatol. 2021 Dec 3. doi: 10.1111/bjd.20909.
PubMed Abstract available

GUELIMI R, Afach S, Regnaux JP, Bettuzzi T, et al
Overlapping network meta-analyses on psoriasis systemic treatments: an overview, quantity does not make quality.
Br J Dermatol. 2021 Dec 2. doi: 10.1111/bjd.20908.
PubMed Abstract available

Do anti-psoriatic drugs work better in women than men?
Br J Dermatol. 2021;185:e200-e213.
PubMed Abstract available

WOLF P
Systemic antipsoriatic treatment: do women respond better than men and if so, why?
Br J Dermatol. 2021;185:1088-1089.
PubMed

KOTB I
Evidence for the long-term efficacy and safety of guselkumab.
Br J Dermatol. 2021;185:1087-1088.
PubMed

ORMEROD AD
Epidemiology, comorbidities and mortality of pyoderma gangrenosum: new insights.
Br J Dermatol. 2021;185:1089-1090.
PubMed

KINOSHITA-ISE M
Refining the diagnosis and assessment methodology in frontal fibrosing alopecia.
Br J Dermatol. 2021;185:1092-1093.
PubMed

LEE HY
Bullous pemphigoid: towards personalized care.
Br J Dermatol. 2021;185:1093-1094.
PubMed

HUFFMAN C, Cardis MA
Image: Atypical chondrodermatitis nodularis due to in-ear headphones.
Br J Dermatol. 2021;185:e199.
PubMed

FINLAY AY, Griffiths TW, Belmo S, Chowdhury MMU, et al
Why we should abandon the misused descriptor 'erythema'.
Br J Dermatol. 2021;185:1240-1241.
PubMed

NIKOLAKIS G, Kristandt A, Hauptmann M, Becker M, et al
Efficacy of short-term intravenous clindamycin prior to oral clindamycin-rifampicin treatment in hidradenitis suppurativa: a retrospective case series.
Br J Dermatol. 2021;185:1270-1272.
PubMed

SUN H, Lim JS, Silva CF, Maczuga SA, et al
Insurance coverage gap for treatment of melasma compared with rosacea: it pays to be light.
Br J Dermatol. 2021;185:1252-1254.
PubMed

WADA-IRIMADA M, Mizuashi M, Takahashi T, Tojo G, et al
A retrospective study evaluating the outcomes of high-dose methylprednisolone pulse therapy for 483 patients with moderate-to-severe alopecia areata.
Br J Dermatol. 2021;185:1267-1269.
PubMed

WESTPHAL D, Garzarolli M, Sergon M, Horak P, et al
High tumour mutational burden and EGFR/MAPK pathway activation are therapeutic targets in metastatic porocarcinoma.
Br J Dermatol. 2021;185:1186-1199.
PubMed Abstract available

DOOLAN BJ, Onoufriadis A, Kantaputra P, McGrath JA, et al
WNT10A, dermatology and dentistry.
Br J Dermatol. 2021;185:1105-1111.
PubMed Abstract available

THOMPSON LL, Yoon J, Chang MS, Polyakov NJ, et al
Advanced care planning, code status and end-of-life care in patients with bullous pemphigoid.
Br J Dermatol. 2021;185:1246-1247.
PubMed

HEBERT V, Bastos S, Drenovska K, Meijer J, et al
International multicentre observational study to assess the efficacy and safety of a 0.5 mg kg(-1) per day starting dose of oral corticosteroids to treat bullous pemphigoid.
Br J Dermatol. 2021;185:1232-1239.
PubMed Abstract available

OLSEN EA, Harries M, Tosti A, Bergfeld W, et al
Guidelines for clinical trials of frontal fibrosing alopecia: consensus recommendations from the International FFA Cooperative Group (IFFACG).
Br J Dermatol. 2021;185:1221-1231.
PubMed Abstract available

BEN ABDALLAH H, Bech R, Fogh K, Olesen AB, et al
Comorbidities, mortality and survival in patients with pyoderma gangrenosum: a Danish nationwide registry-nested case-control study.
Br J Dermatol. 2021;185:1169-1175.
PubMed Abstract available

November 2021

DEAR K, Psomadakis C, Dost S, Lalagianni N, et al
Cutaneous manifestations of PIMS-TS: a single centre experience.
Br J Dermatol. 2021 Nov 29. doi: 10.1111/bjd.20907.
PubMed Abstract available

SINIKUMPU SP, Huilaja L
Challenges of multidimensional atopic dermatitis.
Br J Dermatol. 2021 Nov 24. doi: 10.1111/bjd.20874.
PubMed

DEZOTEUX F, El Mesbahi S, Tedbirt B, Grosjean J, et al
Immunomodulatory or/and immunosuppressive drugs should not avoid skin test for the assessment of drug allergy.
Br J Dermatol. 2021 Nov 22. doi: 10.1111/bjd.20901.
PubMed Abstract available

SUN MD, Kentley J, Mehta P, Duzsa S, et al
Accuracy of commercially available smartphone applications for the detection of melanoma.
Br J Dermatol. 2021 Nov 22. doi: 10.1111/bjd.20903.
PubMed Abstract available

CHUNG JG, Holtkamp H, Nieuwoudt M, Matthews H, et al
The combination of Raman Spectroscopy and Mass Spectrometry to investigate cutaneous metallosis.
Br J Dermatol. 2021 Nov 22. doi: 10.1111/bjd.20902.
PubMed Abstract available

DAND N
Genome-wide scan for structural variation underlying psoriasis.
Br J Dermatol. 2021 Nov 22. doi: 10.1111/bjd.20836.
PubMed

CHALMERS RJG
Recognizing psoriasis in children and adolescents: the DIPSOC study.
Br J Dermatol. 2021 Nov 22. doi: 10.1111/bjd.20825.
PubMed

MARUSIC Z, Calonje E
Skin adnexal tumours in a tertiary dermatopathology service.
Br J Dermatol. 2021 Nov 15. doi: 10.1111/bjd.20816.
PubMed

BERGAMASCHI D
Autophagy protects from photoageing in skin fibroblasts.
Br J Dermatol. 2021 Nov 15. doi: 10.1111/bjd.20822.
PubMed

PARK JH, Yoon JE, Kim YH, Kim Y, et al
The potential skin lightening candidate, senolytic drug ABT263, for photoageing pigmentation.
Br J Dermatol. 2021 Nov 13. doi: 10.1111/bjd.20893.
PubMed Abstract available

COSGAREA I, McConnell AT, Ewen T, Tang D, et al
Melanoma secretion of TGFbeta-2 leads to loss of epidermal AMBRA1 threatening epidermal integrity and facilitating tumour ulceration.
Br J Dermatol. 2021 Nov 13. doi: 10.1111/bjd.20889.
PubMed Abstract available

DE VERE HUNT I, van Egmond S, Nava V, Khodosh R, et al
Telehealth for Older Adults with Skin Disease: A Qualitative Exploration of Dermatologists' Experiences & Recommendations for Improving Care.
Br J Dermatol. 2021 Nov 13. doi: 10.1111/bjd.20891.
PubMed Abstract available

MARNIQUET ME, Seneschal J, Darrigade AS, Staumont-Salle D, et al
Reasons for Discontinuation of dupilumab in Adult Atopic Dermatitis in Clinical Practice.
Br J Dermatol. 2021 Nov 8. doi: 10.1111/bjd.20883.
PubMed Abstract available

WAN J, Shin DB, Syed MN, Abuabara K, et al
Risk of herpesvirus, serious, and opportunistic infections in atopic dermatitis: a population-based cohort study.
Br J Dermatol. 2021 Nov 8. doi: 10.1111/bjd.20887.
PubMed Abstract available

BREGNHOJ A, Thuesen KKH, Emmanuel T, Litman T, et al
HSP90 inhibitor RGRN-305 for oral treatment of plaque type psoriasis: efficacy, safety and biomarker results in an open-label proof-of-concept study.
Br J Dermatol. 2021 Nov 8. doi: 10.1111/bjd.20880.
PubMed Abstract available

JABOURI H, Abbott RA
Sustainability in skin cancer surgery.
Br J Dermatol. 2021 Nov 8. doi: 10.1111/bjd.20886.
PubMed Abstract available

MAZZONI D, Muir J
Response to "Interventions for basal cell carcinoma: abridged Cochrane systematic reviews and GRADE assessments".
Br J Dermatol. 2021 Nov 8. doi: 10.1111/bjd.20878.
PubMed Abstract available

PAPP KA, Gooderham MJ, Albrecht LE, Raymond MA, et al
Treatment satisfaction, safety, and effectiveness of adding methotrexate to adalimumab in psoriasis patients responding sub-optimally to adalimumab in a real-world setting.
Br J Dermatol. 2021 Nov 8. doi: 10.1111/bjd.20885.
PubMed Abstract available

MAEDA T, Hiura A, Uehara J, Toyoshima R, et al
Early tumor response assessment may avoid serious immune-related adverse events in nivolumab and ipilimumab combination therapy for stage IV melanoma.
Br J Dermatol. 2021 Nov 8. doi: 10.1111/bjd.20879.
PubMed Abstract available

CHIESA Z
How important is it to distinguish between eczema and atopic dermatitis in infants? Implications for prognosis and epidemiological research.
Br J Dermatol. 2021 Nov 2. doi: 10.1111/bjd.20814.
PubMed

BATAILLE V, Puig S
COVID-19 vaccines and skin manifestations.
Br J Dermatol. 2021 Nov 2. doi: 10.1111/bjd.20807.
PubMed

BEN ABDALLAH H, Vestergaard C
Atopic dermatitis, hypertension and cardiovascular disease.
Br J Dermatol. 2021 Nov 2. doi: 10.1111/bjd.20802.
PubMed

CAZZANIGA S, Naldi L
Administrative data and scientific evidence: a lesson from France - the safety of systemic treatment for psoriasis during the COVID-19 pandemic.
Br J Dermatol. 2021 Nov 2. doi: 10.1111/bjd.20776.
PubMed

CAMARA NOS
Do the gut and skin microbiomes share thoughts on melanoma development?
Br J Dermatol. 2021 Nov 2. doi: 10.1111/bjd.20811.
PubMed

GAMBICHLER T, Krogias C, Tischoff I, Tannapfel A, et al
Bilateral giant cell arteritis with skin necrosis following SARS-CoV-2 vaccination.
Br J Dermatol. 2021 Nov 2. doi: 10.1111/bjd.20824.
PubMed

PALLER AS, Tan JKL, Bagel J, Rossi AB, et al
IGAxBSA composite for assessing disease severity and response in patients with atopic dermatitis.
Br J Dermatol. 2021 Nov 2. doi: 10.1111/bjd.20872.
PubMed Abstract available

LAMBERT WC, Sy CB, Madari AP, Schwartz RA, et al
Perineal cutaneous basal cell carcinomas in patients with familial seronegative celiac disease: Report of three cases.
Br J Dermatol. 2021 Nov 2. doi: 10.1111/bjd.20870.
PubMed Abstract available

SCHREUDER K, Hollestein L, Nijsten TEC, Wakkee M, et al
A nationwide study of the incidence and trends of first and multiple basal cell carcinoma in the Netherlands and prediction of future incidence.
Br J Dermatol. 2021 Nov 2. doi: 10.1111/bjd.20871.
PubMed Abstract available

KABASHIMA K, Matsumura T, Komazaki H, Kawashima M, et al
Nemolizumab plus topical agents in patients with atopic dermatitis and moderate-to-severe pruritus provide improvement in pruritus and signs of atopic dermatitis for up to 68 weeks: results from two phase III, long-term studies.
Br J Dermatol. 2021 Nov 2. doi: 10.1111/bjd.20873.
PubMed Abstract available

MAURUS K, Kosnopfel C, Kneitz H, Appenzeller S, et al
Cutaneous epithelioid hemangiomas show somatic mutations in the MAPK pathway.
Br J Dermatol. 2021 Nov 2. doi: 10.1111/bjd.20869.
PubMed Abstract available

SZABO A, Brodszky V, Rencz F
A comparative study on the measurement properties of DLQI, DLQI-R and Skindex-16.
Br J Dermatol. 2021 Nov 1. doi: 10.1111/bjd.20765.
PubMed Abstract available

Patients who misuse alcohol have poorer responses to systemic treatments for psoriasis.
Br J Dermatol. 2021;185:e179-e198.
PubMed Abstract available

HWANG E, Tomayko MM
COVID-19 outcomes in patients with autoimmune blistering disease.
Br J Dermatol. 2021;185:1048-1050.
PubMed

HSIAO J, Shi V
Hidradenitis suppurativa: redirecting a life trajectory.
Br J Dermatol. 2021;185:878.
PubMed

ADOTAMA P, Callender V, Kolla A, Young C, et al
Comparing the clinical differences in white and black women with frontal fibrosing alopecia.
Br J Dermatol. 2021;185:1074-1076.
PubMed

TEIXEIRA MS, Gavazzoni Dias MFR, Vilar EAG, Pantaleao L, et al
Histopathological differential diagnosis of frontal fibrosing alopecia and fibrosing alopecia in a pattern distribution.
Br J Dermatol. 2021;185:1069-1070.
PubMed

SINIKUMPU SP, Vahanikkila H, Jokelainen J, Tasanen K, et al
Male patients with rosacea have increased risk for migraine: a population-based study.
Br J Dermatol. 2021;185:1058-1061.
PubMed

PAPADAVID E, Kapniari E, Pappa V, Nikolaou V, et al
Multicentric EORTC retrospective study shows efficacy of brentuximab vedotin in patients who have mycosis fungoides and Sezary syndrome with variable CD30 positivity.
Br J Dermatol. 2021;185:1035-1044.
PubMed Abstract available

CHU CB, Yang CC, Tsai SJ
Global data analysis supports smoking as the fundamental element associated with geographical sex disparities in hidradenitis suppurativa.
Br J Dermatol. 2021;185:1054-1056.
PubMed

CROITORU D, Sibbald C, Alavi A, Brooks S, et al
Challenging the association of hepatitis C and pyoderma gangrenosum.
Br J Dermatol. 2021;185:1047-1048.
PubMed

MOYAL L, Arkin C, Gorovitz-Haris B, Querfeld C, et al
Mycosis fungoides-derived exosomes promote cell motility and are enriched with microRNA-155 and microRNA-1246, and their plasma-cell-free expression may serve as a potential biomarker for disease burden.
Br J Dermatol. 2021;185:999-1012.
PubMed Abstract available

HOWELLS L, Lancaster N, McPhee M, Bundy C, et al
Thematic synthesis of the experiences of people with hidradenitis suppurativa: a systematic review.
Br J Dermatol. 2021;185:921-934.
PubMed Abstract available

LOFVENDAHL S, Norlin JM, Schmitt-Egenolf M
Prevalence and incidence of palmoplantar pustulosis in Sweden: a population-based register study.
Br J Dermatol. 2021;185:945-951.
PubMed Abstract available

PRENS LM, Porter ML, Savage KT, Salian P, et al
Hidradenitis suppurativa disease course during pregnancy and postpartum: a retrospective survey study.
Br J Dermatol. 2021;185:1072-1074.
PubMed

October 2021

HOYER A, Rehbinder EM, Fardig M, Asad S, et al
Filaggrin mutations in relation to skin barrier and atopic dermatitis in early infancy.
Br J Dermatol. 2021 Oct 26. doi: 10.1111/bjd.20831.
PubMed Abstract available

VAN WINDEN MEC, Klosters FM, Hamaker M, Olde Rikkert MG, et al
Optimizing shared decision-making in older adults with basal cell carcinoma: experiences from a specialized outpatient clinic.
Br J Dermatol. 2021 Oct 26. doi: 10.1111/bjd.20833.
PubMed Abstract available

GUTERMUTH J, Pink AE, Worm M, Soldbro L, et al
Tralokinumab plus topical corticosteroids in adults with severe atopic dermatitis and inadequate response to or intolerance of cyclosporine A: a placebo-controlled, randomized, Phase 3 clinical trial (ECZTRA 7).
Br J Dermatol. 2021 Oct 26. doi: 10.1111/bjd.20832.
PubMed Abstract available

OLIVER R, Krueger JG, Glatt S, Vajjah P, et al
Bimekizumab for the Treatment of Moderate to Severe Plaque Psoriasis: Efficacy, Safety, Pharmacokinetics, Pharmacodynamics and Transcriptomics from a Phase 2a Randomized, Multicenter Double-Blinded Study.
Br J Dermatol. 2021 Oct 23. doi: 10.1111/bjd.20827.
PubMed Abstract available

SBIDIAN E, Pina-Vegas L
Head-to-head trials in psoriasis and psoriatic arthritis: how to conclude?
Br J Dermatol. 2021 Oct 20. doi: 10.1111/bjd.20771.
PubMed

GORDON KB, Lebwohl M, Papp KA, Bachelez H, et al
Long-Term Safety of Risankizumab From 17 Clinical Trials in Patients With Moderate-to-Severe Plaque Psoriasis.
Br J Dermatol. 2021 Oct 15. doi: 10.1111/bjd.20818.
PubMed Abstract available

WOLLENBERG A, Beck LA, de Bruin Weller M, Simpson EL, et al
Conjunctivitis in adult patients with moderate-to-severe atopic dermatitis: results from five tralokinumab clinical trials.
Br J Dermatol. 2021 Oct 12. doi: 10.1111/bjd.20810.
PubMed Abstract available

MONNET P, Herms F, Djermane M, Dalac S, et al
Characterization of patients with advanced basal cell carcinoma progressing while receiving Hedgehog pathway inhibitors.
Br J Dermatol. 2021 Oct 12. doi: 10.1111/bjd.20808.
PubMed

HENDERSON BERG MH, Davison K, Popradi G
Real-world effectiveness of brentuximab vedotin in the treatment of CD30-positive cutaneous T-cell lymphoma: A single-centre retrospective review.
Br J Dermatol. 2021 Oct 5. doi: 10.1111/bjd.20786.
PubMed Abstract available

PUELLES J, Fofana F, Rodriguez D, Silverberg JI, et al
Psychometric Validation and Responder Definition of Sleep Disturbance Numerical Rating Scale in Moderate-To-Severe Atopic Dermatitis.
Br J Dermatol. 2021 Oct 5. doi: 10.1111/bjd.20783.
PubMed Abstract available

GOEBELER M, Bata-Csorgo Z, De Simone C, Didona B, et al
Treatment of pemphigus vulgaris and foliaceus with efgartigimod, a neonatal Fc receptor inhibitor: a phase 2 multicentre, open-label feasibility trial.
Br J Dermatol. 2021 Oct 5. doi: 10.1111/bjd.20782.
PubMed Abstract available

EIGENTLER T
Benefits of a nationwide population-based skin cancer screening programme - still a controversial debate.
Br J Dermatol. 2021 Oct 4. doi: 10.1111/bjd.20709.
PubMed

BERMINGHAM WH, Ardern-Jones MR, Huissoon AP, Krishna MT, et al
Forewarned is forearmed: chronic spontaneous urticaria as a potential risk to effective SARS-CoV-2 vaccine uptake and global public health.
Br J Dermatol. 2021;185:838-839.
PubMed

MURRELL DF, Patsatsi A, Stavropoulos P, Baum S, et al
Proof of concept for the clinical effects of oral rilzabrutinib, the first Bruton tyrosine kinase inhibitor for pemphigus vulgaris: the phase II BELIEVE study.
Br J Dermatol. 2021;185:745-755.
PubMed Abstract available

SHOURICK J, Ahmed M, Seneschal J, Passeron T, et al
Development of a shared decision-making tool in vitiligo: an international study.
Br J Dermatol. 2021;185:787-796.
PubMed Abstract available

HAW WY, Al-Janabi A, Arents BWM, Asfour L, et al
Global Guidelines in Dermatology Mapping Project (GUIDEMAP): a scoping review of dermatology clinical practice guidelines.
Br J Dermatol. 2021;185:736-744.
PubMed Abstract available

Shared decision-making for vitiligo.
Br J Dermatol. 2021;185:e158-e178.
PubMed Abstract available

STANDL M
Addressing the causality of the association of atopic dermatitis with depression and anxiety using Mendelian randomization.
Br J Dermatol. 2021;185:694-695.
PubMed

WAN J, Abuabara K
Growing evidence for an association between inflammatory skin disease and chronic kidney disease.
Br J Dermatol. 2021;185:693-694.
PubMed

HO JSS, Asai Y
Commentary on the British Association of Dermatologists guidelines for the management of people with rosacea 2021.
Br J Dermatol. 2021;185:689-690.
PubMed

SIL A, Panigrahi A, Pramanik JD
Isolated cutaneous larva migrans over the scalp in a hod carrier.
Br J Dermatol. 2021;185:e157.
PubMed

VAN DER SCHOOT LS, van den Reek JMPA
Data-driven prediction of biologic treatment responses in psoriasis: steps towards precision medicine.
Br J Dermatol. 2021;185:698-699.
PubMed Abstract available

DRUCKER AM, Shear NH
Bruton tyrosine kinase inhibition warrants further study for pemphigus.
Br J Dermatol. 2021;185:691-692.
PubMed

FREW JW
Therapeutic biomarkers in hidradenitis suppurativa: one step closer to the clinic.
Br J Dermatol. 2021;185:696-697.
PubMed

BRUNNER PM, Conrad C, Vender R, Grond S, et al
Integrated safety analysis of treatment-emergent eczematous reactions in patients with moderate-to-severe psoriasis treated with ixekizumab, etanercept and ustekinumab.
Br J Dermatol. 2021;185:865-867.
PubMed

SANCHEZ MARTINEZ EM, Murray G, Alfageme Roldan F, Garcia Ruiz R, et al
Adalimumab dose intensification in hidradenitis suppurativa: effectiveness and safety results of a multicentre study.
Br J Dermatol. 2021;185:863-865.
PubMed

YU W, Barrett J, Liu P, Parameswaran A, et al
Novel evidence of androgen receptor immunoreactivity in skin tunnels of hidradenitis suppurativa: assessment of sex and individual variability.
Br J Dermatol. 2021;185:855-858.
PubMed

RIQUELME-MC LOUGHLIN C, Iranzo P
Subcutaneous rituximab for autoimmune bullous diseases.
Br J Dermatol. 2021;185:870-871.
PubMed

MA BC, Sahni VN, Edwards LD, Sahni DR, et al
Response to 'A call to standardize the BCC:SCC ratio'.
Br J Dermatol. 2021;185:868-869.
PubMed

JIYAD Z, Marquart L, Green AC
Response to 'A call to standardize the BCC:SCC ratio': reply from the authors.
Br J Dermatol. 2021;185:869-870.
PubMed

STEFANIS AJ, Arenberger P, Arenbergerova M, Gkalpakiotis S, et al
Alopecia barbae severity score: a novel scoring system to estimate the extent of beard loss and success of treatment.
Br J Dermatol. 2021;185:847-849.
PubMed

QUEIROS C, Silva L, Miroux Catarino A, Labareda J, et al
Topical imiquimod as neoadjuvant therapy before Mohs micrographic surgery for basal cell carcinoma in the head and neck region: findings from a large retrospective study.
Br J Dermatol. 2021;185:851-853.
PubMed

WALKER SL, Head MG, Middleton J, Cassell JA, et al
Ivermectin in the management of a scabies outbreak in a long-term care facility.
Br J Dermatol. 2021;185:868.
PubMed

HAMPTON PJ, Berth-Jones J, Duarte Williamson CE, Hay R, et al
British Association of Dermatologists guidelines for the management of people with rosacea 2021.
Br J Dermatol. 2021;185:725-735.
PubMed

JURADO-ESCOBAR R, Dona I, Perkins JR, Laguna JJ, et al
Polymorphisms in eicosanoid-related biosynthesis enzymes associated with acute urticaria/angioedema induced by nonsteroidal anti-inflammatory drug hypersensitivity.
Br J Dermatol. 2021;185:815-824.
PubMed Abstract available

ALANI A, Kibbi N, Oliphant T
Mohs micrographic surgery for patients living with HIV.
Br J Dermatol. 2021;185:836-837.
PubMed

ABDELRAZIK YT, Ali FM, Salek MS, Finlay AY, et al
Clinical experience and psychometric properties of the Cardiff Acne Disability Index (CADI).
Br J Dermatol. 2021;185:711-724.
PubMed Abstract available

BAURECHT H, Welker C, Baumeister SE, Weidnger S, et al
Relationship between atopic dermatitis, depression and anxiety: a two-sample Mendelian randomization study.
Br J Dermatol. 2021;185:781-786.
PubMed Abstract available

CAO Y, Hong F, Conlon DM, Sidur L, et al
Potential predictive biomarkers of adalimumab response in patients with hidradenitis suppurativa.
Br J Dermatol. 2021;185:804-814.
PubMed Abstract available

September 2021

FROMME JE, Zigrino P
Melanoma metastasis, BRAF mutation and GJB5 connexin expression: a new prognostic factor.
Br J Dermatol. 2021 Sep 30. doi: 10.1111/bjd.20756.
PubMed

CHONG BF
Guidance for providers on the treatment and management of cutaneous lupus erythematosus.
Br J Dermatol. 2021 Sep 30. doi: 10.1111/bjd.20746.
PubMed

OH Y, Markova A, Noor SJ, Rotemberg V, et al
Standardized Clinical Photography Considerations in Patients Across Skin Tones.
Br J Dermatol. 2021 Sep 26. doi: 10.1111/bjd.20766.
PubMed Abstract available

NAKAMURA T, Haider S, Fontanella S, Murray CS, et al
Modelling trajectories of parentally reported and physician-confirmed atopic dermatitis in a birth cohort study.
Br J Dermatol. 2021 Sep 26. doi: 10.1111/bjd.20767.
PubMed Abstract available

COTTER C, Solman L, Flohr C
A national audit of oral propranolol for the treatment of Infantile Hemangiomas.
Br J Dermatol. 2021 Sep 2. doi: 10.1111/bjd.20738.
PubMed Abstract available

August 2021

CUST AE
Strengthening melanoma prevention and early detection among people with type 2 diabetes.
Br J Dermatol. 2021 Aug 18. doi: 10.1111/bjd.20633.
PubMed

July 2021

PROCOPIO-AZEVEDO AC, Rabello VBS, Muniz MM, Figueiredo-Carvalho MHG, et al
Hypersensitivity reactions in sporotrichosis: A retrospective cohort of 325 patients from a reference hospital in Rio de Janeiro, Brazil (2005-2018).
Br J Dermatol. 2021 Jul 14. doi: 10.1111/bjd.20646.
PubMed Abstract available

June 2021

CARMIGNAC V, Salomon G, Severino-Freire M, Duffourd Y, et al
Mosaic NEK9 mutation, fibrous dysplasia and premature puberty in nevus comedonicus syndrome.
Br J Dermatol. 2021 Jun 29. doi: 10.1111/bjd.20603.
PubMed Abstract available

BUI H, Skiba PN, Breskin A, Sayed C, et al
Hidradenitis Suppurativa Among Patients with Human Immunodeficiency Virus: Investigating Patient and Disease Characteristics, and Misdiagnosis.
Br J Dermatol. 2021 Jun 22. doi: 10.1111/bjd.20591.
PubMed Abstract available

May 2021

CLAESON M, Baade P, Marchetti M, Brown S, et al
Comparative performance of predictors of death from thin (
Br J Dermatol. 2021 May 12. doi: 10.1111/bjd.20480.
PubMed Abstract available

April 2021

DESSINIOTI C, Geller AC, Whiteman DC, Garbe C, et al
Not all melanomas are created equal: A review and call for more research into nodular melanoma.
Br J Dermatol. 2021 Apr 16. doi: 10.1111/bjd.20388.
PubMed Abstract available

January 2021

NAGORE E, Martinez-Garcia MA, Gomez-Olivas JD, Manrique-Silva E, et al
Relationship between type 2 diabetes mellitus and markers of cutaneous melanoma aggressiveness: An observational multi-centric study in 443 patients with melanoma.
Br J Dermatol. 2021 Jan 16. doi: 10.1111/bjd.19813.
PubMed Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Dermatology is free of charge.